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DNA 5- Cytosine methylation is a modification that occurs in mammalian cells predominantly at 
CpG sequences, through addition of a methyl group to the C5 position of cytosine. It is a 
commonly held view in the current field of epigenetics that the aberrant methylation patterns 
observed in gene promoter regions are associated with transcriptional repression in the absence 
of genetic mutations. This epigenetic phenomenon is frequently reported in malignant 
haematopoiesis, where genes involved in cell growth and differentiation programmes are shown 
to be transcriptionally silenced leading to unchecked cellular proliferation.   
Although strongly implicated in gene shut down, it is still unclear whether promoter region 
methylation triggers gene repression, or if DNA methylation arises as a consequence of 
transcriptional gene silencing via some other mechanism. This is in part because no-one has 
yet managed to dissect in vivo the precise sequence of the events associated with the 
appearance of aberrant methylation patterns at the promoter region of actively transcribing 
genes.  
This thesis documents a research programme aiming to exogenously impose de novo cytosine 
methylation to specific regions of a relevant endogenous promoter in order to study spatial and 
temporal interactions between targeted DNA methylation and other components of the 
epigenetic regulatory network. The gene selected for this study was CDKN2B, a cell cycle 
regulating tumour suppressor gene strongly implicated in Myelodysplastic Syndrome - MDS and 
Acute Myeloid Leukaemia - AML. Site-biased zinc finger: DNA methyltransferase fusion proteins 
were specifically designed with the aim of depositing low and high density de novo methylation 
at different regions of the CDKN2B promoter, in an attempt to simulate methylation patterns 
associated with disease and to thus determine their effect on gene expression. 
We demonstrate here for the first time the establishment of low density de novo methylation at 
this endogenous locus, characterized by highly specific target site methylation downstream of 
zinc finger binding sites. Examination of the distribution pattern and the spread of methylation 
from the seeded methylation hotspots suggest that 5’ CpG positions in flanking sequences 
remain unmethylated, whilst 3’CpG acquire de novo methylation marks derived from the action 
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of endogenous DNA methyltransferases. The effects of methylation spread over longer time 
scales on the formation of broader and more uniform methylation patterns are currently being 
investigated. Our data also shows that once established, the methylation pattern is inherited 
through successive cell divisions. Gene expression analysis indicates sustained transcriptional 
activity of the low density methylated promoter despite the presence of these de novo methyl 
marks. Overall, our results demonstrate that targeted low density methylation to the promoter 
region of the CDKN2B gene can be established and maintained epigenetically through 
subsequent cell generations, but has no effect on the transcriptional regulation of the gene.  To 
date we have not been successful in targeting high density methylation to the same region to 
comprehensively evaluate the bilateral relationship between a densely methylated promoter and 
its transcriptional activity/regulation.  
The contribution of the transcription factor VEZF1 in mediating methylation protection at the 
CDKN2B promoter was also examined, and we showed for the first time that this transcription 
factor is strongly associated with this promoter in vivo. This may have important implications in 
our understanding of CDKN2B expression and regulation in the disease process. Related 
studies also revealed that TET proteins may play a significant role in cell cycle entry, which was 
another hitherto unknown phenomenon. 
In conclusion, we feel that the work in this thesis has advanced the field of targeted methylation, 
the further implementation of which will certainly further our understanding of key epigenetic 
mechanisms such as the cellular response to de novo methylation and its role in the regulation 

































1.1 Mechanisms of Epigenetic Regulation 
 
Epigenetics is defined as “The study of mitotically and meiotically heritable changes in gene 
function that cannot be explained by changes in DNA sequence [1].” DNA methylation is one 
well characterized mechanism for propagating epigenetic information, although other 
mechanisms do exist such as chromatin remodelling events and miRNA silencing machinery. It 
is unclear which of these mechanisms are primary and which secondary epigenetic marks. The 
relationship between chromatin remodelling complexes and the DNA methylation machinery 
appears to be a dynamic one.  DNA demethylation is typically associated with activated 
chromatin, whilst DNA methylation is more reflective of a constituently silenced chromatin state 
[2]. Chromatin architecture in terms of nucleosome space occupancy around gene 
transcriptional units also contributes significantly to the complexity of epigenetic gene regulation.  
Research has demonstrated that both environmental and nutritional factors influence the 
epigenome markedly via mechanistic components of the DNA methylation and chromatin 
modiﬁcation machinery. The processes of gene expression, extracellular signalling and cellular 
differentiation are linked, regulated and defined by the epigenetic mechanisms of chromatin 
signature/DNA methylation interplay. Recent findings suggest that an organisms methylome 
may be the way by which it responds to, and adapts to natural environmental fluctuations [3].  
Epigenetic changes on their own or combined with genetic alterations  are believed to directly 
initiate cancer development [4]. A comparison of the key epigenetic differences between cancer 
and normal genomes shows that the biggest changes occur in the DNA methylation pattern 
between the two states. Similarly, alterations in patterns of covalent histone modifications can 
deregulate the control of chromatin-based processes again, resulting in oncogenic 
transformation. The above epigenetic processes are potentially reversible which given the 





1.1.1 DNA Methylation 
 
DNA methylation is one of the earliest discovered epigenetic modifications. In 1975, Riggs, [5] 
and Holliday and Pugh [6] proposed a role for DNA methylation in cellular memory as a 
mechanism for  X-chromosome  stable silencing early on in development. Analysis of the 
establishment and maintenance of differential gene expression patterns in many other 
developmental processes has further implicated DNA methylation in transcriptional gene 
silencing in a broader context.  These processes include early embryonic Hox gene expression 
[7], differential expression of maternal and paternal copies of the genes (genomic imprinting) [8], 
and haematopoiesis. Roles for DNA methylation in the regulation and maintenance of many 
cellular processes, chromosome stability, and maintenance of chromatin structure and 
transcription control have also been established.  
Gene and tissue - specific methylation patterns established early on in embryogenesis ensure 
stable propagation of the epigenetic code.  X -chromosome inactivation by de novo methylation 
mentioned above, is an example of this mechanism [9]. Transcriptional reactivation of genes  
involved in cellular differentiation programmes occurs through active demethylation processes 
[10].  
A key feature of the mammalian methylome is global hypermethylation, observed most 
frequently in highly conserved, heterochromatic, repetitive regions such as satellite DNA, short 
and long interspersed transposable elements and endogenous retroviral sequences. 
Methylation occurs in  70-80% of CpG sites in this region and serves as a mechanism for keeping 
the region transcriptionally inert [11].  
Exceptions to this state of global hypermethylation are CpG rich islands (CGIs) - short regulatory 
regions, usually 1kb in size, organized in asymmetric clusters,  usually located in the 5’ end of 
the gene, and within the promoter [12]. CGIs are methylation free in all normal tissue types, 
irrespective of gene transcription status. There are a few exceptions such as the regulatory 
regions of the genes involved in X inactivation [13], spermatogenesis [14] and the imprinted 
genes H19  and Igf2r [15, 16]   
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Changes to DNA methylation patterns occur throughout the life of an individual. These changes 
can arise as a consequence of nutritional effects [17], and age -  related cellular degeneration 
[18, 19]. Aberrant methylation patterns implicated in the aetiology of cancer frequently 
associates with global hypomethylation and promoter region hypermethylation. Disruption of 
DNA methylation patterns, in highly repetitive regions such as transposon repeats or viral genes 
can lead to global genomic instability [20], resulting in neoplastic transformation.  This may also 
arise as a consequence of disruptions in transcriptional control of tumour suppressor genes, 
oncogenes, and genes linked to DNA repair machinery.  
These changes in DNA methylation status correlate with the inhibition of gene expression, with 
a potential knock on effect on cellular differentiation and proliferation, cell cycle control, genomic 
imprinting and X chromosome inactivation [21]. However, evidence against a strong association 
between DNA methylation and gene silencing also exists, where for example several genes 
have shown a positive co-relation between DNA methylation and tissues specific expression 
[22-25].  
Like most epigenetic modifications, DNA methylation is a reversible process, subject to cyclic 
changes in gene promoter regions [26].  Global methylation changes during fertilization and early 
development further support the idea that DNA methylation is a dynamic process, while  active 
demethylation which mediates global methylation loss from the parental genome in mammalian 
fertilized oocytes before the onset of DNA replication reinforces this view [27, 28]. In 
preimplantation embryos, mammalian blasto‑cysts acquire de novo methylation patterns [29]. 
The immune response can also be regulated by methylation dynamics. For example,  studies 
on the mouse  Interleukin‑2 gene promoter enhancer region during T‑cell activation, shows that 
the methylation state of a  specific, single CG site is a key regulatory mechanism [30].  
Thus, the global distribution of DNA methylation patterns in human somatic cells and its dynamic 
regulation through the interplay with a variety of epigenetic factors ensures a fluid epigenomic 





1.1.2  Mechanisms of DNA methylation  
 
The C5 carbon of cytosine bases within the palindromic 5 '- CpG-3’ dinucleotides are the 
predominant targets of covalent methyl group addition.  The primary DNA sequence does not 
change as a result of the chemical modification.   
DNA methylation is mediated  by a family of DNA methyltransferase enzymes (DNMTs) using 
S-Adenosyl methionine (SAM or AdoMet) as the universal methyl group donor.  
The C6 position is the site of covalent DNA methyltransferase association during CH3 group 
transfer, whilst S-adenosylhomocysteine (SAH) is the by- product of the reaction and is 
inhibitory at high concentration. Methionine adenosyltransferase catalyses the generation of  
SAM in an enzymatic reaction involving  L-methionine and ATP [31]. Ultimate transfer of the 
CH3 group occurs from the SAM methionine sulphur atom to cytosine base at C5 of CpG in 
DNA.  After methyl group transfer, SAH dissociates from the complex (Figure 1-1).      
 
Figure1-1.  Schematic diagram of DNA methylation process. 
DNA methylation involves transfer of a methyl group (CH3) from SAM onto the C5 position of cytosine residue. The 
process is catalysed by a group of enzymes called DNA methyltransferases DNMT which attacks the C6 position of the 
cytosine residue during the CH3 transfer.  Figure adapted from Nature -Clinical Practice Rheumatology (2007), 




Eukaryotic DNA methylation is catalysed by the DNA methyltransferase (DNMTs) family of 
enzymes. Initial methylation patterns are established by de novo DNMTs which act on 
unmethylated DNA. The family consists of three catalytically active members: the DNMT1 
maintenance methyltransferase, and DNMT3A/ DNMT3B involved in de novo methylation. 
DNMT3L is catalytically inactive. Prokaryotic DNA methyltransferases are smaller than their 
more evolutionary advanced eukaryotic relatives. A major difference is in N-terminal domain of 
eukaryotic DNMTs, which contain a zinc ion binding, and cysteine rich region [32], called the  
plant homeodomain (PHD) or ATRX-like domain with similarity to the PHD region of ATRX gene, 
which is an essential ATP- dependant chromatin associated protein (Figure 2).  This observation 
has led to suggestions that the DNMT family also plays a role in chromatin remodelling events.   
 
 
Figure 1-2. Schematic representation of DNMT regulatory and catalytic regions. 
Amino terminal regions confer DNMT specificity, whilst the C domain contains highly homologous motifs (X,IX ,VI ,IV 
,I). DNMT3A and DNMT3B contain the PWWP domain, implicated in heterochromatin association and the ATRX 
domain composed of PHD and C2 - C2 zinc finger, involved in protein-protein interactions. DNMT1 has several 
specific motifs: BAH, bromo adjacent homology domain for protein/protein interactions, CXXC CpG selective motif, 
RFT replication foci targeting motif, NLS nuclear localization signal and PCNA interacting domain.  Figure adapted 
from [2, 33].  
Besides its general role in mediating protein-protein interactions, the N-terminal domains of 
some DNMTs are essential for their methyltransferase activity as observed for the DNMT1 

















enzyme [34]. The catalytic C- terminal domain is highly conserved between DNMT family 
members and prokaryotic and eukaryotic methyltransferases.   
What follows is a brief review of key methyltransferase enzymes involved in methylation 
establishment and maintenance.   
DNMT1- maintenance methyltransferase 
  
DNMT1 was the first identified mammalian methyltransferase. The human DNMT1 gene resides 
on chromosome 19p13.2, and encodes a 193.5kD protein. It is the most abundantly expressed  
of all methyltransferases in somatic cells [35]. DNMT1 contains two regions; a diversified N- 
terminal  regulatory region involved in C- domain activity regulation and replication foci targeting, 
and a conserved C- terminal catalytic domain with  homology to bacterial cytosine 5-methylase 
[36]. Despite this, the C- domain, on its own is  inactive and requires the N-terminal domain for 
its activation [34, 37]. 
The preferred substrate for this highly processive enzyme  is hemi-methylated DNA, research 
showing that during DNA replication it proccessively methylates only one strand of DNA [38, 
39]. DNMT1 recognizes methylated CpGs on the parent DNA strand.  The enzyme  catalyses  
transfer of methyl groups from SAM onto the daughter strand ensuring symmetrical 
methylation patterns [40].  
This process is maintained by UHRF1 (ubiquitin like containing PHD and RING finger domains 
1, also known as Np95 or ICBP90), a protein responsible for targeting DNMTs to the replication 
fork [41]. UHRF1 preferentially binds methylated cytosines in hemi-methylated DNA through its 
methyl binding Su(var)3-9, Enhancer of zeste Trithorax (SET)  and RING associated (SRA) 
domain. However, it can also bind to DNMTs, bringing them into the proximity to the 
unmethylated cytosines on the daughter strand, which ensures faithful propagation of  DNA 
methylation [42].  UHRF1 also recruits chromatin re-modellers, such as G9a, HDAC1 [43], and 
histone acetyltransferase Tip60 [44] to aid  the establishment of repressive chromatin. Recent 
crystal structure data has shown UHRF1 as one of the first  non- enzymatic DNA binding proteins 
to use a base flipping mechanism in its interactions with DNA [41].   
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A role for DNMT1 in transcriptional repression was proposed based on the observed interactions 
with a variety of proteins such as PCNA, p21WAF1 [45], HDAC1 and HDAC2 [46], MBD2, MBD3 
[47] and MeCP2 [48]. There are several tissue - specific splice variants of DNMT1 which differ 
in their transcription start site and their preference for methylated versus unmethylated DNA. 
DNMT1b is a somatic tissue- specific splice variant.  DNMT1o is an oocyte  specific isoform with 
a role in imprinting [49]. DNMT1p, so far observed only in pachytene spermatocytes is believed 
not to be translated due to inhibition from upstream ORFs [50]. The recently resolved crystal 
structure of DNMT1 (shown in Figure 2-3) provides considerable insight into the structure and 
functional regulation of the enzyme [51].  
 
Figure 1-3. Structural  representation of DNMT1 and its key interacting partners.  
A Functional domains of DNMT1: PBD domain is a site of PCNA replication machinery association and TS domain 
mediates heterochromatin interactions [52].  It is suggested that TS and  CXXC can inhibit substrate DNA binding in 
an auto-inhibitory function [53]. B. Crystal structure of DNMT1. Domains are colour coded as in A. C. DNA/DNMT1 
interaction showing steric clash between CXXC, TS domain and adjacent BAH1linker. Figure from [53].  
The above model suggests that the inhibitory domains CXXC, TS and a linker to bromoadjacent 
homology 1 (BAH1) domain have to be displaced in order to facilitate C- domain DNA binding.   
The auto-inhibitory effects of the DNMT1 domains fit well with the proposed maintenance activity 
for this enzyme. Furthermore, this is likely the mechanism that ensures hemi-methylated site 
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methylation is propagated without errors [54]. The TS domain appears to inhibit constitutive C- 
domain action, which highlights the requirement for specific activating factors. A proposed 
candidate for this role is UHRF1, shown to be required for DNMT1 activity in vivo [55].  
Mouse knockdown studies have shown that DNMT1 silencing leads to abnormalities ranging 
from aberrant imprinting [56], embryonic lethality [57], and reduced DNA methylation, to re 
expression of endogenous retroviruses [58]. 
DNMT1 catalytic activity can be inhibited through its interaction with the pRb protein [59]. This 
was shown in a study where the over expression of pRb in cells results in reduction of overall 
genomic 5-methylcytosine levels [60]. DNMT1/pRb interaction at promoters containing E2F 
transcription factor binding sites is a proposed mechanism for regulating DNA methylation 
events. It has been postulated that the DNMT1/pRb  interaction at precise locations in the 
genome prevents DNMT1 from binding to PCNA [61]. HDAC1 and HDAC2, two highly 
homologous histone deactelyase interact with all DNMT family members via their terminal N 
domains. The exact functional significance of this type of interaction is still unclear although a 
role in the coordination of re-methylation has been suggested [62].  
 
 DNMT2 - TRDMT1 
 
The methyltransferase DNMT2 is located on chromosome 10p15.1. The enzyme is structurally 
similar to other eukaryotic and prokaryotic DNA methyltransferases. Yet, DNMT2 so far shows 
only weak in vivo and in vitro DNA methylation activity [63, 64]. The enzyme was finally proposed 
to be involved in methylation of small aspartic acid transfer RNA  at cytosine 38 in the anticodon 
loop [65]. Consequently, DNMT2 was renamed tRNA aspartic acid methyltransferase 1 
(TRDMT1) in order to reflect better its newly established role. The mechanism employed for  
RNA methyltransferase activity resembles the catalytic process of the DNMT family, based on 
the observation that similar residues from C- domain motifs IV, VI, and VIII are involved in 
catalysis [66]. Interestingly, DNMT2 does not possess the N-terminal domain characteristic of 





DNMT3 de novo methyltransferases 
 
The DNMT3 family of de novo methyltransferases has three members; DNMT3A, DNMT3B and 
DNMT3L. DNMT3A was mapped to human chromosome 2p23, DNMT3B to chromosome 20 
q11.2 [35], and DNMT3L is located on chromosome 21q22.3 [67].  
The enzyme family appears to be highly conserved throughout evolution suggesting a critical 
function. Significant sequence homology exists between DNMT3 and DNMT1 family members. 
DNMT3s do not require hemi-methylated DNA substrate for their activity [68] and are involved 
in the establishment of de novo methylation patterns [69]. However,  DNMT3s may also be 
required for the maintenance function as shown in mouse embryonic stem (ES) cells where 
there is a level of co-operativity between DNMTs to maintain the methylation of repetitive 
elements [70, 71]. Recently, it was shown that DNMT3A/B usually co-localize with nucleosomes 
containing methylated SINE and LINE elements and with CGIs [72]. The DNMT3A/3B PWWP 
domain helps target the enzyme to pericentromeric heterochromatin, most likely via a 
mechanism that does not involve DNA /protein binding interactions. This is proposed because 
the PWWP domain of DNMT3A does not bind DNA, and DNMT3B binds non-specifically [73].  
The mechanism of action of the two enzymes is different, with DNMT3A acting in a distributive 
and DNMT3B in a processive manner [74]. This is significant in light of the suggestion that 
DNMT3B has a preference for sequences such as CpG rich satellite repeats, whilst DNMT3A 
acts more readily to de novo methylate single copy genes [74].  
It was demonstrated that DNMT3A represses transcription actively, independent of its C-domain 
and probably via its PHD domain interactions with histone deacetylases (HDAC) and HP1[75, 
76].  
The DNMT3L enzyme is catalytically inactive. It lacks several key sequences in its conserved 
region such as a PC active site and an ENV cofactor binding region. Instead, DNMT3L may play 
a role in targeting active DNMTs to specific locations in the genome. Another proposed role for 
this enzyme is in scanning highly repetitive DNA regions to direct de novo DNA methylation, as 
demonstrated by observations of silencing in male germ line retrotransposons [77]. DNMT3L, 
via its C-terminal domain, can enhance DNMT3A/B methyltransferase activity  in vitro [78].  
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Recently, it was shown that DNMT3L connects DNMT3A2 to nucleosomes in ES cells. The N-
terminal cysteine rich region of DNMT3L recognizes unmethylated histone H3K4 tails,  and 
recruits or activates DNMT3A2 to induce de novo methylation [79].  
DNMT3L expression analysis indicates significant tissue specificity, with DNMT3A 
predominantly expressed in adult tissue, embryo and ES cells, and DNMT3B in testis, - 
indicating a role in spermatogenesis [80].  Both DNMT3A and DNMT3B are found to be 
overexpressed in carcinogenesis contributing to the hypermethylator phenotype in various 
tissues such as endometrial [81], oesophageal squamous cell carcinoma [82], prostate [83] and 
breast [84].  
Studies on DNMT3A-/-, DNMT3B-/- ES cells have shown loss of de novo DNA methylation, loss 
of global methylation, and more severe embryonic defects compared with each of the single 
knockouts.  These observations have led to the proposal that the functions of DNMT3A and 
DNMT3B  in establishing DNA methylation patterns during developments overlap [85]. 
Many different isoform variants of DNMT3A/B exist, with a role in a number of epigenetic process 
ranging from establishment of global methylation patterns during embryonic development [86], 
gene regulation independent of DNA methylation and modulation of de novo methylation [87-
89]. 
 
Prokaryotic DNA methyltransferases 
 
Bacterial DNA repair mechanisms employ methylation to distinguish between parental and 
daughter strands and directly repair any replication errors. Methyltransferase enzymes are a 
component of the restriction- modification system (RM) used by bacteria for protection from 
foreign DNA, such as bacteriophages. Bacteria use restriction endonucleases to cleave and 
destroy invading DNA. At the same time,  they tag their own DNA with methyl groups to protect 
it from destruction [90]. Over 3000 such systems are known and these can be subdivided into 
three categories. Type I RM systems consist of three polypeptide components, each of which is 
allocated a specific function. ATP dependent interaction of these three polypeptides is required 
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for restriction and methylation to take place. Best characterized are Type II RM systems and 
these are most commonly used as experimental tools. The endonuclease and corresponding 
methyltransferase component act independently of each other and compete for the same DNA 
recognition sites. Type III RM systems are capable of simultaneous modification and restriction 
[91]. This is achieved through the interaction of the two components of this system coded by the 
structural genes mod and res.  Restriction enzyme activity is catalysed by both components, but 
the mod gene product can also function as a modification methylase [92].  
Another important role for DNA methylation in bacteria is to control gene expression and cell 
cycle events. This is achieved in E.Coli through the activity of the DNA adenine methylation 
enzyme (Dam) which catalyses methylation of adenine at GATC sites, leading to retention of the 
origin of replication of E.Coli. in the hemi – methylated, inactive state. This prevents further DNA 
replication events until the cell cycle is completed [93]. Gene expression is regulated through 
varying methylation patterns at bacterial transcription factor binding sites. E.Coli pathogenicity, 
for example, is influenced by methylation changes at the Dam sites in the promoter region of  P-
pili, which affects its gene expression patterns [94].  
Members of the prokaryotic methyltransferase family include M. HpaII (CCGG), M.HhaI (GCGC), 
M.SssI (CG), M.HaeIII, M.TaqI, and M. RsrI. The bacterial methyltransferases have very similar 
catalytic activity and the same highly conserved C- domain region as mammalian enzymes [95]. 
Due to their ability to target and methylate specific DNA sequences, prokaryotic 
methyltransferases are used extensively in biotechnology applications as important analytical 
and research tools. The basic mechanism of DNA methylation was to some extent unravelled 
by studying these enzymes. For example, the important concept of DNA base flipping was first 
observed from functional studies of M.HhaI. First purified from Haemophilus haemolyticus, this 
Ado-Met dependent methyltransferase methylates the internal cytosine in the tetranucleotide 
palindrome 5’-GCGC-3’/3’CGCG-5’ sequence [96]. The target base is made accessible through 
the rotation of the sugar phosphate backbone of the specific base out of the DNA helix and into 
the concave catalytic pocket of the enzyme. This minimizes  steric hindrance of the stacked DNA 
helix [97]. This mechanism of DNA base flipping is now known to be employed by eukaryotic 
DNMTs and DNA glycosylases [98] to gain access to DNA bases.  
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1.1.3  DNA demethylation  
 
The mechanistic details of DNA methylation are well understood. Remarkably little is known 
about the process of active demethylation, and we are still far from a conclusive model for 
describing the process. Proposed mechanisms include cytosine deamination, 5-methylcytosine 
DNA glycosylase enzymes, oxidation, and base excision repair enzymes [99]. It appears that 
the process of DNA demethylation can be either a passive or active one. Passive demethylation 
following replication excludes DNMT1 from the nucleus [100]. 
One active DNA methylation model proposes the existence of demethylase enzymes which 
directly remove the methyl group from 5mC, the subject of which has been controversial and 
unproven. Recent evidence of cyclical methylation/demethylation in transcriptionally active 
promoters in mammalian cells further reinforces the idea of an active rapid process [26, 101]. 
What these studies suggested is that the DNMT3A and DNMT3B enzymes initiate 
demethylation, and the authors speculate that this is achieved by the enzymes’ deaminase 
activity, based on the evidence that DNMTs can convert C to T and C to U.   
Other putative 5mC demethylases have also been put forward as potential candidates for this 
key epigenetic role, none of which have ever been conclusively confirmed. The first ever 
reported active demethylase activity was in the nucleoplasm of murine erythroleukemia cells. It  
demonstrated active removal of tritiated methyl groups from DNA methylated at HpaII sites [102]. 
This was followed by an observed ribozyme-like demethylase activity in rat myoblast whole-cell 
extracts [103], which was soon after refuted as an anomaly in experimental procedure [104]. 
Another disproved demethylase was thymine DNA glycosylase (TDG) put forward as an RNA 
dependant 5mC glycosylase initially in chick embryos, only to be shown subsequently inefficient 
at 5mC removal in vitro [105, 106]. A role for the methyl binding domain 2 (MBD2) transcriptional 
repressor which binds methylated DNA both in vivo and in vitro [107] as a putative demethylase 
was also proposed [108]. The suggestion that MBD2 can actively and independently remove 
methyl groups could not be reproduced by other labs. Studies on the nuclear protein GADD45a, 
and Xeroderma Pigmentosum complementation group G (XPG), a DNA repair endonuclease, 
led to the suggestion that this is an active demethylase. The suggestion was based on the 
observation that upon overexpression of GADD45a global demethylation could be observed 
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concurrent with the activation of methylation silenced promoter. Similarly, silencing of GADD45a 
leads to gene expression silencing and DNA hypermethylation [109]. Gene reactivation and DNA 
methylation analysis that followed this study were again unable to substantiate the original 
findings [110]. 
Recently an entirely new group of enzymes have been implicated in the demethylation process. 
The Ten Eleven Translocation (TET) family of Fe(II) and 2-oxoglutarate-dependent enzymes 
and the Activation-Induced (cytidine) Deaminase (AID) protein were initially  described as 
regulators of other processes.  TET in leukaemia and AID in antibody diversification were 
subsequently assigned a new role as the lead candidates in search for the ever elusive 
demethylase. TET proteins are capable of enzymatically generating 5- hydroxymethylcytosine 
(5hmeC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) derivatives from the initial 
methylated cytosines [111, 112]. The overview of the conversion process is shown in Figure 1-
4.  The 5- hydroxymethylcytosine (5hmeC) was suggested  to be an intermediate of the active 
demethylation pathway given the  recent observations of another two cytosine modifications;  5-
formylcytosine (5fC) and 5-carboxylcytosine (5caC). These modifications were shown to be 
generated by two step oxidative process involving 5hmeC and TET proteins [113].   
 
Figure 1-4. Proposed TET mediated active and passive demethylation process.  
 Proposed mechanism or active and passive demethylation process catalysed by TET proteins.  The conversion of 5mC 
mediated by TET leads to a formation  of a  5hmeC intermediate with a putative role in both active and passive 
demethylation process as well as a direct recruitment or displacement of various proteins.   Passive demethylation would 
probably occur in replication dependant manner, whilst the process of active demethylation would likely involve other 
5meC intermediates 5fC and 5caC and DNA repair mechanisms such as deamination mediated by AID/APOBEC, or 




Generated by oxidation of 5mC, 5hmeC is found enriched at gene promoters and CGIs in 
primary cells. It usually correlates with euchromatin and increased levels of transcription [115]. 
Studies so far indicate that 5hmeC could be a demethylation intermediate, part of a passive 
mechanism where the presence of 5hmeC impairs re-methylation or DNA repair of modified 
cytosines leads to a demethylated state [116].  
AID/APOBEC family members are another group of enzymes currently pursued for their 
possible role in demethylation, first demonstrated in zebra fish embryos [117]. 
The mechanism involves deamination of 5meC to form either 5-methyluracil (5mU) or 5-
hydroxymethyluracil. Studies in AID-/- mice show an increase in global hypermethylation [118] 
but without a profound effect on mice viability, suggesting other compensatory mechanisms 
are taking place [119]. Apart from the observed zebra fish embryo global demethylation 
activity, AID was also implicated in loci specific demethylation events. Fusion of mouse ES 
cells and human fibroblasts led to rapid demethylation at the promoter of two pluripotency 
genes Oct4 and NANOG followed by transcriptional activation [120]. However, the exact 
mechanism for its specific action in this case is unclear as AID does not possess a DNA 
binding domain. 
 
Finally, members of the UDG family of base excision repair (BER) glycosylases such as 
thymine-DNA glycosylase TDG and single-strand selective mono-functional uracil-DNA 
glycosylase 1 (SMUG1) could potentially complement existing mechanism by which the above 
cytosine intermediates are replaced, for example in partnership with TET and AID action [121, 
122]. 
1.1.4  Transcriptional regulation by DNA methylation  
 
Of all the epigenetics processes involved in neoplastic development, promoter region 
hypermethylation is probably the most prominent. In healthy cells, CGIs are normally 
unmethylated irrespective of their expression status.  
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A comprehensive study of methylation changes associated with tumorigenesis in genes which 
encode tumour suppressors, regulators of apoptosis, DNA repair, and cell cycle has shown that 
all of the genes that were silenced possessed promoter hypermethylation. Genes studied 
included tumour suppressors such as CDKN2A, CDKN2B,APC,BRCA1, DNA repair genes 
MLH1, GSTP1, MGMT and metastasis and invasion related genes CDH1, TIMP3 and DAPK 
[123].  These aberrant patterns are frequently cancer or age related. Given that these gene 
promoters easily succumb to aberrant methylation under given circumstances poses the 
question as to what keeps a gene promoter methylation free in normal cells?  
Possible reasons for the methylation free status of CGIs could be due to the high CG content of 
the islands preventing normal methyltransferase activity. However, in cancer or X chromosome 
inactivation such CpGs are obviously methylable. The probable existence of demethylase 
activities involved in the active removal of  methyl CpGs is also a possibility [124]. Finally, it is 
also likely that  TFs binding at CGIs interfere with methyltransferase access/ activity [125]. To 
better understand the mechanisms behind the occurrence of promoter hypermethylation and 
protection, we will review some key mechanisms involved in the regulation of an actively 
transcribing promoter.  
1.1.4.1  Gene transcriptional regulation in mammals   
 
Promoters contain a number of specific sequences such as transcription factors binding sites, 
transcription start site and TATA box recognition elements.  
 
Process of gene transcription commences upon RNA Pol attachment to the promoter via 
recruitment through both general and specific transcription factors. There are three major 
classes of RNA Pol enzymes: RNA Pol I involved in ribosomal RNA (rRNA) transcription, RNA 
Pol II synthesizes mRNA, small nuclear RNAs and microRNAs and RNA Pol III which plays a 
role in transcribing genes encoding tRNAs and other small RNAs.  
 
The RNA Pol II complex is over 3MDa in size comprising nearly 60 proteins which can be 
subdivided into three major components.  
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1) RNA Pol II a 12 polypeptide complex with a molecular weight of over 500 kDa 
responsible for synthesis and proofreading of RNA [126].  
2) Basal transcription factors TFIIA,TFIIB,TFIID,TFIIE,TFIIF and TFIIH that recognize and 
unwind promoter DNA [127]. 
3)  A 25 subunit large polypeptide  component with a molecular weight of 1MDa called a 
Mediator which interacts with activators and repressors [128]. 
The process of transcriptional activation can best be explained through a  step-wise model which 
proposes chromatin opening [129], followed by binding of transcriptional activators to one or 
more regulatory sequences  located in the promoter region of a gene. A key feature of this 
process is the assembly of the pre-initiation complex (PIC) mediated by basal transcription 
factors TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH. 
 
Initially, the TBP (TATA box binding protein) subunit of TFIID in co-operation with TAFs (TBP 
associated factors) binds to the TATA box.  
 
TFIIB (transcription factor II B) then joins this complex, recruiting RNA Pol II which together with 
TFIIE, TFIIF and TFIIH leads to the promoter associated formation of PIC. This assembled 
complex forms a mobile clamp around promoter DNA with the active site of the enzyme buried 
in the cleft between the two largest subunits RBP1 and RBP2. ATP dependent TFIIH helicase 
mediated promoter melting occurs leading to transcriptional initiation [130]. In the RNA Pol II 
complex the DNA is further unwound and the DNA template is transcribed into a complementary 
RNA transcript where new nucleotides get continuously added to the 3’OH end of the RNA [131]. 
Finally, promoter clearance and transcriptional elongation are facilitated through 
phosphorylation of the RNA Pol II subunit Rpb1- CTD (C-terminal domain) by TFIIH [132]. 
 
1.1.4.2  DNA methylation mediated transcriptional regulation in mammals   
 
Accumulated evidence so far suggests that promoter methylation is associated with the stable 
silencing. There are a number of proposed mechanisms by which this occurs. The first is that 
the presence of methylated cytosines directly blocks and thereby prevents methylation sensitive 
27 
 
transcription factors such as c-Myb, YY1, and MLTF from binding to their recognition sites in 
EMSA assays. The transcription factor Sp1, although insensitive to CpG methylation within its 
recognition site is sensitive to combination of CpG and non-CpG methylation in the same site, 
suggesting methylation mediated regulation of Sp1 in stem cell scenario. Insensitivity to CpG 
methylation has led to the proposal that Sp1 binding serves as a mechanism for maintenance 
of methylation - free CpG islands [133].   
The second proposed mechanism involves the binding of methyl cytosine binding domain (MBD) 
proteins, which in their function as “readers” of the epigenetic code can selectively bind to 
methylated DNA to facilitate transcriptional silence. There are five known members of the MBD 
family with MBD1, MBD2, MBD3 and MeCP2 which share a methyl - CpG binding domain with 
a high affinity for methylated DNA and are partially involved in transcriptional repression [134]. 
In contrast, MBD4 with its DNA N-glycosylase activity is believed to be involved in DNA repair 
[135]. 
The MBD protein family members “read” methylation patterns and translate them into an 
appropriate chromatin functional state. This is achieved through interactions with various nuclear 
factors [136]. MeCP2, MBD1, MBD2 and Kaiso protein when recruited  to meC  interact with co-
repressor complexes such as NurD/HDAC leading to an inactive chromatin configuration and 
gene silencing [134, 137]. MeCP2 is involved in transcriptional regulation through its 
transcriptional regulation domain (TRD) interactions with chromatin modifying enzymes such as, 
histone deacetylase corepressor Sin3a [138] or the SWI/SNF chromatin re-modelling catalytic 
component Brahma (Brm) [139].  
1.1.5  Chromatin modifications 
Chromatin is a dynamic macro molecular structure. It consists of DNA nucleosome repeats that 
can be classified into euchromatin and heterochromatin. Euchromatin is a decondensed form 
that permits transcription, whereas heterochromatin is highly compacted and transcriptionally 
silent. Heterochromatin can be subdivided into constitutive - permanently silent and facultative - 
repressed states [140].  
Histones mediate DNA organization into nucleosomes. A nucleosome consists of 147bp DNA 
wrapped in left handed superhelical turns around an octamer of core histones H2A, H2B, H3 
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and H4 [141]. Subsequent nucleosomes are connected via linker DNA of characteristic length. 
One histone linker molecule  H1 binds in the region which is at the point where DNA enters and 
exits the nucleosome [142]. Nucleosomes are further stabilized by H1: linker DNA interactions. 
DNA : histone octamer binding is through interaction with the phosphodiester backbone via three 
to six hydrogen bonds, which permits DNA sequence independent binding to the core of the 
nucleosome [143]. Tight aggregation of nucleosomes generates a transcriptionally repressed 
heterochromatin structure.  
1.1.5.1 Histone modifications 
Transcriptional activity is thought to be influenced by covalent modifications to the histone tail 
residues, which protrude out of the nucleosome. These modifications include phosphorylation 
of serine and threonine residues, acetylation of lysine residues, methylation of lysine and 
arginine, ubiquitination, sumoylation, ribosylation, glycosylation, biotinylation and carbonylation 
[144]. The modifications can mark regions of chromosome for specialized functions.  
By default, heterochromatin is non-permissive to transcription. Highly repressed chromatin 
structure arises from DNA: histone and DNA: histone tail interactions.   
Histone modifications are established through the activity of chromatin modifying enzymes. The 
four principal enzymatic systems involved in histone modification catalysis and their antagonists, 
that are involved in modification reversal, are listed in Table 1. 
Histone modifying enzyme Histone modification Antagonist 
HAT –Histone acetylase Lysine acetylation HDAC- Histone deacetylase 
Serine,Threonine Kinase  Phosphorylation PPtase- phosphatases 
PRMT- Protein arginine 
methyltransferase 
Arginine methylation Arginine Deiminase 
HKMT-Histone lysine 
methyltransferase 




Table 1-1. Histone modifying enzymes, modifications and their antagonists. 
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Most known histone modifications correlate with either activating or repressive activity in the 
cells, although splicing and replication have also been inferred. The functional consequences 
of these histone modifications are disruption of chromatin architecture which can affect DNA: 
histone interactions.Table 1-2 shows a list of best characterized histone modifications. The 
information was gathered by HIstome: The histone infobase [145]. 
Modification  Histone position 
Lysine Acetylation H3: K4, K9, K14, K18, K23, 
K27,K36,K56 
H4: K5, K8, K12, K16, K91 
H2B: K5, K12, K15, K16, K20, 
K46, K120  
H1K25, H2AK5,  
Serine,Threonine,Tyrosine 
Phosphorylation 
H1: S171, S172, S17, S186, 
S26, T10, T137, T145, T153, 
T154,T17, T30  
H3: S10, S28, S31, S6,T11,T3, 
T45, T6, Y41, H4S1 
Arginine methylation H3: R17me1, R17me2, R26, 
R2me1, R2me2, R8me2, H4R3, 
H4R3me2 




Lysine biotinylation H2A: K125,127,129,K13,K9 
H3: K18, K19, K9, H4K12, 
H4K8 




Lysine ubiquitination H4K91, H2AK119, H2AK121, 
H2BK120 
 
 For instance, HAT catalysed histone  acetylation of N-tail lysine residue results in loss of 
positive charge which can potentially weaken DNA: histone interaction [146]. This leads to a 
transcriptionally permissive, open chromatin configuration.  Similarly, HDAC mediated 
deacetylation of histones restores the lysine positive charge, promoting a strong histone: DNA 
phosphate backbone interaction resulting in formation of a condensed transcriptionally 
repressive chromatin signature.  
Gene regulation by histone modifications is further regulated through interactions with non- 
histone proteins and chromatin re-modellers. Regulated genes in their repressed state have 
promoters with nucleosomes and TFs effectively competing for the regulatory sequences. 
These promoters rely on chromatin re-modellers  for their activation [147]. 
 
In humans, there are three classes of ATP dependant re-modellers; the hSWI/SNF, ISWFI 
families and NuRD. Studies indicate that such re-modellers can expose nucleosomal DNA 
either by sliding  of  DNA  in relation to the histone octamer [148] or by conformational 
changes, which lead  to an alternate nucleosomal DNA exposure  on the surface of the histone 
octamer. ISWI re-modellers with the exception of NURF and Isw1b help organize nucleosomes 
promoting gene repression[149]. The ISWI/NURF chromatin remodelling complex is involved 
in nucleosome positioning, usually by sliding nucleosomes along the DNA [150]. In Drosophila, 
NURF catalyses progressive distribution of nucleosomes along the hsp70 promoter DNA, 
whilst maintaining the histone octamer integrity [151]. This is achieved through the use of DNA 
linkers to facilitate nucleosome sliding, to create uniform nucleosome arrays.  SWI/SNF family 
re-modellers on the other hand, disorganize chromatin by nucleosome ejection leading to gene 
activation. It is believed that they are targeted to active promoters due to their ability to bind 
acetylated histone tails [152, 153]. SWI/SNF or Brahma complexes usually work in synergy 
with chromatin modifying enzymes and use ATP-hydrolysis to influence nucleosomal 
remodelling and disrupt histone : DNA contacts [154].    
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The binding of non-histone proteins to modified histone residues can recruit further histone 
modifying enzymes. For instance, the Heterochromatin protein 1 (HP1) via its chromo domain 
reads H3K9 trimethylation to transcriptionally regulate surrounding chromatin [155]. HP1 has 
three isoforms, which can be further modified. HP1alpha, and HP1beta associate with 
heterochromatin region and serve as guardians of methyl H3K9 mediated silencing, but 
phosphorylation of HP1gamma at Ser 83 is typically associated with euchromatin and 
transcriptional elongation [156].   
As shown in Table 1 two groups of enzymes, HATs and their antagonist HADACs, catalyse the 
processes of histone acetylation and deacetylation respectively. Core histone lysine residues in 
the N-terminus are hyperacetylated in transcriptionally active genes [157], and the overall 
process of addition and removal of acetyl groups ifs facilitated by HAT (histone acetyl 
transferase) [158] and HDAC (histone deacetylase) [159] enzyme complexes respectively. 
These complexes, when targeted to gene promoter regions, create specific patterns of 
acetylation which influence transcription. HATs are brought to promoters by interaction with DNA 
bound activators resulting in the recruitment of  the general transcription machinery [160]. 
Histone tail acetylation occurs in the presence of the co-factor acetyl Coenzyme A. Acetylation 
occurs predominantly on the lysine residues of histones H3 and H4.  Transfer of an acetyl group 
results in neutralization of positive charge, and a subsequent reduced electrostatic interaction 
with DNA. This opens up the chromatin structure [161]. The lowered positive charge on 
acetylated N termini which affects the stability of DNA interactions might also be a contributing 
factor to TF recruitment. HATs can exist as Type A (nuclear) and Type B (cytoplasmic) involved 
in free histone acetylation. It has been shown that histone acetylation can also reduce 
nucleosome compaction by disrupting histone tail internucleosomal interactions [162]. 
Nuclear HATs include diverse families of Gcn5/PCAF, MYST and p300/CPB[146]. Of these, the 
best studied is p300/CBP, capable of non -histone protein acetylation, for instance the c-Myc 
oncoprotein [163]. Furthermore, the same HAT protein was shown to have a role in cell cycle 
control G1/S progression via its interaction with retinoblastoma RB [164].  
HDAC activity mediates removal of acetyl groups from N-acetyl lysine and is associated with 
transcriptional repression. The enzymes are part of a superfamily and can be divided into four 
classes (I to IV), which are then further subdivided to give 18 different members (HDAC 1-11) 
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and Sirtuin family members (SIRT 1-7)[165]. In the yeast model, permanently silent 
heterochromatin was shown to be formed through the interactions of  histone H3 and H4 tails 
with the SIR3 and SIR4 proteins, which prevents tail acetylation [166]. Apart from Class III, all 
of the HDACs are Zinc dependent enzymes [167].  
Histone methylation can also be associated with heterochromatic DNA silencing as 
demonstrated for the lysine methyltransferase enzyme Su(var)39 (Suppressor of variegation 
39),  which methylates  lysine 9 of histone H3. This modification was shown to function in 
heterochromatic silencing in D. melanogaster [168].  
 
An additional level of complexity is afforded by the fact that lysines can be mono, di or tri -
methylated, whereas arginines can only be mono or di-methylated [169, 170].  The best 
characterized lysine methylated sites are on histone H3 (K4, K9, K27, K36, K79) and histone 
H4(K20). Marks associated with transcriptional activation are histone H3K4, H3K36 and H3K79, 
whilst all the others are repressive marks [171]. 
Histone methylation is regulated by methyltransferases which aid transfer of methyl groups from 
the SAM donor site to either lysine’s ε-amino or arginine ω-guanidino group.   
HKMT-Histone lysine methyltransferase activity is mainly facilitated through the catalytic SET 
domain, in a site specific and a level of methylation specific manner (i.e. mono, di or tri 
methylation. The exception is Dot 1, H3K79 specific enzyme [146]. 
Prominent members of the SET domain super family of proteins include Suppressor of 
variegation 3-9 (SUV39), Polycomb-group chromatin regulator Enhancer of Zeste (EZ), SET1, 
SET2, EZ, RIZ, SMYD, and SUV4-20 families. The SUV39 family specifically methylates H3K9 
residues [172]. Members of the family are SUV39H1, SUV39H2, G9a, GLP1, ESET, and CLLL8 
and they can be associated with both heterochromatin and euchromatin structure [173]. For 
instance, HP1 protein was shown to associate with SUV39H1 giving rise to a repressive 
chromatin architecture [174].  
The EZ subgroup of HKMTs belongs to Polycomb repressive complex (PcG), involved in gene 
silencing. Group members EZH1 and EZH2 mediate methylation of H3K27 as a part of  
PRC/EED-EZH1/2 complex [175]. H3K27/H3K4me3 is often seen as a bivalent switch, marking 
33 
 
a region that is poised to adopt either an active or repressed state [176]. Genome wide studies 
indicate that H3K27me3 typically localizes with active promoters, throughout gene bodies, and 
in intergenic regions whilst H3K4me3 can be found at promoters and the 5′ ends of genes, 
together with histone acetylation. Recently transcribed genes are marked by H3K36me3, all of 
which suggests that specific modifications serve to index structurally and functionally distinct 
chromatin regions [177]. Arginine methylation of histone tails is catalysed by the PRMT family 
of proteins. They can be subdivided in  five Type I enzymes (PRMT1, 3, 4, 6 & 8) and a single 
Type II enzyme (PRMT5) [169].  
Initially believed to be an irreversible process, histone methylation is now known to be dynamic. 
This was experimentally confirmed with the discovery of the first histone demethylase the lysine 
specific demethylase, LSD1 [178, 179]. A explosion in the field identified a number of additional 
demethylases, which can now be grouped into three key classes; LSD1, Jumonji C domain 
containing histone demethylase (JHDM), and peptidylaragnine demethylase 4 (PADI4). LSD1 
removes methyl groups from mono and di methylated H3K4 and H3K9 residues [179, 180]. 
Nucleosomal recognition by LSD1 is conferred through its interaction with co-repressor 
complexes such as CoREST [181].  
The JHDM family of histone demethylases are capable of demethylating tri-methylated lysines 
and possess the catalytic jumonji domain [182, 183]. JHDM1 preferentially demethylates 
H3K36me1/me2; JHDM2 demethylates trimethylated H3K9 and H3K36, whilst JHDM3 shows 
preference for H3K36me3 [184].  
Histone phosphorylation is a process modulated by kinases and phosphatases and involves the 
addition or removal of a phosphate group from ATP onto the hydroxyl group of serine, threonine 
or tyrosine side chains [185].  Serine 10 histone H3 phosphorylation has been linked to 
transcriptional activation [186]. The presence of negatively charged phosphate groups along the 
histone tail is believed to reduce their affinity for DNA [187].  It has also been found that several 
HATs have an increased affinity for phosphorylated serine on histone H3 [188].  It is important 
to note however that histone phosphorylation  has also been shown to be involved in 
chromosome compaction during mitosis and meiosis, for example, H3 phosphorylation on serine 
10 and serine 28 [189] and expansion during gene expression. Both phosphorylation and 
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acetylation are  required for transcriptional activation, with phosphorylation promoting  
acetylation [190]. 
Another layer of chromatin mediated transcriptional modulation comes from histone variant 
substitutions. These substitutions appear to index chromosomes for a specialized function. For 
example, CENP-A (histone H3 centromere specific variant) is essential for chromosome 
segregation [191]. The whole process of histone variant replacement is not restricted to any 
particular phase of the cell cycle but occurs in response to on-going mechanisms. For example, 
the histone H2 variant, H2.A.X. responds to  DNA damage lesions and recruits repair complexes 
to the damaged sites [192]. Gene activation can also be influenced by the presence of specific 
histone variants such as H2A.Z. This is believed to form a less stable nucleosome, allowing 
nucleosome eviction and exposure of binding sites within a promoter [193]. H2A.Z is highly 
enriched at open TATA-less promoters [194]. This histone variant has a unique N-terminal tail 
which becomes acetylated when the gene is active. Histone variant H3.3 was shown to have a 
role in heterochromatin formation and silencing via  RNA-interference (RNAi) pathway during 
reprogramming [195].   
Modifications to the N-tail of histones have been extensively analysed. However, the core 
structure of histones can also be the subject of modifications, with knock on effects on the overall 
nucleosomal structure. An example of such modification was the observed phosphorylation of 
H3T45 mediated by kinase C-delta enzyme in neutrophil apoptotic cells [196].  
In summary, histone modifications exert their influence on chromatin architecture either directly 
or by affecting effector molecule interactions. DNA methylation of CpG residues typically 
associates with transcriptional silencing, while strong evidence proposes a mechanistical link 
between DNA methylation and histone modifications. A number of interactions coupling DNA 
methylation machinery components with histone modifiers include methyl-CpG binding proteins, 
DNMT1 and DNMT3B which were all shown capable of HDAC activity recruitment ultimately 
resulting in chromatin remodelling and transcriptional silencing [197-199]. The Polycomb group 
repressive complex component EZH2 was also shown to associate with DNMT activity in vivo 





1.2  Myelodysplastic Syndrome 
  
The Myelodysplastic Syndrome (MDS) is a heterogeneous group of a hematopoietic clonal 
stem cell disorders, manifested in progressive bone marrow failure, which often transforms to 
Acute Myeloid Leukaemia (AML). A common clinical hallmark of the disease is defective 
haematopoiesis, which affects erythrocytic, granulocytic and megakaryocytic lineages.  The 
effects are defective peripheral  blood cell production (cytopenia), as well as hypercellular 
“dysplastic looking” bone marrow [201]. MDS is characterized by cytogenetic abnormalities 
such as deletions of chromosome 5 and/or 7 in patients with poor prognosis, isolated deletion 
of 5q or trisomy 8 that define different patient subgroups [202]. The epigenetic components of 
DNA methylation, histone modifications and microRNAs are key drivers of the disease 
phenotype in MDS [203].  
 
 
1.2.1 Epigenetic factors in MDS 
 
The role of aberrant DNA methylation and histone modifications in altering neoplastic cell 
physiology has been a subject of intense interest over the last decade or so. Cancer is marked 
by several key DNA methylation events. Firstly there is a global loss of methylation from 
transcriptionally silenced loci such as repetitive elements, satellite DNA and intron located 
CpGs [204].   Increased DNMT expression in neoplastic transformations has also been 
observed for both DNMT1 and DNMT3s [205]. Finally, unmethylated CGIs become 
hypermethylated, probably as a consequence of chronic exposure to DNMTs or through a 
loss/disruption of promoter protective mechanisms[206]. Gene silencing process associated 
with promoter hypermethylation has been described for a number of genes, notably RB1, p16, 
VHL and MLH1 [207-210].  
Analysis of genome - wide DNA methylation in a large cohort of MDS patients has shown a 
change in global methylation patterns compared with age matched healthy individuals. 
Although, this review focuses on one particular gene, CDKN2B that is of interest to this project, 
it should be highlighted that promoter hypermethylation has also been observed in several 
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other genes, in MDS.  These genes are Hypermethylated In Cancer (HIC), E cadherin [211], 
and Oestrogen Receptor (ER).  The functional consequences of their transcriptional silencing 
are unknown. 65% of MDS patients exhibit Calcitonin gene hypermethylation [212], and 31%  
hypermethylation of Suppressor Of Cytokines (SOCS) SOCS-1 gene [213].  
The promoter region of the tumour suppressor CDKN2B  gene is frequently hypermethylated  
in MDS [214]. There is also a correlation between CDKN2B methylation and DNMTs over 
expression [215] in samples from patients with AML. In contrast, this does not occur in MDS 
[216]. In normal haematopoiesis CDKN2B is responsible for maintaining a hematopoietic stem 
cells in a quiescent state [217]. This gene is upregulated during  granulocytic and 
megakaryocytic differentiation and down regulated at erythroid commitment [218]. In MDS, 
CDKN2B  silencing is proposed to result in increased  proliferation of stem cells in the absence 
of differentiation leading to cytopenia and excess blasts [219, 220].  
Methylation profiling studies have shown that it is possible to use this gene as a prognostic 
and diagnostic marker for MDS. CDKN2B promoter methylation status analysis in patients with 
MDS, prior to 5-Azacytidine treatment showed promoter hypermethylation in 68%, CD34+, 
77% CD33+, 86% CD34-/CD33- cells using MS-PCR.  Following 5-Azacytidine treatment no 
significant changes in CDKN2B methylation pattern could be observed [221].  It has been 
suggested that the incidence of CDKN2B promoter methylation can be correlated with blast 
expansion and disease progression towards AML, but this is yet to be fully confirmed [222]. At 
the early stages of MDS, levels of CDKN2B promoter methylation are relatively low (23%),but 
increase with the disease progression [223]. Gene inactivation and observed CDKN2B 
promoter hypermethylation is associated with high risk MDS, with incidence ranging from 58% 
for Chronic Myelomonocytic Leukemia (CMML) [224] to 60-75% in MDS/AML [225]. CpG 
methylation density and frequency in therapy - related MDS and AML was shown to increase 
disease progression and severity and is prevalent in patients with 7q deletions [226]. Histone 
modifications have also been implicated in carcinogenesis related changes in gene expression 
patterns. Histone modifying enzymes were observed to be genetically altered, translocated, 




Examples of such events include acetyltransferase CBP  mutation and  H3K4 methylase MLL 
re-arrangement in acute leukaemia [227, 228]. An activating mutation of Janus kinase 2 
(JAK2) tyrosine kinase was shown to phosphorylate histone H3Y41 thereby preventing its 
interaction with HP1α in haematological malignancies [229]. Another H3K9 methylase RIZ-1 
was shown to be downregulated in Chronic Myelogenous Leukaemia (CML) patients [230] and 
in prostate cancer overexpression of H3K27 tri-methylase, EZH2, directly co-relates with the 
disease progression [231].  
 
1.2.2  Methyltransferase Inhibitor therapy 
 
DNA methyltransferase inhibitor (MTI) drugs are currently being investigated for their potential 
therapeutic applications in the treatment of cancer. The observation that CDKN2B promoter 
hypermethylation, is potentially reversible has led to attempts to use MTIs as a treatment 
alternative in MDS [222]. Treatment of MDS patients with MTIs such as 5- Azacytidine (5-Aza) 
and its nucleoside analogue 5 Aza 2’ deoxycytidine was shown to be effective in Phase III trials 
in up to 60% of patients [222]. 5- Azacytidine is a cytotoxic nucleoside chemical compound first 
synthesized in 1964. It was shown to incorporate into DNA and  bind to DNMTs irreversibly [232]. 
Furthermore, 5-Aza leads to genome - wide DNA demethylation and inhibition of de novo 
methylation [233]. Three Cancer and Leukemia Group B (CALGB) and a Phase III randomised 
study have been conducted so far to assess the effectiveness of 5-Aza in MDS treatment. These 
studies indicate an overall response rate of around 50%, with 12% achieving complete 
remission, 15-25% partial remission and 12%-27% an improvement in their blood counts. All 







1.3  CDKN2B – Role in the Cell Cycle  
 
The mitotic cell cycle involves the duplication of chromosomes and other cellular components 
and their subsequent segregation into each of two daughter cells. The fidelity of the process, its 
timing, and coordination, is tightly regulated by a cell cycle control feedback loop system. Cyclin 
- Cdk complexes are extremely important in these processes (Figure 1-5). The loop consists of 
several significant stages and checkpoints: Gap 0 (G0) cell resting phase, Gap 1 (G1), first 
checkpoint, Synthesis (S), DNA replication phase, Gap 2 (G2) second checkpoint, and Mitosis 
(M), cell division stage.     
 
1.3.1  Cell cycle control system 
 
The cyclin dependent kinases (Cdk) are a family of serine/threonine kinases (34-40kDa) 
involved in cell cycle control. There are twelve known human Cdks all showing characteristic 
motifs [234]. These include a T – activation loop, the PSTAIRE and L12 helix, the highly 
conserved 100 amino acid Cyclin Box, required for Cdk binding and activation, and the 
Degradation Box located in the N – terminal region, which confers specificity to different classes 
of cyclins. The process of Cdk activation involves binding of ATP at the Cdk active site which is 
usually shielded by the T loop, followed by binding of a cyclin at the cyclin box, which results in 
conformational changes that facilitate phosphotransfer from ATP to the neighbouring threonine 
residue, catalyzed by Cdk-activating kinases CAK [235]. The levels of cyclin proteins were found 
to oscillate as the cell cycle progresses [236]. Transition through the early stages of the cycle is 
associated with activation by Cdk6-cyclin D3 and Cdk4-cyclin D2/3 complexes. Cells are 
prevented from entering cell cycle quiescence by inhibition of these complexes by the INK4 
family  of proteins (p16INK4A,  p15INK4B, p18INK4C, p19INK4D) and Cip/Kip proteins (p21Cip1, p27Kip1 
and p57 Kip2). Two other pertinent factors in G0/ G1 progression are the pRB and p130 proteins. 
Initially hypo - phosphorylated in quiescent cells, these proteins are capable of restricting 
transcription through binding to various transcription factors such as E2Fs and by recruiting 
HDAC and other chromatin modifiers. Phosphorylation of pRb and p130 by Cyclin D-cdk4/6 and 
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Cyclin E-Cdk2 to hyper – phosphorylated states releases E2F transcription factors from 
repression. E2Fs then induce genes that are required for entry into S - phase and transition 
through the remainder of the cell cycle. Cyclin E –cdk2 complexes are rapidly degraded by the 
anaphase promoting complex (APC) as the cell enters S phase followed by the Cyclin A-cdk2 
activity through the proliferating cell nuclear antigen (PCNA) interaction. These interactions lead 
to DNA replication initiation, followed by inhibition of new replication complexes thereby 




Figure 1-5.  The cell cycle control checkpoints. The cell cycle is characterized by DNA replication and chromosome duplication is S phase, followed by M phase, which is composed of mitosis 
and cytokinesis. The two phases are separated by gap phase G1 before S phase and G2 before M phase. These two phases allow the cell to respond to external stimuli or internal DNA damage. During G1, 
the cell becomes committed to enter S – phase by passing the Restriction Point.  G0 phase is a prolonged nondividing stage. Different Cdk/Cyclin complexes govern different phases of cell cycle transitions, 
where each cyclin-cdk complex acts on the next step in the sequence, ensuring orderly progression through the cell cycle stages. Figure adapted from [238].   
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1.3.2 Cdk inhibitors 
 
There are two distinct groups of cdk inhibitor proteins, which can be grouped into INK4 and 
Cip/Kip families. The Inhibitor of cyclin dependent kinase 4 (INK4) family specifically inhibit cdk4 
and cdk6 [239]. They share a common 32 amino acid ankyrin motif, a protein-protein interaction 
domain which enables each member of the family to bind to cdk [240].  p16INK4A encoded by 
CDKN2A shares 82% sequence homology with p15INK4A which encodes CDKN2B.  
The expression of CDKN2B is stimulated by Miz-1 regulatory protein during quiescence. Miz-1 
binds to the Initiator response (Inr) region of CDKN2B.  It then interacts with the Myc/Max 
complex, which is also recruited to the CDKN2B promoter region to inhibit its transcriptional 
activation [241]. CDKN2B expression was observed to increase dramatically upon stimulation 
with anti-mitogen transforming growth factor beta (TGF-β) [242]. The process is mediated by the 
SMAD group of proteins. SMAD activity is directed at Miz-1 either directly, or through E2F4 and 
5 mediated c-Myc inhibition [243]. Loss of CDKN2B function arsing as a consequence of DNA 
deletions or mutations results in increased proliferation. This was shown in studies on a 
hematopoietic CD34+ pluripotent progenitor stem cells, consistent with a role for CDKN2B in 
maintaining quiescence [244].  
Other members of the INK4 family are p18INK4C encoded by CDKN2C and p19INK4D encoded by 
CDKN2D. CDKN2C is required for T cell quiescence [245] and CDKN2D may be required in 
proliferating macrophages during S – phase [246]. The INK4 group of proteins binds cdk4 and 
cdk6 that are not bound by cyclins, whereas Cip/Kip family members bind cdk-cyclin complexes 
[247]. 
 p21Cip1   is encoded by CDKN1A. The gene is induced during the G0-G1 transition and acts as 
a chaperone that enhances cdk-cyclin stability. It can also be induced at higher levels for 
example by p53, leading to cell cycle arrest at G1 and G2/M. This protein  acts as a cyclin 
dependent kinase inhibitor of cyclin-cdk2 and Cyclin –cdk4 complexes [248]. Several  other roles 
for CDKN1A have been proposed in DNA damage responses such as S phase DNA replication 
via PCNA interactions [249], and  apoptosis [250]. p27Kip1 encoded by CDKN1B has a role in 
regulating the transition from G1 to S. In quiescent cells it binds and inhibits cyclin E-cdk2. In 
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response to mitogenic stimulation, the cdk – cyclin complexes are re –sorted; CDKN1B is 
phosphorylated by one of the three kinases LYN, BCR-ABL or SRC [251, 252] , polyubiquilated 
by the SCF complex, and degraded by the proteosomes pathway [253, 254].   
 
1.4    Project Description 
 
This project will study the epigenetic and functional consequences resulting from variable 
targeted DNA methylation of the CDKN2B gene promoter. The rationale for initially targeting 
specific promoter regions is based on transcription factor binding site information. Previous work 
in our lab has highlighted methylation patterns in MDS patients where just the CpGs present 
within the c-Myb or YY1 sites are methylated, suggesting such methylation as a potential early 
event in CDKN2B gene shutdown. Zinc finger methyltransferase fusions have been designed to 
target these regions. Synthetic, CDKN2B promoter - specific zinc finger modules fused with 
prokaryotic methyltransferase have been used to determine the role methylation plays in 
regulating transcription processes in the context of aberrant methylation in disease. Previous 
studies in our department showed a variable methylation of CDKN2B promoter in MDS. The 
promoter methylation study in myeloid, lymphoid and CD34+ stem/progenitor cells obtained from 
MDS patient samples showed a low level, non-clonal and variegated methylation patterns 
(Figure 1-6). The study further confirmed previously reported intra- and inter-individual 












Figure 1-6.  The variable methylation patterns at the CDKN2B promoter in MDS  
This figure originates from [256] and shows CDKN2B promoter methylation analysis of MDS patients samples. Patients 
presented with chromosome 7 loss, with and without deletion of 17p or normal cytogenetics. The myeloid (CD33+), 
lymphoid (CD3+, CD19+) and CD34+ stem/progenitor cells were isolated from the bone marrow of the 17 patients and 












1.4.1    Zinc finger module platform technology 
 
Classical zinc finger proteins (ZFP) Cys2His2(C2H2) were first discovered in the transcription 
factor TFIIIA and are now known to exist in 2% of all human transcription factors [257]. The zinc 
finger domain typically has  two antiparallel beta strands and an alpha helix (ββα) structure of 
around 30 amino acids in size, stabilized by the presence of a zinc ion bound by two cysteine 
residues in the β sheets, and two histidine residues in the α helix.  Alpha helix residues contain 
DNA interacting regions with key amino acids (circled and numbered relative to their helical 
positions in Figure 1-7), capable of contacting three base pairs of DNA. The specificity of the 
zinc finger can be manipulated through the variation in the way the helix is presented. As a 
consequence, the zinc finger motif has been widely used as a template for the rational design 













Figure 1-7.  The Zif268- DNA showing key residues involved.  
A DNA helix (in blue) interacting with a three module ZF. Each domain is coloured differently. Zinc ions which help to 
stabilize the structure are shown in grey. There is more than one zinc ion shown probably an artefact from x-ray 
crystallography. B.The key residues involved in making contact are colour coded  -1,2,3 and 6 relative to the first amino 
acid residue of the helix have a major impact on the sequence specificity. Other residues in the vicinity also play an 
important role in DNA binding interactions.   Reproduced from [258].  
 
Much of the information on zinc finger DNA interactions comes from studies on the three zinc 
finger protein Zif268 [259]. Zif268 has been one of the most frequently used zinc fingers in a 
variety of design, modelling and DNA targeting studies due to its well -known and characterized 
structure [260]. Initially discovered in mouse, Zif268 is also known as Early growth response 
protein1 (Egr1), and it is a three zinc finger of the C2H2 type, with a pair of cysteine residues on 
the β strand and a pair of histidines on theα helix, held together by a zinc ion.  
The strategy to design and assemble a zinc finger protein employs either combinatorial selection 
of ZFPs or modular assembly of zinc finger arrays. The later approach was utilized for the 
purposes of this project.  
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The combinatorial strategy approach uses phage display to select a protein that binds specific 
DNA regions being studied. M13 filamentous bacteriophage is used to express on its surface 
pools of zinc finger proteins in which key residues of α helix involved in DNA recognition are 
randomised. The bacteriophage that binds to the DNA sequence of interest is then selected, 
amplified and sequenced to establish the identity of the amino acid residues involved in DNA 
recognition. Work on zinc finger phage display libraries has revealed that zinc finger DNA 
interactions predominantly follow a set of rules with specific amino acids targeting specific bases 
in a triplet configuration. 
The rational design of zinc finger proteins involves the generation of modular units where each 
module of the three ZFP recognizes three base pairs of DNA 5’-GNN-3’, 5’-ANN-3’, 5’-CNN-3’ 
and 5’-TNN-3’ subunits [261-264]. The specific ZF modules can be selected using databases 
such as the Zinc Finger Consortium of published recognition triplet sequences. One drawback 
of this approach is that modules targeting certain triplets such as GTG and GCG, show low 
sequence specificity and can result in poor gene targeting of the assembled arrays [265].  
ZF proteins can be made more specific by module - linking and recombination to increase the 
array size e.g. create four or six ZFPs, capable of targeting more extended 12bp and 18bp DNA 
contiguous sequences (Figure 1-8). For in vivo targeting studies this kind of set up should 
provide the highest level of specificity given that the probability of 18bp sequence occurring more 
than once in the genome is once in 68x109 bp of sequence. These kind of arrangements have 
been observed in nature with five finger human glioblastoma protein and nine finger TFIIIA [266, 









Figure 1- 8. Zinc finger assembly.   
Three zinc finger modules capable of recognizing 9 base pairs can be linked via TGKEP linker (horizontal bar) to create 
six finger proteins. Figure adapted from [257].   
 
 
Zinc finger proteins can be fused to a variety of different molecules such as gene repressor and 
activators as well as functional domains such as methylases, integrases and nucleases, 
enabling diverse applications [268]. Six finger polydactyl ZFproteins fused with the VP16, 
transcriptional activation domain and the Krupel associated box A repression domain were 
shown to bind with very high  affinities to their target region [269].  
 
1.4.2 Zinc fingers methyltransferase fusion  
 
The ability to methylate endogenous gene promoter regions would facilitate further 
investigations into the role methylation plays in transcription/translation mechanisms associated 
with that gene, and enable us to mimic the early onset aberrant methylation that has been 
suggested to occur as part of the disease process. For the purpose of this project, de novo 
methylation will be targeted at the CDKN2B promoter using zinc fingers fused to 
methyltransferase catalytic domains with different specificities. Targeting mitochondrial DNA  
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using synthetic zinc finger fused to the catalytic domain of DNMT3A showed that these systems 
can bind selectively and cause site - specific methylation at the target sites [270]. Intracellular 
localization studies in this case showed mitochondrial localization of these ZFP – methylase 
proteins [271]. Targeted methylation has been carried out initially using non-genomic targets. 
Targeting constructs harbouring the TK (Human herpes virus 1 thymidylate kinase), c-Has-ras 
promoter and the immediate early IE175k promoter of HSV with promoter - specific zinc fingers 
and a catalytic domain of mouse DNMT3A and DNMT3B methyltransferases was shown to lead 
to gene repression. Furthermore, it was demonstrated that targeted methylation led to a 
decidedly distinct pattern of dense methylation observed on both strands of DNA [272].  
These observations were followed by our own studies of targeting DNA cytosine methylation to 
a TK promoter driving a CAT reporter gene,that had been integrated into the genome of NIH3T3 
cells. The TK promoter contained zinc finger recognition sites and was flanked by HpaII and 
HhaI sites.  Methylation was targeted using four - zinc finger HpaII fusions linked by a (Gly4Ser)3 
linker and led to gene silencing and the formation of repressive chromatin. It was also 
demonstrated that this gene repression was epigenetically maintained, through many cell 
divisions, long after the loss of the targeted methyltransferase enzyme from the cell, presumably 
through the action of the endogenous cellular methylation machinery. This important study by 
our group showed that DNA methylation could be targeted to a specific site in the genome and 
proved that a repressive histone code could be initiated as a consequence [273].  
In the Chapters to follow in this thesis, I will give a detailed description of the ZF specific 
sequences targeting the CDKN2B promoter region and the rationale for the selection of the 
target sites.  Further, the cloning and assembly strategy employed to construct site-biased ZFP-
methyltransferase fusions will be described. Different approaches to characterize and evaluate 
the specificity, binding affinity and activity of the target fusion proteins will be presented. Finally, 
I will demonstrate successful regional methylation delivery to the key regulatory CDKN2B 
promoter region by some of the targeted methyltransferases, which represents a significant 





















2.1 General consumables and reagents 
 
Phosphate Buffered Saline (PBS)  
Dimethyl sulfoxide (DMSO) 
Bacto tryptone 




Cell culture media 
Glycerol 
Glutathione- Agarose 
Isopropyl β-D thiogalactoside (IPTG) 
X-Gal 
Xylenol orange 
Coomassie Blue R-250 
N,N,N’,N’-Tetramethylethylene diamine (TEMED) 
Glycogen 
Whatman 3MM paper 
Sigma  
40% (w/v) Acrylamide/Bis Solution 37.5:1 Bio Rad 
Hybond-c extra membrane 
Electrogenerated chemiluninesence (ECL) detection 
kit 
Glutathione sepharose 4B 
GE Healthcare 
Topo-TA vector 
TOP10 Competent cells 
Trizol 
Novex Sharp protein marker 
Invitrogen 
DNA Miniprep kit 
RNAeasy extraction kit 
Genomic DNA kit 
Epitec Bisulfite kit 




Microcentrifuge ‘Eppendorf’ tubes 1.5ml 
PCR tubes 0.2ml 
Pipette tips  
Neubauer Improved Haemocytometer 
Starlabs 
Spin-X Centrifuge Tube Filter Costar 

























NEB buffers 1,2, 3 and 4 
EcoRI buffer 
Calf Intestinal Alkaline Phosphatase (CIP) 
T4 Ligase 
Standard Ligase Buffer 
NEB Express Competent E.coli 
Phusion High-Fidelity DNA Polymerase 
Deoxyribonucleotide triphosphate (dNTP) 
S- adenosylmethionine (SAM) 
New England Biolabs 
18s VIC labelled RT-PCR 
RT Taqman Kit 
Applied Biosystems 
 
2.3 Tissue culture reagents and consumables 
 
Dulbecco’s Minimal Essential Medium (DMEM) 
Rosswell Park Memorial Institute medium (RPMI-1640) 





Tissue Culture plates and flasks 
Falcon tubes (15ml and 50ml) 
Pipettes (5, 10, and 15ml) 
VWR international ltd 
RT Mix for RT-PCR 
IcaFectin™ 441 DNA Transfection Reagent 
Eurogentec 
Cell Line Nucleofector Kit V and R Amaxa 




2.4  Solutions and Buffers 
 
Annealing Buffer 0.1M Tris-HCl, 100mM MgCl2 
GST resuspension buffer (RP1) 50mM Tris-HCl (2.5ml 1M Tris-HCl pH 7.5), 1M NaCl (10ml 
5M NaCl), 1mM EDTA (100µl 0.5M EDTA), 1mM EGTA (2ml 
25mM EGTA), 100µM ZnCl2 (5µl 1M ZnCl2), 0.1mM DTT (5µl 
1M DTT) and distilled water (dH2O) to 50ml.  
GST Elution Buffer (RP2) 10mM reduced glutathione: 0.0154g Glutathione, 4ml 50mM 
Tris-HCl, (pH 7.5) and 1ml glycerol. 
Luria-Bertoni (LB) Broth 1% (w/v) bactotryptone 0.5% (w/v) yeast extract, 0.5% (w/v) 
NaCl. Autoclaved and ampicillin added to a concentration of 
100 µg/ml. 
LB-Agar LB broth, 1.5% (w/v) agar. Ampicillin to a final concentration of  
100µg/ml 
10x TBE 0.9 M Tris-HCl, (pH 8.0), 0.9 M Boric Acid, 12.5mM EDTA 
10xTAE Buffer 10mM Tris-HCl (pH 8.0), 1mM EDTA 
Ampicillin (1000x stock) 100mg/ml in dH2O 
Sodium Dodecyl Sulphate (SDS) 
loading buffer 
4% SDS (w/v), 0.1 M Tris-HCl (pH 8.9), 2mM EDTA, 0.1% 
(w/v) bromophenol blue 
RNAase A 10 mg/ml in dH2O 
STE(TEN) 0.1M NaCl,10mM Tris-HCl (pH 8.0),  
1mM EDTA (pH 8.0) 
MPI (miniprep buffer 1) 50mM Glucose, 25mM Tris-HCl (pH8.0), 10mM EDTA, dH2O 
to 100ml. Autoclaved and stored at 4 ̊ C. 
MPII (miniprep buffer 2) 0.2M NaOH, 1% SDS (w/v) 
MPIII (miniprep buffer 3) 5M KoAc 60ml, Acetic acid 11.5ml, dH2O 28.5ml. Autoclaved 
and stored at 4 ̊ C.  
4x Upper buffer(stacking gel) Tris-HCl 0.5M, dH2O to 1L and pH to 6.8, SDS 0.4% (w/v). 
4x Lower buffer (running buffer) Tris-HCl 1.5M, dH2O to 1L and pH to 8.8, SDS 0.4% (w/v). 
Coomassie Blue Stain 230ml Methanol (MeOH), 230ml water, 40ml Acetic acid, 2g 
Coomassie - R 250.  
Coomassie destain solution 30% MeOH, 10% Acetic acid (v/v), dH2O 1L. 
DNA loading Buffer 30% (v/v) Glycerol, 0.25% (w/v) Orange R.  
 
DNA Elution Buffer (EB) 10mM Tris-HCl (pH 8.5) 
T4 DNA Ligase Buffer 50mM Tris-HCl (pH 7.5), 10mM MgCl2, 10mM dithiothreitol, 
1mM ATP. 
NEB Buffer 1 10mM Bis Tris Propane-HCl, 10mM MgCl2, 1mM dithiothreitol 
(pH 7.0) 
NEB Buffer 2 50mM NaCl 50mM Tris-HCl, 10mM MgCl2, 1mM dithiothreitol 
(pH 7.9) 
NEB Buffer 3 100mM NaCl 50mM Tris-HCl, 10mM MgCl2, 1mM dithiothreitol 
(pH 7.9) 
NEB Buffer 4 50mM potassium acetate 10mM Tris-acetate, 10mM 
magnesium acetate, 1mM dithiothreitol (pH 7.9) 
BSA Storage Buffer 20mM KPO4 50mM NaCl, 0.1mM EDTA, 5% glycerol (v/v) (pH 
7.9) 
EcoRI Buffer 50mM NaCl, 100mM Tris-HCl, 10mM MgCl2, 0.025% Triton X 
-100 (v/v) (pH 7.5) 
ChIP Sonication Buffer 50mM Hepes pH 7.9, 140 mM NaCl ,1 mM EDTA , 1% Triton 
X-100, 0.1% Na-deoxycholate , 0.1% SDS, 0.5 mM PMSF, 
Protease inhibitor cocktail (Roche) 
ChIP Wash Buffer A 50mM Hepes pH 7.9, 500 mM NaCl ,1 mM EDTA , 1% Triton 
X-100, 0.1% Na-deoxycholate , 0.1% SDS, 0.5 mM PMSF, 
Protease inhibitor cocktail (Roche) 
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ChIP Wash Buffer B 20mM Tris, pH 8.0, 1mM EDTA, 250mM LiCl, 0.5% NP-40, 
0.5% Na-deoxycholate, 0.5 mM PMSF, Protease inhibitor 
cocktail (Roche) 
ChIP Elution  Buffer  50mM Tris, pH 8.0, 1mM EDTA, 1% SDS,50mM NaHCO3 
2x PHEM  Buffer 100mM PIPES, 10mM HEPS, 10mM EGTA, 2mM MgCl2 pH7.  
PFA Buffer  PFA 3.75%, 10mM KOH, 5m dH20, 5ml 2x PHEM Buffer.  
 
2.5 Primers, probes and oligonucleotide sequences 
Al the primers and oligonucleotides were purchased from either MWG Biotech (Eurofins Operon) 











































Zp15-all F 5’-CATATGAGATCTGGAGGCGGTGAACGC-3’ Forward primer 
ZFP 
amplification 
Zp15-all R 5’-AAGCTTGCCGGATCCCTTTTCCC-3’ Reverse 
primer ZFP 
amplification 































P15LF1 5’-GCGCAAGCTTATGACAGGTTCAGCCTGTTTAAT-3’ Forward primer 
for CDKN2B 
amplification. 










































oligo strand.  
3'HPA 1 
BIS F3 
GGA GGG TAA TGA AGT TGA GTT TAG G COBRA 3’ 1st 
round 
3' HPA 1 
BIS R2 
CTC CTT TTC TCC CCA ATT CAA TC COBRA 3’ 1st 
round 
3' HPA 2 
BIS F1 




TCT CCC CAA TTC AAT CTA TTC C COBRA 3’ 2nd 
 Round 
 
F1 AGT TTA AGG GGG TGG GGA GA COBRA 5’  
round 
R1 CCA CCC TAA CCA AAC CCT CAT C COBRA 5’  
round 
F2 GAG TTT AAG GGG GTG GGG AGA COBRA 5’  
round 









GAC ACC CAT GAG AGC TTT TCC C TET PCR 
TET2 R 
 
AGA GAA GGA GGC ACC ACA GGT T TET PCR 
TET2 F 
 
GCT TAC CGA GAC GCT GAG GAA A TET PCR 
TET3 F 
 
CCA CAA GGA CCA GCA TAA CCT C TET PCR 
TET 3R 
 












TCG AAC AGG AGG AGC AGA GAG CGA ChIP 
GAPDH 
For 5' 
TAC TAG CGG TTT TAC GGG CG ChIP 
ET1 REV 
 
GCA GAG GCG CGT CTG ACT T ChIP 
ET1 FW 
 
TGC ACG TTG CCT GTT GGT ChIP 
 
 









pGEX5mcs  GST purification and expression plasmid Bacterial cells 




pCMV Expression plasmid with CMV promoter Mammalian 
cells 






















Rat anti mouse 
IgG1 
BD Pharmingen™  
553443 
IF 
Alexa Fluor® 633 
Goat anti-rabbit IgG 





















Active Motif  
39769 
IF 
Alexa Fluor® 488 –
rabbit polyclonal 
antibody 




Alexa Fluor® 633 
rabbit polyclonal 
antibody  





mouse IgG (H+L) 
Life Technologies  
A11059 
IF 
























2.8 DNA and RNA procedures 
 
2.8.1 DNA electrophoresis 
 
Agarose powder was dissolved in 1x TAE, or 1x TBE buffer to 1-2% (w/v) by boiling in a 
microwave oven. After cooling to ~ 50°C, ethidium bromide was added to a final concentration 
of 0.5µg/ml and the gel solution was then poured into a tray with removable combs and left to 
set at room temperature. Loading dye was added to DNA samples prior to gel loading and 
running, typically at 80V for 20-50 minutes (depending on the size range of DNA to be analysed 
size). DNA was visualized on a UV transilluminator. DNA ladders of known sizes were used to 
determine the size and the approximate concentration of the DNA.  
 
2.8.2 DNA Purification 
 
Agarose gel slices containing the desired DNA fragment were placed in a Spin-X column, 150µl 
dH2O was added, the tube frozen at –20°C for 30 minutes.  The sample was then centrifuged at 
14,000xg in a microcentrifuge (which was the speed for all subsequent centrifugation steps) for 
10 minutes. 300µl of phenol/CHCl3/IAA (25:24:1) was added to the filtrate and the solution 
vigorously vortexed then centrifuged for 2 minutes. The upper phase layer was carefully 
removed to a fresh tube for a further phenol extraction. DNA was precipitated by addition of 1µl 
of glycogen, briefly mixing and then adding three volumes of 100% ethanol (EtOH) (-20°C). After 
storing at -20°C for 30 minutes, the solution was centrifuged for 20 minutes. EtOH was carefully 
removed, the DNA pellet washed with 0.5ml of 70% v/v EtOH and centrifuged for 5 minutes. The 
EtOH was removed by aspiration, the pellet air dried and resuspended in 50µl EB buffer.  The 




2.8.3 Genomic DNA extraction and Bisulphite modifications 
 
The Genomic DNA Kit (Qiagen) was used for genomic DNA extractions. The EpiTec ® Bisulfite 
Kit (Qiagen) was used for bisulfite modification. Manufacturer’s instructions were followed for 
both procedures. Briefly, genomic DNA was extracted from several human cell lines and the 
DNA concentration determined at 260nm using a Nanodrop 1000 (Thermo Scientific). Genomic 
DNA (1µg) was converted with sodium bisulphite treatment using EpiTec® bisulphite kit (Qiagen) 
in a 140µl total volume reaction containing 85µl of Bisulphite Mix, 35µl of DNA Protect Buffer 
and DNA. The bisulphite conversion was performed in a thermocycler with following settings: 
Step Time Temperature (°C) 
Denaturation 5 minutes 99 
Incubation 25 minutes 60 
Denaturation 5 minutes 99 
Incubation 3 hours 60 
Denaturation 5 minutes 99 
Incubation 6 hours 60 
Hold Indefinite 20 
 
Following bisulphite conversion, the PCR tubes were centrifuged briefly and the sample 
transferred to a new microcentrifuge tube. Buffer BL (560µl) containing 10µg/ml carrier RNA was 
added to the samples, mixed by vortexing, centrifuged briefly and transferred to an EpiTec spin 
column. The column was spun at 13,000xg (which was the speed used for all following 
centrifugation) and the flow through discarded. The column was washed with 500µl of BW Buffer. 
DNA desulfonation was carried out by addition of 500µl of Buffer BD and incubation for 1 hour 
at 37°C. The column was spun again to remove the flow through and washed twice with 500µl 





2.8.4 Combined Bisulphite Restriction Analysis (COBRA) 
 
Bisulphite converted DNA was PCR amplified using a nested PCR approach which involved 
using two sets of primers in two successive PCR reactions. In the first reaction typically multiple 
PCR products are generated, visualised as a smear on an agarose gel. This is used as a 
template for a second PCR, using primers which are “nested” within the first set, which typically 
generates a single product. The typical cycling conditions are given in the table below. This PCR 
product was digested with methylation sensitive enzymes (Combined Bisulfite Restriction 
Analysis (COBRA) in order to determine approximate methylation status. Specifics for different 
target products are explained in more detail in Chapter 4 of this thesis. Additionally bisulphite 
PCR libraries were directly sequenced (commercially) or TOPO®-TA cloned if evaluating 
individual clones.  
 
 
Cycles Temperature Time Requirement 
1 95oC 5 minutes Enzyme activation 
 
  35 
95oC 30 seconds Denaturation 
54/57oC  2 minutes 40 
seconds (1st 
round PCR), 50 
seconds (2nd 
round PCR) 
Primer annealing temperature 
72oC 1 minute 20 
seconds 
Elongation 








2.8.5 Restriction Digests 
 
Typically restriction digests contained 2µl of 10x restriction enzyme buffer, 2µl 10x Bovine Serum 
Albumin (BSA, 1mg/ml), 0.5-1µl of restriction enzyme(s) (5-10 units/µl), 1µl RNAase (1mg/ml) 
and 3µl of DNA (approximately 1µg) in a total volume of 20µl.  All digestions were incubated 
between 1 and 2 hours at the appropriate temperature. Vector DNA to be used for cloning was 
additionally treated with 1µl (10 units/µl) of Calf Intestinal Phosphatase (CIP) during the 
restriction process. CIP treatment of the vector DNA removes 5’ phosphate groups, thereby 
reducing self-ligation.  
The table below lists single and double digests used for different cloning procedures. 
Enzyme(s) Buffer  Cloning procedure 
EcoRI EcoRI buffer  TOPO®-TA 
HindIII/NdeI NEB buffer 2  pGEX/ZFP subcloning 
BamHI/NotI NEB buffer 3 pGEX/ZFP/HpaII subcloning 
BamHI/HindIII  
BglII/HindIII 
NEB buffer 2 pGEX/ZFP A+B 6 ZFP subcloning 
XhoI/HindIII NEB buffer 2 pBLCAT/CDKN2B subcloning 
XbaI/BglII NEB buffer 2 Litmus 28i vector cloning 
NdeI/AccIII NEB buffer 2 pCMV-SssI ZFP subcloning 
  
 
2.8.6 DNA cloning  
 
2.8.6.1 pGEX ZFP Cloning 
Assembled zinc fingers (see 2.8) were excised from TOPO®-TA vectors using R.NdeI/Hind III 
double digests.  The pGEX -5mcs plasmid was digested using the same set of enzymes. DNA 
was separated by agarose gel electrophoresis and the fragments of interest were gel extracted 
and ligated as described in section 2.7.2. This generated the three zinc finger vectors ZFPA and 
ZFPB. 
The six zinc finger vector was assembled as a fusion of ZFPA and ZFPB modules. The pGEX 
ZFPA vector was R. BamHI/HindIII restricted to accept the R. BglII/HindIII restricted ZFPB 
fragment. For M.HpaII cloning for example, the pGEX ZFA plasmids were double digested using 
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R. Bam HI/NotI enzymes. This was used as a platform for subsequent swapping of ZF 
components. 
2.8.6.2 pBLCAT CDKN2B Cloning 
The pBLCAT plasmid was digested with R. XhoI/HindIII enzymes and the CDKN2B-730 R. 
XhoI/HindIII fragment was subcloned into this vector.  
 
2.8.6.3 TOPO®-TA Cloning  
All TOPO vector cloning procedures were carried out using the TOPO®-TA cloning kit and 
TOP10 competent cells. The typical reaction volume was 6µl, consisting of 1µl Salt solution 
(1.2M NaCl, 0.06M MgCl2), 1µl (5ng) TOPO- TA vector and 4µl DNA fragment (~100ng). The 
reaction was incubated for 5 minutes at room temperature then added to 50µl of competent 
TOP10 cells for transformation, as described in section 2.7.8.  
2.8.6.4 Litmus 28i Cloning  
The Litmus 28i vector was digested using R. XbaI/BglII enzymes. Oligonucleotides harbouring 
either zinc finger recognition sites or non-relevant specific DNA sequences were heated for 5 
minutes at 100 ̊ C in annealing buffer and allowed to anneal by cooling to room temperature 
overnight. Annealed oligonucleotides with XbaI/BglII overhangs were subcloned into the Litmus 
28i vector. Positives clones were confirmed by sequencing.  
 
2.8.7 DNA Ligations 
 
DNA ligations were typically carried out in a 20µl reaction volume containing 2µl Ligase buffer, 
1µl T4 Ligase (10 units/µl) and a ratio of vector to insert DNA typically between 1:3 to 1:5. 
Ligation negative controls containing no insert DNA were also set up. The reaction was 




2.8.8 DNA Transformations 
 
Chemically competent TOP10 cells (genotype F- mcrA Δ (mrr-hsdRMS-mcrBC) φ80lacZΔM15 
ΔlacX74 recA1 araD139 Δ (araleu) 7697 galU galK rpsL (StrR) endA1 nupG) were thawed on 
ice. 50µl of the competent cells were added to the ligation mix. Following incubation on ice for 
30 minutes, the reaction was subjected to heat-shock for 30 seconds at 37oC, followed by an 
additional 2 minutes on ice. Transformed cells were supplemented with 250µl of LB media and 
incubated for a further 1 hour at 37oC with shaking. The cells were then plated out on LB-Amp 
agar pre-warmed plates and incubated at 37oC overnight. For blue / white selection of colonies 
80µl of 40mg/ml X-gal was plated out 10 minutes prior to seeding. The TOPO-TA vector is 
unable to re-circularize due to its 3’dT overhangs. White colonies result from DNA being inserted 
into the vector thus disrupting the β-galactosidase gene. Blue negative colonies are a result of 
X-gal staining and indicative of a functional β-galactosidase gene.    
 
2.8.9 Small and large scale DNA preparations  
 
Selected individual colonies were inoculated in 5ml of LB media overnight at 37°C. The cells 
were pelleted by centrifugation at 2000xg for 3 minutes and the pellet re-suspended in 100µl of 
MP I solution. The cells were then lysed in 200µl of MP II lysis solution and incubated for 5 
minutes at room temperature. The mixture was neutralised by the addition of 150µl of MPIII 
solution and the lysate was then clarified by centrifugation for 10 minutes at 13,000xg. The 
supernatant was removed, mixed with 400µl of phenol/CHCl3/IAA, vortexed and centrifuged for 
3 minutes at 13,000xg. The separated aqueous upper phase layer was transferred into a fresh 
1.5ml tube and ethanol precipitated. The pellet was washed in 70% (v/v) EtOH, allowed to air 
dry and re-suspended in 40µl of dH2O.  
For large scale plasmid DNA preparations (used for all transfections), a Qiagen plasmid Maxi 
Kit or GenElute™ HP Plasmid Kit (Sigma Aldrich) were used according to manufacturer 
instructions. Selected individual colonies were inoculated in 150ml of LB media with ampicillin, 
overnight at 37°C in a shaking incubator at 150rpm. The culture was centrifuged for 15 minutes 
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at 4000xg in a chilled centrifuge and the pellet re-suspended in re-suspension buffer, lysed with 
lysis Buffer, neutralised and extracted according to the manufacturer instructions.  
 
2.8.10 RNA extraction and cDNA synthesis procedure 
 
Cell lines (typically 1x106 cells) were harvested and pelleted. The cells were then homogenized 
with 750µl of Trizol and incubated at room temperature for 5 minutes. The lysed sample was 
mixed with 200µl of chloroform and centrifuged at 12,000xg for 15 minutes. An equal volume of 
70% (v/v) ethanol was added to the separated upper aqueous phase in a fresh tube and applied 
to an RNA binding column RNAeasy Kit (Qiagen). The column was centrifuged for 15s at 8000xg 
and the eluate discarded. DNAaseI (80µl) was added to the column followed by a 15 minute 
room temperature incubation.  Subsequent washing with 700µl of Qiagen wash buffer was 
followed by elution of purified RNA with 20µl of RNAase free water, by centrifugation for 1 minute 
at 15000xg.  
Extracted RNA was reverse transcribed using the RT –Taqman™ Applied Biosystems Kit. 
 
  Reagent Volume 
10mM dNTP Mix (2.5mM each) 2.1µl 
Random hexamer (50µM) 0.56µl 
RNA 2.0µl (1-5µg) 
25mM MgCl2 2.31µl 
10x RT buffer 1.05µl 
RNAase Inhibitor 0.2µl 




Total volume 10µl 
 
The reverse transcription reaction was incubated for 10 minutes at 25°C, followed by 30 minutes 




2. 9 Zinc Finger Assembly -Splicing by Overlap Extension PCR 
 
Splicing by overlap extension (SOE) was used for zinc finger assembly.  DNA coding for zinc 
finger proteins specific for differing regions of the CDKN2B promoter were designed using 
published zinc finger recognition code information software [274], based on extensive published 
zinc finger : DNA recognition data. Briefly, six oligonucleotides coding for the alpha helix and 
beta sheet regions of zinc fingers were designed to contain 15 base complementary overlap 
regions. Oligonucleotides were annealed, extended, and the flanking strands were ‘filled in’ 
using four cycles of RT PCR, followed by 25 cycles of primer specific PCR.  
PCR reactions were set up according to the table below. 
Reagent Volume 
10mM dNTP Mix 1µl 
Phusion Polymerase (2 units/µl)   1µl 
Oligonucleotide 100ng/µl 
10x HF® buffer 5µl 
dH2O To make up a total volume of 50µl 
 
PCR cycling conditions used were: 
Cycles Temperature Time Requirement 
 
  5 
 
95oC 5 seconds Enzyme activation 
35oC 10 seconds RT step 
72oC 20 seconds Elongation 
Reaction was stopped and 1µl of reverse and forward primers added. The reaction was re-
started using the following conditions.  
 
  35 
95oC 5 seconds Denaturation 
55oC 10 seconds Primer annealing temperature 
72oC 20 seconds Elongation 





The PCR product was gel purified and prepared for TOPO®-TA cloning as follows: 5µl of PCR 
product, 1µl Taq polymerase (5 units/µl), 2µl Taq Standard Buffer, 1µl dNTP at 10mM, and 11µl 
dH2O, was incubated at 72°C for 20 minutes and TOPO cloned for sequence verification.  
 
2.9.1 Quick-change mutagenesis 
 
Primers coding for the region of interest were gel purified and set up in the following reaction: 
Reagent Volume 
10mM dNTP Mix 1µl 
Phusion Polymerase (2 units/µl)   1µl 
DNA  30µl (100ng/µl) 
10X HF® buffer 5µl 
Forward primer 10µM 1µl 
Reverse primer 10µM 1µl 
dH2O To make up a total volume of 50µl 
 
PCR programme used was:  
Cycles Temperature Time Reaction 
 
18 
95oC 5 seconds Enzyme activation 
55oC 10 seconds RT step 




The product was then incubated with 6µl of Buffer 4, 1µl 100x BSA and 1µl DpnI enzyme for 40 
minutes at 37°C, gel purified, and then used to transform E.Coli. More details on the quick-
change procedure are provided in Chapter 3, Section 3.2.1. The same chapter also contains a 





2.10 Cell culture 
 







HL60 Human promyelocytic 
leukaemia  
Suspension 
Jurkat Human leukemic T cell 
lymphoblast 
Suspension 
Raji Human Burkitt's lymphoma Suspension 
HeLa Human cervix epitheloid 
carcinoma 
Adherent 
A549 Human Caucasian lung 
carcinoma 
Adherent 




2.10.1 Suspension cell culture 
 
Frozen stocks of non-adherent cell lines were revived in RPMI 1640 media supplemented with 
20% (v/v) Foetal Bovine Serum (FBS), L-glutamine (2mM final) penicillin (2,000 units/ml).  
Suspension cells were maintained at 0.2-0.5x106 cells/ml in 75cm2 flasks. The FBS 
concentration was gradually reduced to 10% (v/v), when the cells became confluent and viable 
as determined by Trypan blue count. Cells were harvested by centrifugation at 200xg for 10 
minutes.  
2.10.2 Adherent cell culture  
 
Adherent cell lines were initially revived in 25cm2 tissue culture flasks and further propagated in 
75cm2 tissue culture flasks. The cells were routinely split at 1:3 dilution when they had reached 
~80% confluence. Cells were washed with 10ml PBS following media removal, trypsinized with 
0.6 ml of EDTA-trypsin and incubated at 37oC to allow detachment. Trypsinization was stopped 
with 10ml of DMEM media supplemented with 10% (v/v) FBS, L-glutamine (2mM final) penicillin 
(2,000 units/ml) and the cells re-seeded at the appropriate ratio.  
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The same procedure was applied for the routine passage and harvesting of transfected cell 
samples. These well were grown in either 24 well, 12 well, 6 well plates or 10 cm dishes 
depending on the assay time point. Volumes of PBS and Trypsin were adjusted accordingly.  
Harvesting of disaggregated adherent cells involved centrifugation at 200xg for 10 minutes to 
pellet the cells. The supernatant was removed, the pellet washed in 1ml of 1x PBS and pelleted 
again by centrifugation at 200xg for 10 minutes. The pellets were frozen at -20°C until required 
for analysis.  
 
2.10.3 Cell Transfections  
 
To establish the best transfection procedure for the cell lines used, several transfection methods 
were evaluated and the transfection efficiency determined using FACS analysis of GFP 
transformed cells. Transfection reagents evaluated were Nucleofector Kit V for HL60 (Amaxa), 
Nucleofector Kit R for HeLa (Amaxa), IcaFectin™ 441 Transfection reagent (Eurogentec) and 
JetPEI™ Transfection reagent (Autogen Bioclear).  
 
2.10.3.1 Amaxa Nucleofection – Electroporation Method 
 
The Amaxa Cell Line Nucleofector™ Kit V or R was used to transfect either plasmid constructs 
(maxi-prep 1-5µg) or siRNAs, using the Nucleofector® Device from Amaxa (Lonza). The 
transfection solution was prepared by mixing Supplement solution (0.5ml) and Nucleofector 
reagent (2.5ml). The solution was pre-warmed for 30 minutes at room temperature. 
Supplemented media (RPMI 1640 media or DMEM) was pre-warmed at 37°C. Cells were 
counted and adjusted to 2x106 cells/ml, for each sample. The cells were then centrifuged at 
200xg for 5 minutes, the supernatant carefully removed and the pellet re-suspended in 100µl of 
the Nucleofector mix. 1µg of pGFP (Amaxa) or expression plasmid was then added to the cell 
suspension, which was subsequently transferred carefully to avoid air bubbles, into the Amaxa 
certified cuvette. The cuvette was capped and placed into the Nucleofector Device. The correct 
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Nucleofection program was selected for each specific cell type, for either high efficiency or high 
viability. The transfected cell preparation was then supplemented with 0.5ml of pre-warmed 
media and the samples transferred to 4ml of media in 6-well plates and incubated at 37°C for 
24 hours.  Following incubation, the transfected cells were centrifuged for 5 minutes at 200xg, 
washed once in 1ml PBS, centrifuged again at 200xg for 5 minutes and re-suspended in 1ml 
PBS. The cells were then analysed for GFP transfection efficiency via FACS analysis.  
 
2.10.3.2 IcaFectin™ 441/Lipofectamine™ Transfections 
 
Cells were grown in 24 well plates to ~50% confluence (1x105 cells/ml) 24 hours prior to 
transfection and moved to antibiotic free medium 30 minutes prior to transfection.  20µl of 
IcaFectin™441 (Eurogentec) was incubated with 1µg pGFP (Amaxa) plasmid for 30 minutes at 
room temperature. The DNA: reagent solution was then added to the cells drop-wise and 
incubated for 24 hours at 37°C, 5%CO2.  The cells were then analysed for GFP transfection 
efficiency via FACS analysis.  
 
2.10.3.3 JetPEI™ Transfections  
 
Cells were prepared for transfection as described in the previous section. pGFP (1µg) plasmid 
was incubated with 50µl of JetPEI™ reagent for 10 minutes at room temperature. The DNA: 
reagent solution was then added to the cells drop-wise and incubated for 24 hours at 37°C. Cell 







2.10.3.4 CaBES Transfections 
 
The CaBES method was used to transfect adherent cell lines only. 24 hours prior to transfection, 
cells were grown in 10cm tissue culture plates to ~60% confluence and the media changed 1 
hour prior to transfection. The transfection mixture was prepared by incubating pDNA expression 
vector (10µg) or pGFP (1µg) Amaxa, with 500µl of 2XBES and made up to 875µl with sterile 
dH2O. The mixture was gently vortexed and centrifuged briefly.125µl of 1M CaCl2 was added to 
the mixture slowly drop wise whilst swirling the tube at room temperature. Following 20 minutes 
incubation, the transfection mixture was added drop-wise to plated cells, gently swirled to ensure 
even distribution of the mixture, and left overnight at 37°C, 5% CO2. 
 
2.11 EMSA assay 
 
Complementary oligonucleotides harbouring zinc finger recognition sites or non- specific DNA 
were heated for 5 minutes at 100°C in annealing buffer and allowed to cool to room temperature 
overnight. Annealed oligonucleotides were designed to have 5’ overhangs to allow labelling via 
Klenow polymerase enzyme action.  
 
2.11.1 Labelling oligonucleotides 
 
The annealed oligonucleotides were labelled according to the procedure described in the table 
below.  
Reagent Volume µl 
Oligonucleotides (100ng) 4 
NEB Buffer 2 3 
2mM dATP/dGTP/ dTTP (each) 1 of each 
Klenow fragment 5U/µl 1 
[32P] dCTP (3 000 Ci/mmol) 3 
10x BSA 3 




After incubated at 37°C for 1 hour, the labelling reaction was stopped by adding 100µl of 1x 
STE, 400µl of phenol/CHCl3/IAA, mixing and then centrifuging for 2 minutes at 13,000xg. The 
upper aqueous layer was transferred into a spin column containing Sephadex G50 resin (pre-
equilibrated in STE) and centrifuged for 4 minutes at 2500xg. Eluted samples were stored at 
4°C for EMSA assays.  
 
2.11.2 EMSA assay procedure 
 
Labelled probes were initially run on a 4% DNA poly acrylamide gel (19:1, Acryl: Bis) in 1x TBE 
in order to determine relative labelling efficiencies between probes. Gels were pre run for 30 
minutes at 80V prior to sample loading.  A master mix consisting of labelled oligonucleotides 
was set up for 10 samples to contain: 10x BSA, 25µl; Poly dI:dC/dI:dC (100ng/ml), 25µl; 5x 
McNabind zinc finger buffer and 25µl probe, in a final total volume of 125µl. This mix was 
aliquoted into 10 separate tubes and GST fusion proteins were added to individual tubes 
according to the dilution table below. The binding reaction was allowed to proceed for 30 minutes 
at room temperature. After this time, 2µl of orange loading dye was added and samples run at 
80V, until the dye front reached the bottom of the gel (approximately 40 minutes). 
The gel was removed, placed on Whatman filter paper, sprayed with water, wrapped in Saran 
wrap, dried under vacuum for 1 hour at 80°C and exposed to a Fuji Phosphorimager plate for 1 





Probe (add 9 µl of 
master mix) 
Protein µg H2O µl 
1 
 
Probe 1 0 11 
2 
 
Probe 1 0.008 10 
3 
 
Probe 1 0.006 8 
4 
 
Probe 1 0.004 6 
5 
 
Probe 1 0.08 10 






Probe 1 0.04 6 
8 
 
Probe 1 0.8 10 
9 
 
Probe 1 0.6 8 
10 
 
Probe 1 0.4 6 
 
2.12 The In vitro methylation activity assay 
 
The in vitro methylation activity assay reaction mixture was set up as follows: 
5x McNabind zinc finger buffer 20µl 
10x BSA 10µl 
SAM (32mM) 1.5µl 
LI-ZFP or LI-NS 2.5µg 
dH2O To make 100µl 
 
ZF/HpaII protein fusion was added to separate tubes at the levels shown in the table below and 
9 µl of the above reaction mixture was added to each of the tubes:  
Tube 1 2 3 4 5 6 7 8 9 10 
Protein(µl) 
(2µg/µl), 
0 1 2 3 4 5 6 7 8 9 
dH2O (µl) 11 10 9 8 7 6 5 4 3 2 
 
Following a 45 minute incubation at 37°C, the reaction was terminated by heat killing the protein 
at 100°C for 15 minutes. Following this incubation, 2.5µl NEB Buffer 2 and 1µl R.HpaII restriction 
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enzyme was added and the reaction incubated overnight at 37°C. The restriction digests were 
then separated by electrophoresis through a 2% (w/v) TBE gel at 95V for 60-80 minutes.  
 
2.13 Construction of CDKN2B reporter construct 
 
HL60 genomic DNA was used as a template for these PCR reactions. The primers were 
designed to amplify various CDKN2B promoter regions and to introduce XhoI/HindIII restriction 
sites, to enable subsequent subcloning into pBLCAT. The first primer pair amplified the region -
253 to + 472 from the Transcription Start Site (TSS) and the second was -791 to + 398 (for more 
details see Chapter 3, Figure 3-2). The PCR conditions were as follows: 
 
Reagent Volume 
10mM dNTP Mix 2µl 
HotStarTaq™ polymerase (Qiagen) 1µl 
HL60 genomic DNA  0.5µl (1µg/µl) 
PCR buffer 5µl 
Forward primer (100µM) 1µl 
Reverse primer (100µM) 1µl 
MgCl2 (25mM) 3µl 
dH2O To make up a total volume of 50µl 
Cycles Temperature Time Reaction 
1 95oC 15 minutes Enzyme activation 
35 94oC 30 seconds Denaturation 
57oC 45seconds (ramp 
rate 20) 
Primer annealing temperature 
72oC 60 seconds Elongation 
1 72oC 10 minutes Elongation period to fill in nucleotide ends. 
 
PCR fragments were gel purified, restricted, re-purified and subcloned into pBLCAT as R. 





2.14 Gene Expression Analysis  
 
2.14.1 CDKN2B RT-qPCR 
Real time PCR was performed using an ABI Prism 7900HT with Quantitative PCR Master Mix -









2.14.2 p15INK4B Western Blot 
 
2.14.2.1 SDS PAGE Protein Gel preparation 
 
A 15% acrylamide gel consisting of resolving and stacking gel layers was made according to the 
table below. Samples and low molecular weight marker were loaded at 30µl per well and the gel 
run at 80V in 1x SDS running buffer, until the dye front passed the stacking gel layer (1-2 hours). 
The voltage was then increased to 120V until the bromophenol dye reached the bottom of the 
resolving gel. The gel was stained overnight with Coomassie blue stain, and destained as 
required.  
Reagent Volume 
Quantitative  Master Mix Plus 
UNG with ROX 
12.5µl 
F Primer  (10mM) 1µl 
R Primer  (10mM) 1µl 
dH2O 5.5µl 
cDNA 5µl  
total 25µl 
Real Time PCR programme: 
94°C 4min 






Reagent Running gel  Stacking gel  
40% (w/v) Acrylamide 
(37.5:1)  
3.75ml 1.125ml 
Running gel buffer 2.5ml  
Stacking gel buffer  1.25ml 
dH2O 3.75ml 2.625ml 
 Mix and add immediately prior to gel loading 
10%  (w/v) APS 100µl 50µl 
TEMED 10µl 5µl 
 
2.14.2.2 Protein sample preparation 
 
Frozen cell pellets (at 2x105-1x106cells/ml) were resuspended in 20l of 2xSDS loading buffer, 
vortexed and heated for 5 minutes at 100oC to denature the protein. Proteins were separated by 
SDS–PAGE.  
2.14.2.3  Western blotting 
 
Western blotting was performed following the SDS-PAGE resolution. The SDS PAGE gel was 
overlaid with nitrocellulose-coated nylon membrane and sandwiched between Whatman filter 
papers and sponge pads, pre-soaked with Tris-glycine, 20% (v/v) methanol. Proteins from the 
gel were transferred onto the nitrocellulose membrane by electrophoresis at 20A, 40V for 60 
minutes.  
2.14.2.4 Protein detection 
 
The nitrocellulose membrane was blocked with 5% (w/v) dried skimmed milk (Marvel) diluted in 
PBS-0.05% (v/v) Tween 20 for 1 hour. Following a PBS-Tween-20 rinse, the membrane was 
incubated overnight in anti-p15 mouse monoclonal antibody (1:500), diluted in 5ml PBS 0.05% 
(v/v) Tween 20 and 1% (w/v) dried skimmed milk, at 4C.  The membrane was then washed 
three times for 5 minutes in PBS-0.05% (v/v) Tween-20. This was followed by a 1 hour incubation 
with anti-mouse Horse Radish Peroxidase (HRP) conjugated secondary antibody (1:2000) in 
1% (w/v) dried skimmed milk diluted in PBS-0.05% (v/v) Tween.  The membrane was 
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subsequently washed three times in PBS-0.5% (v/v) Tween-20 for 5 minutes, incubated for 5 
minutes in ECL-plus detection reagent, wrapped in saran wrap and then exposed to X-ray film.
  
2.15  Immunofluorescence Staining  
 
Transfected cells were trypsinized 24 hours post transfection, suspended in 400µl of complete 
media and plated out onto Poly-L-lysine coated slides. Cells were allowed to attach to the slides 
by incubation for 24 hours at 37°C. Excess media was removed via aspiration following 
incubation and the cells were fixed with 400µl of PFA for 15 minutes at RT. Slides were then 
washed three times with PBS and lysed in a solution of 0.5% Triton for 10 minutes. This was 
followed by another three washes with PBS and blocking using 10% donkey serum in PBS for 
30 minutes. Serum was removed via aspiration and primary antibody was added to the slides 
and incubated O/N at 4°C. Following this incubation, antibody solution was removed and the 
slides were washed three times with PBS and blocked again using 10% donkey serum in PBS 
for 30 minutes. Serum was removed under suction and a secondary anti-conjugate antibody 
diluted in PBS with 10% donkey serum, was added to the slides and incubated for 2 hours at 
room temperature in the dark. Slides were then washed three times with PBS and stained with 
400µl of DAPI solution. The slides were incubated for 10 minutes in the dark at RT, fixed with 
mounting solution, covered with a coverslip and left overnight.  Slides were viewed using a 
fluorescent microscope with oil immersion. 
 
2.16 Formaldehyde cross linking  
 
1x105HeLa cells were seeded 24 hours prior to transfection in 6cm TC plates and allowed to 
reach ~70% confluence. The following day, cells were transfected using the CaBES method 
described previously. GFP expression was used to measure transfection efficiency, recorded at 
24, 48 and 72 hours post transfection. Cells were trypsinized and transferred to a 10cm dish 48 
hours post- transfection and left to incubate at 37°C for a further 2 days. At day 4 cells were 
trypsinized, washed with PBS two times and suspended in 37 ml of complete media with addition 
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of 1% (w/v) formaldehyde. The cells were then incubated for 10 min at room temperature for the 
cross- linking reaction to take place. The reaction was stopped by adding glycine to 45mM final 
concentration. The cells were then placed on ice and washed three times with 20 ml of ice-cold 
PBS/0.5mM PMSF/Protease inhibitor mix (Roche). Following the final wash, cells were pelleted 
for 5 minutes at 1000xg, flash frozen on dry ice and stored at -80°C.    
 
2.17 Chromatin Immunoprecipitation (ChIP)   
 
Cell pellets were suspended in 400µl of ChIP Sonication Buffer and sonicated in Bioruptor® 
(Diagenode). To assess chromatin status  following sonication, 50µl samples of sonicated 
material were removed and reverse cross- linked by adding 0.25µl of Proteinase K (25 mg) and 
0.5µl of RNAase Solution (10 mg/ml) and heating O/N at 65°C. DNA was subsequently purified 
using a PCR clean up column and visualized by agarose gel electrophoresis. Samples were 
only used for ChIP analysis if the DNA was in the region between 200-1000 nt, with the lower 
molecular weight DNA being the most dominant species.  The lysate was pre-cleared by 
incubating with 50µl Protein A Sepharose beads and 10µg yeast t-RNA for 2 hours at 4°C with 
constant rotation. The samples were then centrifuged at 300xg for 5 min at 4°C and the pre-
cleared soluble chromatin supernatant was removed.  50µl of the total soluble chromatin, which 
is 1/20th of  the amount used per IP was removed and stored at -20°C, for the latter preparation 
of input DNA. The protein concentration of each sample was determined by BCA. In total 20µg 
of nucleosome material was used for each ChIP and the volume was adjusted to 1 ml with ChIP 
incubation buffer.  The samples were then mixed with 5µg of the antibody of interest (VEZ-F1, 
FLAG) or 5 µg of polyclonal rabbit anti-mouse immunoglobulin (IgG) as a negative control. The 
ChIP complex was then rotated at 20-30 rpm for 2 hours at 4°C. Following incubation, 40µl of 
pre-washed magnetic protein A beads (AdemTech 04230-AD) were added and incubated for 
12-16 hours at 4°C with agitation. (Previous studies in this lab have shown no requirement for 
pre-blocking of these beads in ChIP experiments). All subsequent washes were carried out at 
room temperature. The reaction tubes were placed in a magnetic rack (Dynal, Invitrogen) until 
the beads were drawn to the tube surface (~30 sec). The unbound fraction was collected, the 
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beads washed three times with each Buffer A, B and C, finally suspended in 200µl ChIP elution 
buffer and incubated at 65°C for 10 min to release bound fraction. This step was repeated once 
more with another 200µl of elution buffer and the two eluates were combined giving a 400µl final 
volume. In parallel 50µl of input sample was thawed and supplemented with 350µl of Elution 
buffer. To all samples, 21µl of 4M NaCl was added and the samples were left to incubate 
overnight at 65°C. Following incubation, 1µl of RNAase A (from 10 mg/ml, DNAaseI-free stock) 
was added and the samples were left to incubate at 37°C for 1 hour. This was followed by 
addition of 4 µl EDTA (from 0.5 M stock) and 2µl Proteinase K (from 10 mg/ml stock). The 
reaction was incubated for 2 hours at 42°C. Samples were cleaned up using Qiagen PCR clean 
up columns.  IP and INPUT samples were eluted in 20µl 10 mM Tris (pH 7.5) before proceeding 
to PCR analysis.  
 
2.18 Bicinchronic Acid Assay (BCA)     
 
Protein concentration was measured using the BCA Protein Assay Kit (Pierce) according to the 
manufacturer instructions. The protein concentration was extrapolated for the Albumin (BSA) 
standard curve which was prepared in the range of 2mg /ml to 0.225mg/ml. The samples and 
standards (25µl) were incubated for 30 minutes at 37°C in BCA reagent, prepared according to 
manufacturer instructions. The protein concentration was determined by absorbance 









2.19 CAT Assay 
 
The Chloramphenicol acetyl transferase (CAT) assay is based on the imaging of 14C acetylated 
forms of chloramphenicol.  The CAT gene transfers the acetyl group from acetyl co-enzyme A 
to chloramphenicol. The relative differences in the resulting chloramphenicol products migrating 
down a thin layer chromatography plate are measured to determine the varying amount of CAT 
proteins present. 
The cell samples prepared as described in Section 2.10.2. were lysed by addition of three cell 
volumes of 0.25mM Tris pH 8and three repeated freeze/thaw cycles (37°C for 5 minutes, 
vortexed, followed by snap freezing in dry ice). The cell suspension was centrifuged for 5 
minutes at 13,000xg and the supernatant containing protein retained to a clean tube.  
The protein concentration of each sample was determined using the BCA assay as described in 
previously. Typically, 5µg of the sample protein was prepared for the assay by addition of Tris 
pH 8.0 to 0.25M and then incubated at 60°C for 5 minutes. A mixture consisting of 0.5µl 14C 
chloramphenicol, 2.5µl 40mm acetyl co-enzyme A and 17µl of 0.25M Tris pH 8 was added to 
the protein samples. Following 1 hour incubation at room temperature, the reaction was stopped 
by addition of 1ml ethyl acetate, vortexed and centrifuged for 5minutes at 13,000xg. Following 
centrifugation the upper solvent phase layer which contained chloramphenicol was removed to 
a fresh tube and left to evaporate O/N in a fume hood. 20µl of ethyl acetate was subsequently 
added to the dried samples and applied directly onto a silica gel TLC plate. The sample spots 
were placed 3 cm from the bottom of the plate with 1 to 1.5cm spacing between each sample. 
The sample spots were then air dried and the TLC sheet placed into a TLC containing 250ml of 
95% chloroform/5% methanol. Migration was allowed to proceed until the solvent front was 
approximately 1 cm from the top of the plate. The plate was removed, dried in the fume hood 
and placed into a Phosphorimager cassette O/N. The Phosphorimager plate was scanned using 
a Fuji FLA 2000 Phosphorimager and the data evaluated by densitometry analysis using AIDA 





2.20 T cell Isolation and Stimulation    
 
The anonymous single donor buffy coats obtained from the National Blood Service with ethical 
consent were used for primary quiescent T cell isolation.  Histopaque (Invitrogen) was used to 
separate blood mononuclear cells (MNC) by density gradient, followed by a 560xg centrifugation 
for 30 minutes with no brake. The interphase containing the mononuclear cells was then washed 
twice with 30ml of PBS with 10% (v/v) FBS. A T cell negative isolation kit (Dynal,Invitrogen) was 
used to isolate quiescent T cells by negative selection using immunomagnetic beads,as 
specified in manufacturer instructions. The cells were counted using an improved Neubauer 
chamber and the 20µl of immunomagnetic beads conjugated to an antibody mix consisting of; 
anti CD-14 (depletes monocytes), HLA Class II DR/DP (to deplete B cells, activated T cells, 
neutrophils and monocytes) CD16 (a and b) (depletes NK cells), CD56 (activated T cells) and 
CD235 (erythroid cells) was added per 1x107 cells. The cells were incubated with the mixture of 
antibodies for 20 minutes on a roller at 4°C, followed by centrifugation at 400xg for 8 minutes. 
The cells were then washed twice with 15ml of PBS supplemented with 2% (v/v) FBS. Cell 
pellets were resuspended in 50ml of PBS and incubated with anti-immunoglobulin conjugated 
beads for 15 minutes on a roller at room temperature. The cell bead complex was placed in a 
magnetic rack (Dynal, Invitrogen) and the supernatant containing the quiescent CD4+, CD8+ T 
cells transferred to a fresh tube. The collected cells were seeded in RPMI-1640 supplemented 
with 10% (v/v) FCS (Invitrogen) at 1-4x 106 cells/ml. 
T cells were stimulated, when required by addition of CD3/CD28 magnetic beads (Dynal, 
Invitrogen) typically at 10µl of beads per 1x106 cells). For the immunofluorescence experiments, 
the beads were dissociated from the cells with a magnet.  
The T cell suspensions at 1x104 were Cytospin were loaded into the cytospin cuvette containing 
the filter paper and lysine slides (as for IF procedure). The samples were centrifuged in a 







2.21 Cell Cycle Analysis  
 
Cell samples at 2x105 cells were taken prior to and following stimulation and fixed in 400µl of 
70% (v/v) EtOH at -20°C. Following centrifugation  at 400xg for 8 minutes the pellet was 
resuspended in 400µl of FITC/PI cell cycle stain consisting of 40µg/ml PI (to stain for DNA 
content),  5µg/ml FITC (protein staining), and  1µg/ml RNAse1). The mixture was incubated at 
37°C for 30 minutes and analysed on FACS Calibur flow cytometer. To analyse cell cycle data 
WinMDI 2.9 program was used to plot PI (FL2A) against FITC (FL-1H). Plotting area (FL2-A) 
against width (FL2-W) created a doublet discriminator gate to exclude doublets from the 
analysis. The cell cycle phase cell percentage was calculated by applying gates manually 
around cell populations in various cell cycle stages.  
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3.1 Introduction  
 
3.1.1 Recombinant Zinc Finger Protein design, assembly, expression and purification 
 
Four sites within the promoter region of CDKN2B were selected for methylation targeting 
studies. Prior to in vivo application I needed to determine that the ZF/Mtase components were 
functional in in vitro settings and could specifically bind to their intended target site. To do this, 
in vitro characterization of CDKN2B specific ZFs fused with prokaryotic methyltransferase 
M.HpaII was conducted.   
What follows is the rationale for ZF selection and a description of their design, assembly, 
purification and an in vitro characterization of the affinity, binding specificity and enzymatic 
activity of the protein fusions used in this project.  
To assess the in vitro binding specificity and targeted methylation activity of zinc finger 
methyltransferase fusions, the M.HpaII (F35H) prokaryotic methyltransferase was subcloned in 
frame 3’ to various ZFs in a pGEX vector backbone, expressed and purified. The F35H mutation 
in M.HpaII has previously been shown to reduce the activity of the Mtase protein, allowing the 
zinc finger to dominate during targeted methyltransferase action [275].  
The zinc finger and methyltransferase components of the construct were separated by a 
(Gly4Ser)3 linker, which allows a degree of independent function for each component of the 
targeted methyltransferase enzyme. The cloning strategy employed for the assembly of the GST 










Figure 3-1 ZF/HpaII Cloning Strategy 
The HpaII methyltransferase (F35H) gene was restricted with BamHI/NdeI and cloned into the multiple cloning 
site (MCS) of a pGEX plasmid vector already containing the three finger zinc finger proteins 3ZFA, 3ZFB, and six 
finger zinc finger protein  6ZFAB.  Other commercially synthesized 6ZFs (PU1, MIZ, and MYC) were subcloned 
in the same manner.  The expression of the cloned fragments under the control of the TAC promoter was induced 
by the lactose analogue isopropyl β-D thiogalactoside (IPTG). Additionally, pGEX vectors contain an internal lacIq  
gene coding for a repressor protein involved in the regulation of expression through its ability to bind TAC promoter 
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3.1.2 CDKN2B regulatory region  
 
The rationale behind the selection of site biased ZFs to target CDKN2B promoter was based on 
extensive literature searches of what is known about this key cell cycle regulatory gene. 
Additionally, the Wisconscin GCG software package was used to search for TF binding sites in 
the CDKN2B regulatory region. The outcome of those searches is presented in Figure 3-2 which 
shows the key TFs with a role in CDKN2B regulation.  CDKN2B (Genbank Accession Number 
ID AF513858) is a TATA- less promoter with an initiator sequence CCCCACTCT (Inr) [276]. The 
Regulatory Domain (RD) for  the IN4/ARF locus  lies in proximity to CDKN2B, and promotes 
locus repression via CDC6 [277]. This RD region was shown to be a region of Polycomb PRC2 
(EZH2) and PRC1(BM1 and M33) localization and CDC6 interaction [278, 279].  The specific 
transcriptional regulators of CDKN2B includes signalling by TGF-β, which down regulates c-Myc 
[280].  Other factors that contribute to this TGF-β responsiveness are several Sp1 binding sites 
(consensus sequence GCCTCC, GGGGTGGGG and GGGGCGGAG) in proximity to the Inr 
element, and Miz-1 [281]. The Miz- 1 zinc finger protein is an essential interacting partner of the 
Myc: Max complex but can also bind to GFI-1 [282]. This interaction takes place in the region of 
the CDKN2B Inr and interferes with the recruitment of p300 to Miz-1, thereby preventing 
transcriptional activation of CDKN2B.  The Myc: Max complex can also activate transcription via 
E – box elements. A potential E Box binding site within CDKN2B (TATGACAGGT) lays 420bp 
upstream from the Inr. Transforming growth factor-β (TGFβ) signalling is mediated through the 
SMAD family of signal transducer proteins. SMAD4 acts as a common mediator involved in the 
translocation of  phosphorylated SMADs to the cell nucleus to effect cellular responses to TGF-
β [283]. A potential SMAD3/SMAD4 site (consensus sequence CAGACAT) lays at around -400 
from the initiator sequence. SNAIL1, SP1, and EGR1 were also demonstrated to be able to 
activate the  CDKN2B promoter upon TPA stimulation [284]. Transcription factor PU.1 along 
with the interferon consensus sequence-binding protein/interferon regulatory factor 8 
(ICSBP/IRF-8) was also shown to be able to bind to CDKN2B promoter upon IFNβ treatment 
[285]. A putative CCCTC binding site for a CTCF promoter insulator binding factor is located at 
the 5’ end of the gene. Proposed functions for CTCF are in blocking enhancer activity and 
chromatin insulation.  
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Figure 3-2 CDKN2B promoter regulatory region.  
Key TF sites, Transcription Start Site, zinc finger binding and methylation sensitive sites highlighted. YY1 consensus sequence CCTGGCGGC -180 from Inr and c-Myb CTAACGA at + 145 for Inr, are known 
to be sensitive to methylation of their binding sites, [286, 287], while TFs such as Sp1 are thought to be sterically blocked by binding of methylcytosine binding proteins to its methylated binding site. Inr 
sequence is highlighted in blue text which will be discussed later on in the Chapter. The scale of the blue line at the top of the diagram representing the CDKN2B CpG and the target sites of the ZFPs is 
650bp, starting at -170bp to +480bp from TSS. 
5-ATCTTCAGAA GAGAATTTAA TGACAGGTTC AGCCTGTTTA ATGACAAGCC CAGCACCACA CCCCTCTCTT-3' 70 
5'-ATGATGTTTC ATTATTACTG CATAAATTTC CTTTATTACT CATGATAAAT AAAAATAAGA TACCTGACAA-3' 140 
5'-AGTGGGTTTA AATAGGTAAG AGTGCAAACA AAGATTTACT GTACAAATAT GATGAAACTG GGATCTCAGA-3' 210 
5'-TTCTTAAAGT ATAATTTTTT TTTGTCTTAT GTGTGCCAGG TTGCCACTCT CAATCTCGAA CTAGTTTTTT-3' 280 
5'-TCTCTTTTAA GGGTTGTATC CATAATGCAA AAATGGAAAG AATTAAAAAG CACACGCAAA ACATGATTCT-3' 350 
5'-CGGGATTTTT CTCTATTTTT ATGGTTGACT AATTCAAACA GAAAGACACA TCCAAGAGAA AATTGCTAAG-3' 420 
5'-TTTGATACAA GTTATGAAAC TTGTGAAGCC CAAGTACTGC CTGGGGATGA ATTTAACTTG TATGACAGGT-3' 490 
5'-GCAGAGCTGT CGCTTTCAGA CATCTTAAGA AACACGGAGT TATTTTGAAT GACTTTCTCT CGGTCACAAG-3' 560 
5'-GGAGCCACCA ACGTCTCCAC AGTGAAACCA ACTGGCTGGC TGAAGGAACA GAAATCCTCT GCTCCGCCTA-3' 630 
5'-CTGGGGATTA GGAGCTGAGG GCAGTGGTGA ACATTCCCAA AATATTAGCC TTGGCTTTAC TGGACATCCA-3' 700 
5'-GCGAGCAGTG CAGCCAGCAT TCCTGGCGGC TCCCTGGCCC AGTCTCTGGC GCATGCGTCC TAGCATCTTT-3' 770 
5'-GGGCAGGCTT CCCCGCCCTC GTGACGCGTC GGCCCGGGCC TGGCCTCCCG GCGATCACAG CGGACAGGGG-3' 840 
5'-GCGGAGCCTA AGGGGGTGGG GAGACGCCGG CCCCTTGGCC CAGCTGAAAA CGGAATTCTT TGCCGGCTGG-3' 910 
5'-CTCCCCACTC TGCCAGAGCG AGGCGGGGCA GTGAGGACTC CGCGACGCGT CCGCACCCTG CGGCCAGAGC-3' 980 
5'-GGCTTTGAGC TCGGCTGCGT CCGCGCTAGG CGCTTTTTCC CAGAAGCAAT CCAGGCGCGC CCGCTGGTTC-3' 1050 
5'-TTGAGCGCCA GGAAAAGCCC GGAGCTAACG ACCGGCCGCT CGGCCACTGC ACGGGGCCCC AAGCCGCAGA-3' 1120 
5'-AGGACGACGG GAGGGTAATG AAGCTGAGCC CAGGTCTCCT AGGAAGGAGA GAGTGCGCCG GAGCAGCGTG-3' 1190 
5'-GGAAAGAAGG GAAGAGTGTC GTTAAGTTTA CGGCCAACGG TGGATTATCC GGGCCGCTGC GCGTCTGGGG-3' 1260 
5'-GCTGCGGAAT GCGCGAGGAG AACAAGGGCA TGCCCAGTGG GGGCGGCAGC GATGAGGGTC TGGCCAGCGC-3' 1330 
5'-CGCGGCGCGG GGACTAGTGG AGAAGGTGCG ACAGCTCCTG GAAGCCGGCG CGGATCCCAA CGGAGTCAAC-3' 1400 
5'-CGTTTCGGGA GGCGCGCGAT CCAGGTAGCT GGGGCCCCAG GGCCTCGCCG GCAGGGGGCG CGCGAACGCG-3' 1470 
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The zinc finger proteins were designed using the software Zinc Finger Tools, which is available 
freely through an organization established to promote zinc finger engineering called the Zinc 
Finger Consortium, designed by Barbas’ laboratory [260] (www.zincfinger.org). The modular 
approach and Base function of the  Zinc Finger Tools software  ensures that each zinc finger 
targeting a triplet code is assigned a score [288]. This score predicts a number of ‘off- target’ 
sites that a zinc finger might recognise and is calculated from ELISA specificity graphs. As a 
general rule of thumb, the higher scores generated by Base function correlate with the lower 
number of ‘off- target’ sites that a zinc finger recognises. ZFs were commercially synthesized 
with the exception of one which was assembled in the lab using the SOE-PCR approach. Figure 
3.3A-C shows the process of construction of all the CDKN2B specific six finger ZFs described 
in this thesis. Figure 3-3D describes the process of SOE-PCR 6ZFAB assembly process.  
Designed zinc finger proteins contain two N terminal beta strands (YKCPECGKSFS) and an 
alpha helix C terminal backbone (HQRTH) which is a region not involved in DNA recognition 
and contact. Zinc finger modules are joined via fixed sequences at the N (LEPGEKP) and C 
termini (TGKKTS) to form a TGEKP linker.  
The 6ZFAB was generated by fusion of two three zinc finger modules to target consecutive 
CDKN2B promoter regions. Each single zinc finger module recognizes three base pairs of DNA, 
which means that following the assembly, zinc finger proteins can target an 18 (six zinc finger) 
base pair contiguous DNA sequence. The oligonucleotides coding for the beta sheet and alpha 
helix modules were synthesized, assembled using the Splicing by Overlapping Extension (SOE-
PCR) approach, and cloned into pGEX vectors for expression in E.Coli and GST purification.  
The Zinc finger array was selected to bind to an 18bp sequence 5’-
GCCGCAGAAGGACGACGG-3’.  The site is located +180 from the CDKN2B Transcription 
Initiator element Inr [289].   
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Figure 3-3A. Construction of CDKN2B specific zinc finger arrays using Zinc Finger Tools.  
A CDKN2B promoter region with the location of 6ZFMIZ recognition region (underlined blue). The amino acid sequence of the zinc finger array predicted to bind to this CDKN2B promoter target sequence 
was generated by entering the target site of interest into the Zinc Finger Tools software.  For 6ZFMIZ the target site was 5’ GCT CCG CCT ACT GGG GAT 3’.  B The modular zinc finger best able to bind 
each target triplet code was generated by the software using a scoring system based on base function. This scoring system uses ELISA specificity graphs to predict a number of off -target sites that a zinc 
finger may recognise, with the highest score assigned to the fewest number of the off- target sites. 6ZFMIZ has several off-target sites (arrowed). C All of the zinc finger arrays designed and constructed for 
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Figure 3-3B. Construction of CDKN2B specific zinc finger arrays using Zinc Finger Tools.  
A The location of the 6ZFMYC binding site in relation to the CDKN2B gene is shown highlighted in blue and the location of each CpG site is shown in red. The target site 5’ TGAAGCTGAGCCCAGGTC 3’ 
for 6ZFMYC was entered into the Zinc Finger Tools software to generate the amino acid sequence of the zinc finger array predicted to bind to the CDKN2B. B  The ELISA specificity graphs were generated 
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Figure 3-3C. Construction of CDKN2B specific zinc finger arrays using Zinc Finger Tools.  
A The location of the 6ZFPU1 binding site in relation to the CDKN2B gene is shown highlighted in blue and the location of CpG sites is shown in red. The amino acid sequence of the zinc finger array 
corresponding to the CDKN2B target sequence was generated by entering the target site of interest into the Zinc Finger Tools software.  For 6ZFPU1 the target site was 5’ GAT CGG GGC TGG AAC CTA 
3’. B The ELISA specificity graphs were generated using a scoring system based on a base function and the off-target site is arrowed as already explained in Figure 3-3A. C The general modular composition 
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Figure 3-3D. Construction of CDKN2B specific 6ZFAB using SOE-PCR approach.  
Zinc finger proteins were sequentially assembled by PCR overlap to generate two 3ZFmodules 3ZFA and 3ZFB. The oligonucleotides were designed to contain 15-20 bp overlaps to allow the complementary 
fragments to anneal. The template sequence was then filled in using DNA polymerase to create longer DNA fragments [290]. This was followed by a standard PCR reaction using primers specific for 
sequences in the extreme 5’ and 3’ ends of the assembled gene, leading to PCR product amplification. The primers had 5’ NdeI and 3’ HindIII overhangs for subsequent cloning into pGEX vector. 
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Following SOE-PCR assembly the gene products for the two different zinc finger arrays 
(designated ZFA and ZFB) were gel purified (Figure 3-4A) , TOPO cloned  and sequenced. 
 
 
Figure 3-4. Gel purification and QC mutagenesis of 3ZF Arrays.  
Panel A shows gel resolution of  two three ZF arrays ZFA and ZFB which are 288bp PCR products.  Panel B Quick-
change mutagenesis products were generated for both TOPO/ZFA shown here and TOPO/ZF not shown. Negative 
control was TOPO/ZFA subjected to the quick-change reaction in the absence of Phusion enzyme.  
 
 
Sequencing data revealed a consistent single base insertion in the β sheet region 
CATATCCGCCATCC (ABI File sequencing data in Appendix Section 1 CD-ROM) for ZFA and 
a single base deletion in the ZFB α helical region ATTTAACAAGG. Quick-change mutagenesis 
was used to correct for these errors. Self- complementary oligonucleotide primers were 
synthesized using the Quick-Change protocol described in the Methods Section 2.9.1. The 
primers containing the desired mutation were designed to anneal to both strands of the 
TOPO/ZFA or ZFB plasmid at the same region. Primers were extended during temperature 
cycling with Phusion DNA polymerase PCR and the reaction treated with R.DpnI endonuclease. 
This enzyme only cuts Dam+  methylated DNA (5´-Gm6ATC-3´) and therefore digests only 
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3.1.3 Recombinant protein purification 
 
NEB-Express competent cells (genotype: fhuA2 [lon] ompT gal sulA11 R (mcr-73 mini Tn10- - 
Tets) 2 [dcm] R( zgb-210..Tn10- - Tets) endA Δ(mcrC-mrr)114.IS10) were transformed with the 
pGEX AB or AB plasmid. A single colony was used to inoculate 25ml of LB medium containing 
ampicillin. The culture was grown overnight at 37°C, and the cells were collected by 
centrifugation at 2000xg for 10 minutes at 4°C. The cell pellet was resuspended in 1ml of LB 
media, and used to inoculate 250ml LB media supplemented with 100µl 1M ZnCl2, glucose 0.1% 
(w/v) and 250µl ampicillin and incubated at 37°C until O.D.600 nm reached 0.8 (around 2 hours).  
5ml of culture was retained for use as an un-induced control.  IPTG (0.5mM) was then added to 
the remainder of the cell solution, for a further 2 hour incubation at 30°C.  Following incubation, 
the cells were pelleted by centrifugation at 5000xg for 15 minutes at 4°C, and the pellet was 
washed in 25ml PBS on ice by pipetting up and down gently to disperse clumps. The cell 
suspension was then centrifuged at 5000xg for 10 minutes at 4°C and the pellet was either 
frozen at -70°C for subsequent purification or processed immediately. The cell pellet was 
resuspended in 10ml GST resuspension RP1 buffer. The protein suspension was then sonicated 
for 30 seconds twice at 60Hz, followed by the addition of 1ml of Triton-x-100 10% (v/v) to the 
suspension and left for 30 minutes on a roller at 4°C. During this incubation, GST-sepharose 
beads were pre-washed with 10ml RP1 buffer. Following 30 minutes incubation, the protein 
suspension was centrifuged at 3500xg for 10 minutes at 4°C, and the supernatant was 
transferred to the GST-sepharose beads for a further 30 minutes roller incubation at 4°C. The 
GST beads: protein complex suspension was centrifuged at 900xg for 5 minutes and the 
supernatant decanted.  The beads/protein complex was then washed four times with 50mM Tris-
HCl. The GST beads were then resuspended in 1ml of 50mM Tris-HCl, supplemented with 20% 
glycerol (v/v) and transferred onto a 5ml disposable column (Pierce). The column was washed 
with 2ml of 50mM Tris-HCl 20% glycerol (v/v), and the protein was then eluted with 5ml of 
reduced glutathione RP2 buffer. Five 1ml fractions were collected and frozen at -80°C. Purified 
GST tagged protein was run on 10% SDS-PAG to detect GST tagged eluted zinc finger protein 
using Coomassie blue staining shown in Figure 3-5.  
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Figure 3-5 SDS PAGE Analysis of GST purified ZF-Mtase 
To determine the quality of the expressed and GST purified protein, the proteins were analysed by SDS PAGE. Figure 
shows GST 6AB Fractions 1-3 (lanes1-3), 6ZFAB/HpaII Fractions 1- 3 (lanes 4-6) and 3ZFB/HpaII Fractions 1-3 (lanes 
7-9) eluates. Empty pGEX- 5MCS cloning vector produces a 24kDa GST protein, while the six zinc finger protein ZFAB 
is 22kDa and HpaII is ~ 40kDa, so the expected size for 6ZFAB/HpaII fusion protein is ~ 86kDa. The expected size for 
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3.2 Measurement of ZF/Methyltransferase binding affinity using 
EMSA 
 
Six finger proteins were chosen to target a single unique site within the mammalian genome and 
initially their binding affinity and specificity was evaluated using Electrophoretic Mobility Shift 
Assay (EMSA). Using EMSA it is possible to determine the binding affinity and specificity  of a 
protein for its target DNA sequence, as well as the binding kinetics of those interactions [291, 
292]. Binding kinetics analysis depends upon the law of mass action which is based on several 
assumptions. Firstly, that all of the binding sites on a DNA sequence are equally accessible to 
the binding protein. Secondly, only free or bound interactions are accounted for whilst partial 
binding interactions are not allowed by this model. Binding is a result of a collision event 
occurring by diffusion between the zinc finger/methyltransferase and the target DNA which once 
bound remain so for a random amount of time. When the rate at which new ZF/Methyltransferase 
: DNA complexes are formed  (kon rate) equals the rate at which the ZF/Methyltransferase : DNA 
complexes dissociate (koff rate), equilibrium is reached. The equilibrium dissociation constant Kd 




Receptors with a high affinity for a particular ligand will have low Kd values, because a low 
concentration of ligand will be required to bind half the receptors. The assay is conducted 
routinely in our lab and the previous work using a time course for six finger proteins has shown 
that the equilibrium for the binding reaction to occur is reached following 10 minutes incubation 
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Four six zinc finger protein (PU1, MYC, MIZ and JMJ) HpaII methyltransferase fusions were 
subcloned into pGEX vectors, expressed in E.Coli and purified as described in 3.1.1 and 3.1.2. 
Six finger proteins are capable of recognizing a contiguous 18bp sequence, considered 
statistically unique and  highly unlikely to occur at random when looking at the context of the 
human genome of around 4x1018  bases in size  [293].  The expression profile of purified 
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Figure 3-6 SDS PAGE Analysis of GST purified 6ZF/HpaII fractions 
Four different GST purified 6ZF/Mtases Fractions 1-4; 6ZFMIZ/HpaII, 6ZFMYC/HpaII, 6ZFJMJ/HpaII and 6ZFPU1/HpaII 
were resolved on a 10% SDS PAG to determine the quality of the purified protein fractions. Novex ® Sharp Standard 
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The quality and purity of the purified protein fractions were evaluated using SDS gel 
electrophoresis. In Figure 3.5. 6ZFAB/HpaII purified protein is seen as a dominant band 
corresponding to the predicted molecular weight of 84kDa.  Faint, lower molecular weight bands, 
likely corresponding to products of degradation are also seen. In Figure 3.6. all six finger proteins 
are confirmed to be of the identical size and approximately equivalent purity.  Lower molecular 
weight bands that can be observed for all those proteins could be attributed to either degradation 
or protease cleavage of the purified protein resulting from purification process. However, 
addition of protease inhibitors was standard practice during protein isolation and purification. 
These low molecular weight bands are approximately 26-40kDa in size and correlate with; GST 
(26kDa) or GST tagged six finger ZFs (48kDa) degradation by-products. It is however, unlikely 
that any of the observed by- products contain methyltransferase component. This is because 
the 6ZF/Methyltransferase proteins are expressed and purified as N terminal – GST – ZF – 
fusions. Purification of the protein using GST beads is unlikely to capture any of the 6 potentially 
degraded methyltransferase which lack the N- terminal GST – ZF component.  Protein 
dimerization during purification is however a possible explanation for the observed additional 
bands. Similar, observations in the lab were made previously during the purification process of 
ZF-Mtase-GST fusions, and the resulting by-products were confirmed by western blot with anti 
GST antibody to be zinc finger/GST fusions resulting from proteolytic cleavage.     
Purified protein fractions visualized using denaturing SDS electrophoresis with the least 
degradation, or cleavage by- products were used for subsequent EMSAs (Figure 3.7). Purified 
protein was more accurately quantitated using the Bicinchronic Acid Assay (BCA) (for assay 
details see Methods Chapter 2 Section 2.18). Briefly, the BCA was used to determine 
quantitatively the concentration of a protein calibrated against the Albumin Standard at 2mg/ml. 
The assay is based on a colorimetric measurement of the intensity of purple product formed as 
a result of BCA and Cu+ reaction under alkaline conditions.  Protein present in the solution is 
involved in a  reduction of Cu2+ to Cu+, so there is a direct correlation between the concentration 
of a protein, presence of Cu+ and the intensity of the purple coloured reaction product as 
measured by a spectrophotometer.  For ZFAB/HpaII protein fusion, fraction 1 and for all the 
other HpaII fusion proteins, fractions 4 were used for all of the subsequent analyses. Protein 
fractions were incubated with DNA duplex oligonucleotides containing ZF target sequences 
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labelled with 32P as described in Methods Chapter 2.11. This section also describes EMSA assay 
set up and visualization of protein-DNA bound complexes.  
Previous work in our lab has shown that the binding affinity of the ZFs increases with the number 
of zinc fingers, so that by increasing the number of modules from three to four for example leads 
to an approximate 2-3 fold increase in binding affinity of that ZF for its target site. Using 
comparative protein levels, the upper limit binding affinity for each of the five six finger ZFs was 
evaluated for target and non-specific DNA (Figure 3.7). Although SDS PAGE analysis showed 
intact proteins of the correct size and of comparable quality to all other ZFs analysed, 
6ZFMYC/HpaII did not bind at all to its target sequence. A possible explanation is that this protein 
has not folded properly in bacterial cells. All the other ZFs bind to their respective target 
sequences, but with different binding affinities. 6ZFMIZ/HpaII binds to its recognition site with 
the lowest apparent affinity and 6ZFPU1/HpaII with the highest apparent affinity. For 
6ZFAB/HpaII a clear band signifying protein binding appears at lower protein concentration 
compared to 6ZFMIZ/HpaII. The 6ZFAB/HpaII contains the only zinc finger component not 
synthesized commercially. It was assembled from designed oligonucleotides in the lab by the 
SOE-PCR method and subsequent fusion of the two individual 3 finger ZFs.  Following its 
assembly, sequencing and purification it became clear that during the oligonucleotide synthesis 
one amino acid was omitted which resulted in a compromised, though functional final module 
for each of the three finger proteins.  
For each of the ZFs used in EMSAs, controls using DNA with HpaII sites but lacking the ZF 
target sequence show the appearance of DNA/protein complex bands only at the highest 
protein concentrations. This suggests that there exists a low level of non-targeted binding by 
the methyltransferase component of the ZF/HpaII fusion protein binding to its intrinsic HpaII 
binding site which is present of the non-specific probe too. This is in line with the data from 
previous work in our laboratory on four finger ZFs confirming that the HpaII methyltransferase 
used in ZF fusions has an intrinsic binding affinity for its binding site [294]. The overall binding 
affinity of the ZF/HpaII fusion is significantly higher than the binding affinity of ZF alone.   
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Figure 3-7 EMSA assay of 6ZF/HpaII proteins. 
EMSA analysis of four different 6ZFs; 6ZFMYC/HpaII, 6ZFMIZ/HpaII, 6ZFAB/HpaII and 6ZFPU1/HpaII binding to ZF/HpaII binding site (top panels) and ZF negative site (bottom). The first lane on each slide 
contains no protein and the range for all of the 6ZFs used in these EMSAs is 1pmol to 0.6nmol.   32P labelled oligonucleotide complexes with or without ZF target site (blue box representing 18bp target 
sequence for a given ZF) and/or containing a HpaII site (red lollipop) were incubated with their respective ZF.  When the ZFs (with the exception of 6ZFMYC/HpaII which did not bind at all)  were incubated 
with the oligonucleotide containing its target sequence and HpaII site, bound protein/DNA complexes were observed arrowed A and their intensity  increases with the amount of  ZF-Mtase protein. ZFs 
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The Kd values were calculated from two sets of independent gel shifts. The results in Figure 3.8 
show the difference in Kd values between different ZFs. It was important to gain insight into 
relative binding affinities of these 6ZFS as a prelude for studies in the endogenous setting when 




Figure 3-8 Binding curves and Kd values generated for each of the 6ZFs.  
EMSA data was analysed using Graph Pad prism software. Four different 6ZFs; 6ZFMYC/HpaII, 6ZFMIZ/HpaII, 
6ZFAB/HpaII and 6ZFPU1/HpaII targeted to the CDKN2B promoter were examined.  The concentration range for the 
6ZFs used was from 1pmol to 0.6nmol.  Binding of 6ZF to the radioactively labelled oligonucleotide containing the target 
sequence is represented by the graph. Prism – GraphPad Software was used to quantify the binding affinity for each of 
the ZFs.  The Kd values, and binding curves were generated, using a non- linear regression (curve fit), based on one- 
site binding (hyperbola) to generate a best fit curve (y axis = % protein bound). The Kd (nM) is calculated as the protein 
concentration at which 50% of the protein is bound and varied significantly between the four 6ZFs used from Kd 5.2nM 
for 6ZFPU1, 43nM for 6ZFMIZ, 11nM for 6ZFAB, and 992nM for 6ZFMYC. 
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3.3 In vitro methylation activity assay 
 
In order to evaluate the catalytic activity of methyltransferase fusion proteins, ex vivo assays 
were employed to look at in vitro targeted methylation using Litmus™ 28i vectors. Having 
confirmed the binding affinity of the 6ZF/HpaII fusions, the same protein fractions used for 
EMSAs were employed to determine the intrinsic levels of DNA methyltransferase activity.  
Initially, a crude estimate of methyltransferase activity was obtained from a restriction analysis 
of the coding plasmids for one of the ZFs, 6ZFAB fused with the CpG methyltransferase SssI. 
The expression plasmids coding for 6ZFAB/SssI were expressed and purified from E.Coli (as 
described previously). The plasmid was then restricted for 4 hours using enzymes R. HpaII or 
R.MspI and electrophoresed on an agarose gel. Restriction enzyme R.MspI is only sensitive to 
methylation at the first cytosine of its recognition sequence (5’CCGG3’) which it cuts at CG. On 
the other hand, R. HpaII is sensitive to methylation at the second cytosine (5’CCGG3’), and 
although it restricts an identical sequence to R.MspI, it does so in a methylation dependant 
manner. So if the CG within the 5’CCGG3’ recognition pattern is methylated then cleavage by 
the R.HpaII enzyme will be blocked. This principle therefore, allowed for expression vectors to 
be scrutinized for the level of ‘self’- methylation. Products of higher molecular weight were 
observed when R.HpaII restriction was blocked as a consequence of methylation as shown in 
Figure 3-9 A for 6ZFAB/SssI. This allows for a crude assessment of the methyltransferase 
activity of the fusion proteins coded by the plasmid. The results show that the prokaryotic 
methyltransferase SssI is enzymatically active as evident by the presence of high molecular 










Figure 3-9. SssI methyltransferase activity assessment using methylation sensitive restriction 
analysis. 
6ZFPU1/HpaII and 6ZFPU1/SssI plasmids were restricted for 4 hours with either R.MspI(M) or R.HpaII(H) restriction 
enzymes. Different restriction pattern profiles can be seen when the plasmids are restricted with R.HpaII enzyme which 
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Plasmid restriction demonstrates variable methyltransferase activity of all ZFAB/SssI constructs. 
In order to investigate in more detail specific targeted methylation by these constructs the ex 
vivo binding assay previously developed by our lab was employed.  Oligonucleotides with (LZF) 
or without (LNS) zinc finger specific sites were synthesised and cloned into the Litmus™ 28i  
target vector as XbaI/BglII fragments. The vectors contain 22 HpaII sites uniformly distributed 
through the 3kb sequence. All of the 6ZF/HpaII fusion proteins (same fractions as used in 
EMSAs) as well as the 6ZFAB/SssI fusions were used to target HpaII/CpG sites within the target 
Litmus™ 28i vector. The ability of zinc finger protein methyltransferase fusions to selectively 
distinguish between the LZF and LNS target vectors and the resulting methylation patterns were 
assessed via subsequent restriction of plasmids with R. HpaII restriction enzyme. Detailed assay 
set up is described in Methods Section 2.12. Targeting of ZF/methyltransferases involved 
incubation of purified protein with target plasmids, followed by a restriction digest for analysis of 
targeted methylation. The restriction analysis is based on the methylation sensitivity pattern of 
R.HpaII restriction enzyme between target and non-specific plasmid substrates. A unique 
restriction pattern should be generated following successful targeted methylation shown in 
Figure 3.-10A. Titration of protein with the target plasmid should lead to a comparable increase 
in the appearance of high molecular weight restriction products.  Figure 3-10C shows a selection 
of results obtained for the fusion proteins. As the results show it was not possible to clearly 
distinguish protein activity at target vs. non-target plasmids using the assay. Numerous 
troubleshooting steps were taken to improve the assay conditions such as varying the amount 
of protein used, changing reaction buffer conditions and varying the reaction time, all with no 
success. Target plasmid comprising the CDKN2B promoter region was also evaluated in an 
attempt to mimic as closely as possible target site contact that these ZFs were ultimately 
designed to bind to. The promoter region of the CDKN2B gene was generated by PCR from the 
haematological cell line HL60 and subcloned into the pBL- CAT vector for the CAT reporter 
assay (This is described in more details in the next section (3.4) of this Chapter). The CAT 
plasmid harbouring the CDKN2B promoter (pBLCAT/CDKN2B) was used as a target vector and 
a pBLCAT empty vector was used as a non- target site vector control. These vectors gave the 
same result as previous LZF and LNS target vectors shown in Figure 3-10B.  




Figure 3-10. In vitro methyltransferase activity assay for 6ZFMIZ/HpaII, 6ZFAB/HpaII, 
6ZFPU1/HpaII, and 6ZFAB/SssI proteins titrated with target plasmids pNS and pLZF pBL 
CAT/CDKN2B and pBLCAT.   
A  Diagrammatic representation of the basic principle of the in vitro methylation assay. B Titrated 6ZFAB/SssI protein 
was incubated for 45 minutes with the target plasmids pBL-CAT/CDKN2B and pBLCAT. This was followed by R.HpaII 
restriction to look for a unique restriction pattern consisting of higher molecular weight bands if the plasmid is methylated.  
Marker used was a 1kb DNA ladder. C 6ZFMIZ/HpaII (1), 6ZFAB/HpaII (2), 6ZFAB/SssI (3) and 6ZFPU1/HpaII (4) 
purified proteins were incubated for 45 minutes with the target plasmid pNS and pLZF. This was followed by heat 
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3.4 CAT Reporter Activity Assay  
 
The previous section described the attempts to assess the in vitro methyltransferase activity of 
the fusion proteins. I have demonstrated that the ZF/methyltransferase fusions we generated 
were capable of binding to their target sites in short oligonucleotides, but the information on the 
activity of the methyltransferase component was not conclusive. The next step was to target 
methylation using fusion proteins specific to the region of a CDKN2B regulatory region driving 
the Chloramphenicol Acetyltransferase (CAT) reporter gene in an in vivo setting. Following 
ZF/Mtase targeting, promoter transcriptional regulation was assessed by quantitatively 
measuring CAT expression in eukaryotic cells by CAT ELISA assay.  It has previously been 
demonstrated that directing DNA methyltransferase activity to predetermined sites in DNA led 
to the transcriptional silencing/downregulation of Renilla luciferase reporter gene under control 
of the cytomegalovirus (CMV) promoter [295]. Although, the ultimate aim of this project is to 
target methylation to the promoter region of an endogenous gene, in the light of data from EMSA 
vs. ex vivo assays, reporter system evaluation was considered necessary.  
CAT is a bacterial resistance gene that inactivates the chloramphenicol antibiotic by acetylating 
one or both of its hydroxyl groups. As eukaryotic cells do not possess this gene, it is an ideal 
candidate for reporter gene studies. Its activity is directly proportional to the rate of acetylation 
observed in the CAT assay.  By monitoring CAT activity, it is possible to monitor accurately and 
sensitively transcriptional regulation of a promoter.  
An alternative reporter system based on Green Fluorescent Protein (GFP) was also used driven 
by a high molecular weight CDKN2B promoter fragment. GFP is a 283 amino acid protein, which 
when excited, exhibits green fluorescence [296].  A fragment of the CDKN2B promoter (1206bp) 
was cloned upstream of the GFP coding sequence and output in terms of GFP expression was 
measured by FACS.  In both settings, the expected outcome is that if the CDKN2B promoter 
becomes methylated, it should lead to the transcriptional downregulation of the CAT or GFP 
report system.  
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3.4.1 Cloning of CDKN2B promoter regulatory region 
 
To investigate the targeted delivery of different CpG methylation patterns to gene regulatory 
regions in vivo, I constructed two reporter vectors driven by CDKN2B promoter regions. These 
PCR products contained all of the ZF binding sites as well as the most important regulatory 
sequences within the CDKN2B promoter, and the main difference between them is that the 
shorter 734bp PCR amplicon lacked the first 472bp of the 5’ region shown in Figure 3-2 of this 
Chapter. Genomic DNA was isolated from the haematological cell line HL60 (Human 
promyelocytic leukaemia cells) as described in the Methods Chapter Section 2.8.3. The choice 
of the cell line was based on the fact that the methylation status of CDKN2B is known to be 
unmethylated in this case, unlike in the majority of haematological cell lines where this gene is 
either hypermethylated or deleted. Isolated genomic DNA was used as a template for PCR 
amplification to generate 734 bp and 1206 bp PCR fragments of CDKN2B promoter regions 
(Figure 3-11A).   
The generated CDKN2B fragments were subcloned into pBLCAT or pGFP reporter system 
vectors for subsequent methylation targeting and gene expression analysis. In principle, the 
CDKN2B promoter targeted with ZFs lacking HpaII methyltransferase should have no effect on 
reporter gene expression. Conversely, targeting with ZFs containing methyltransferase 










Figure 3-11. PCR Amplification of CDKN2B promoter regions  
A CDKN2B 734bp fragment and B CDKN2B 1206bp fragment. Fragments were amplified from HL60 cells using primers 
with XhoI/HindIII overhangs. Following gel purification, PCR products were subcloned into pBLCAT and transfected into 
A549 cells. B Schematic diagram of basic principle behind the reporter assay showing CDKN2B promoter driving the 
reporter gene (GFP or CAT). Targeted methylation delivery to the CDKN2B promoter region should result in methylation 
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PCR fragments were generated with XhoI/HindIII overhangs as described previously, for 
subsequent cloning into the chloramphenicol acetyltransferase (CAT) expression plasmid pBL-
CAT.  This resulted in two plasmids being generated, pBL-CATL12 (1206bp fragment) and pBL 
–CATS7 (734bp).   
Zinc Finger: methyltransferase constructs were subcloned into a modified CMV FLAG 
mammalian cell expression vector as described in Chapter 4 Section 4.5, in preparation for 
endogenous in vivo targeting studies. ZF vectors used for this study were ACMVMZH, 
ACMVABH and ACMPU1H. Two cell lines; A549 (Human lung adenocarcinoma epithelial cell 
line) and HeLa (Human Cervical cancer) were used for  transient co-transfection with pBL-
CATL12 or pBL –CATS7 and  one of the above described CMVZF vectors or non- specific 
4ZFCMV/HpaII was used as a negative control. The A549 cell line was chosen for this purpose 
due to its demonstrated homozygous 9p21 segment deletion [297], which would exclude the 
possibility of background CDKN2B signal interfering with the assay readout. Due to the fact that 
A549 was difficult to transfect with high efficiency by nucleofection (using Amaxa pGFP plasmid, 
maximum efficiency was 20%), HeLa cells were selected as an alternative. 
Transfected cells (A549 or HeLa) were harvested 96 h post-transfection, and CAT levels were 
determined using the CAT ELISA kit (Roche) using the protocol provided by the manufacturer. 
Briefly the cells were lysed in CAT ELISA kit lists buffer and cell extracts prepared. The basic 
principle of the assay is a sandwich ELISA. Lysed cells were added to the wells of the micro 
plate, already pre-coated with a polyclonal antibody to CAT (anti-CAT) (Figure 3.11). This anti-
CAT antibody is bound to the plate surface and captures CAT protein present in the cell extract. 
Following the incubation step, the plates are washed 4x in CAT Elisa Wash Buffer and the 
digoxigenin-labeled antibody to CAT (anti-CAT-DIG) is added and allowed to incubate for 1 hour 
at 37°C. The plates were washed as previously described, followed by the addition of an 
antibody to digoxigenin, conjugated to peroxidase (anti-DIG-POD), which binds to digoxigenin.  
Finally, the peroxidase substrate ABTS is added to catalyse the cleavage of the substrate, 
producing a coloured reaction sample. The absorbance of that coloured sample is determined 
using a spectrophotometer   and is directly proportional to the level of CAT present in the cell 
extracts.
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Figure 3-11. CAT Reporter Assay Description 
Reporter vector pBLCAT vector, containing either a full or partial fragment of the CDKN2B promoter (1µg) was co-nucleofected with a CMV vector expressing one of the ZF/HpaII fusions (1µg) and an 
Amaxa GFP (0.5µg) plasmid to monitor transfection efficiency. Nucleofection was carried out as described in the Methods Chapter  Section 2.10.3.1. Nucleofection Programmes were selected from the 
Amaxa cell database for ‘High Efficiency’.  The transfection efficiency was measured at 24, 48, and 72 h intervals.  Four days following transfections, cells were evaluated by monitoring GFP fluorescence 
by microscopy and A549 efficiency was found to be 25% compared to 70% for HeLa cells.  Therefore HeLa cells were selected for CAT Analysis using CAT ELISA. 



















5. CAT ELISA 
Detection Assay
Amaxa pGFP
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Following the CAT ELISA assay no CAT expression could be detected. The maximum 
concentration of reporter plasmid available in nucleofection experiments was 2µg/transfection 
so I was limited when troubleshooting in changing the amount of plasmid used. An alternative 
approach was to change the transfection protocol and a number of different transfection 
procedures were investigated including Lipofectamine 2000™, Fugene™, Icafectin 441 ™, Jet 
PEI™ and CaBES as described in Methods Chapter 2 of this thesis. A CAT signal was 
eventually detected using CaBES and a Jet PEI™ method perhaps reflecting the fact that 
these methods allowed for the highest concentration of DNA (5µg) to be used (Figure 3.12). 
However, the results were not reproducible, and an extremely high amount of cell lysate 







Figure 3-12. CAT ELISA curve following CaBES and JetPEI™ transfections. 
Transfected HeLa cells (1x106) were lysed and the cell protein concentration determined by BCA. CaBES lysates were 
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Following unreliable detection of CAT protein expression, an alternative approach was to use 
the GFP reporter system. The CDKN2B (1206bp) fragment was subcloned upstream of GFP 
to generate the p15GFP vector. HeLa cells were co-transfected using the CaBES method 
under the same conditions as for the CAT assay.  Cells were trypsinized four days following 
transfection and resuspended in DMEM media supplemented with 10% (v/v) FBS. GFP 
fluorescence was analysed by FACS (n=3). Unfortunately, only very low levels of GFP signal 






Figure 3-13. FACS Analysis of p15GFP transfected HeLa cells 
HeLa cells (1x106) were transfected with 5µg of p15GFP only or 2.5µg of p15GFP and 2.5µgpACMVPU1/HpaII plasmid. 
96h post transfection cells were collected for FACS analysis. GFP signal was gated on p15GFP transfected cells which 
were used as a negative control against a p15GFP+ACMPU1/HpaII transfected cells. Only a small increase in GFP 
signal of around 0.250% under both sets of conditions could be detected which was deemed insufficient for the reporter 
analysis following targeted methylation. FlowJo software was used to analyse transfection efficiency and the FL-1 
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A final attempt at analysis of targeted methylation using an in vivo reporter system was made 
by changing the readout assay for the CAT reporter activity. Traditionally, CAT activity is 
measured using a radioisotopic CAT assay.  
 
The radioactive CAT assay procedure was conducted as previously described. Briefly, a BCA 
assay was carried out to determine the concentration of the protein extract from the 
transfected cell lysate. Following incubation with 14C chloramphenicol and co-factor Acetyl 
Coenzyme A, the complexes were spotted onto a thin layer chromatography plate (TLC) and 
placed in a chloroform/methanol solution. Following product migration through the TLC plates, 
when the solvent reached the top of the TLC sheet, the plates were dried and then placed into 
a Phosphorimager cassette overnight for quantitative imaging analysis. Imaging was 
performed using a Fuji Phosphorimager 400 that uses storage phosphor technology for 
visualization purposes [298]. Different states of chloramphenicol acetylation, which appear as 
spots of different mobility,  appear in three forms – two forms of chloramphenicol with one 
acetyl group (monoacetylated),  one form with two acetyl groups (di-acetylated) and all of the 
unused chloramphenicol (Figure 3.14). The density of the spots can then be scanned for 
quantitative analysis using AIDA 2D densitometry software. CAT assay was kindly conducted 
by Dr Ford. 
 
As the result in Figure 3-14 shows, only un-acetylated forms of 14C could be clearly detected.  
The band intensity of migrated forms was measured using AIDA densitometry and no 
significant differences were observed between various samples. This is in line with the findings 



















Figure 3-14. CAT Assay TLC schematic representation  
Typical CAT assay result.  The reaction is placed onto the origin spot, allowed to dry the TLC plate lowered into the 
solvent and allowed to resolve up the TLC sheet until the solvent reaches the top of the plate. The plate is then dried 
and the spots can be visualised using either X-ray film or Phosphorimager. Five samples prepared from transfections 
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3.5 Conclusion  
 
Following successful subcloning and purification of different ZF/methyltransferase permutations, 
it was necessary to evaluate how fit for purpose newly generated fusion proteins were. The 
evaluation involved in vitro characterization of purified proteins for their binding affinity, 
specificity, ex vivo enzymatic activity, and ability to methylate and repress an artificial reporter 
system.  
Titrative EMSA analysis employed to evaluate the binding affinity of fusion proteins showed 
efficient and specific binding to their target sites. Four ZF/Mtase fusions were evaluated and 
found to bind to their target site with varying degree of affinity and specificity to the ZF target site 
compared to non-specific targets. Kd values ranged from high for 6ZFPU1/HpaII, to exceptionally 
poor for 6ZFMYC/HpaII. The results for 6ZFPU1/HpaII and 6ZFAB/HpaII compare favourably to 
similar six finger protein evaluations previously conducted in our lab.   Binding affinity data 
analysis showed that the PU1/HpaII binds to its target sites most strongly (apparent Kd 5.2nM); 
the AB/HpaII protein binds with intermediate strength (Kd 11nM). The Miz/HpaII fusion protein 
bound weak to its target site (Kd 43nM), and Myc/HpaII bound very weakly (Kd 992nM). Binding 
of the same fusions to the scrambled zinc finger and HpaII binding site was observed only at the 
extremely high concentrations of the proteins used (Figure 3-7). This indicates that the zinc 
finger dominates binding, while the non-target binding by the ZF: methyltransferase fusion 
protein a HpaII site only, occurs at very high concentrations of the proteins used.  However, it 
should be pointed out that the Kd values given are a guide only, as variations in protein purity, 
concentration measurements, and probe concentration make such comparative measurements 
prone to error.  
Given that most of the ZFs studied in these assays were designed and synthesized using the 
same approach, the differences in the binding affinities are perhaps surprising.  Zinc finger 
proteins are modular in nature, with each module capable of triplet base subsite recognition.  
DNA:ZF interface interactions are  believed to be highly diverse and complex, making attempts 
at developing  a definite recognition code extremely difficult.  In some cases, amino acid residues 
can recognize extended targets of four even five nucleotides [299]. These target site overlaps 
(TSO) can sometimes influence modularity of the adjacent fingers.  For instance, in a modular 
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array with TSO issues one zinc finger can interfere with the target-site of the zinc finger adjacent 
to it. They are  typically created by an aspartate residue at position 2 of the α-helix  (observed 
in GNN, ANN, CNN and TNN recognition  triplets)  making contacts outside the triplet base [300]. 
This potential to specify overlapping 4bp subsites can affect inter-finger synergism  as observed 
for Zif 268 where it was shown that deleting contacts from finger three can affect the adjacent 
binding site in finger  two [301]. However, TSO analysis shown in ELISA graphs in Figure 3-3 A-
C showed no TSO unmet preferences. 
Following successful targeting of two of the ZFs to a specific DNA target gave a degree of 
confidence that once fused with various methyltransferases for in vivo endogenous gene 
targeting, these proteins would be able to recognize a contiguous 18bp sequence within the 
mammalian genome.   
However, in vitro enzymatic activity evaluation was disappointing as all attempts to target 
methylation to the HpaII sites present on a ZF site containing plasmid did not succeed.  Previous 
results in our lab, when using these assays, have shown a clear trade-off between the binding 
affinity of the ZF component of the fusion protein and the methyltransferase enzyme activity. It 
may be that the binding of ZF with high affinity could compromise/restrict methyltransferase 
activity leading to the observed non - targeted methylation seen in these assays. This statement 
is based on the observed requirement for a large conformational change to occur in the 
methyltransferase component, in order for the methyl transfer reaction to occur. 
Another important point to consider is the orientation of the methyltransferase target in relation 
to the ZF binding site. This can often determine the success of targeting of the 
ZF/methyltransferase protein, especially if the HpaII sites are some distance away from the ZF 
site. The topology of the target vectors also needs to be considered as a contributing factor to 
the observed results. It is possible that supercoiled plasmid does not allow the ZF to ‘see’ its 
target site, or alternatively might present a high affinity substrate for the Mtase component, 
overriding the target properties of the ZF component. 
 Final point to consider is the flexibility between the fused domains of this enzyme. In this study, 
fusion proteins were joined by the flexible linker, (Gly4Ser)3. It has previously been reported that 
the use of linkers in fusion proteins can affect their folding stability due to issues of linker flexibility 
and hydrophilicity. The linker used for this project has been demonstrated to have an optimum 
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length and composition [302]. This is because Glycine has no unfavourable  β – carbon allowing 
the polypeptide backbone to access dihedral angles which are energetically forbidden to other 
amino acids [303]. Therefore, a linker which is glycine rich is more flexible than a linker of the 
same length composed of other residues. Conversely, too much linker flexibility will affect the 
single chain protein stability, which was avoided by inclusion of Serine residues in the linker. 
Studies using serine containing linkers indicate that there is a decrease in the unfolding rate of 
the protein inversely proportional to the increase in the number of the serine residues used. 
Serine residues within the linker will also increase hydrophilicity  due to the ability of serine to 
form hydrogen bonds, allowing the formation of new stabilizing interactions [302].  
Unfortunately, attempts to characterize the ability of ZF/Mtase fusions to target methylation to 
the CDKN2B promoter region of the CAT and GFP reporter constructs in vivo were not 
successful. The CDKN2B fragment was amplified from HL60 cells, and the region selected was 
believed to contain all the key regulatory sequences. Unfortunately, very low to undetectable 
levels of reporter activity (CAT or GFP) in HeLa cells or 293 cells were detected during this 
study.  I have found an example of a study using CDKN2B promoter reporter system. In this 
study, various CDKN2B fragments were used to evaluate Smad 4 recruitment to the promoter 
region in Capan-1 and CFPac-1 human pancreatic cancer cells. Two of the fragments they 
studied covered the region evaluated in my own study and showed a significant luciferase 
reporter activity following Smad4 binding to CDKN2B. However, the luciferase construct they 
used, p3TP-lux also contained a 3TP promoter with three consecutive TPA response elements 
(TREs) and a segment of plasminogen activator inhibitor 1 (PAI-1) [304].  An alternative study 
on Sp1 mediated activation of CDKN2B used a CDKN2B driven luc reporter system successfully  
only upon the TGFβ activation [305]. 
In conclusion, the promoter fragments used in this thesis were designed to cover the region 
between - 863 to + 273 region of CDKN2B with the long fragment 1206bp and a -383 to + 273 
for the short fragment of the CDKN2B. The CDKN2B promoter linked to the reporter system CAT 
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4.1 General Introduction  
 
Constitutively expressed and some tissue and lineage specific genes have CpG islands (CGIs) 
co-localized  with their promoters, leading in part to the observed uneven distribution of CpGs 
within the genome [306]. These CG rich regions can harbour the transcription start site (TSS) of 
genes and are usually associated with transcriptionally permissive chromatin [307]. 
There are suggestions that CGIs serve as a recruitment locus for transcription factor (TF) 
binding. This is based on an analysis of the density of transcriptional elements in the promoter 
and non-promoter CGI sequences, which showed around 40% relatively higher enrichment for 
TFs in promoter regions [308].  
 
Characterization of the chromatin structure associated with unmethylated CGIs reveals a strong 
correlation between CpG density and the presence of specific histone marks of actively 
transcribing genes i.e. H3K4 trimethylation, and H3 acetylation. Further support for a 
mechanistic interdependence between chromatin modifications and CGIs comes from 
observations that certain CpG binding proteins such as Cfp1, which exclusively associate with 
non-methylated CpGs, also interact with the H3K4 methyltransferase SETD1, to drive 
establishment of H3K4me3 [309].  
 
A majority of CGIs can be found within the 5'-untranslated region or exon 1 of genes, with only 
a few exceptions found in the gene body or 3'-region. It has been suggested that these atypically 
located CGIs are more likely to be DNA methylated [310]. In the majority of cases, promoter 
based CGIs are maintained methylation free, correlating with gene expression.  
 
Methylation of CpG rich promoters is often associated with down regulation of gene expression. 
A common question is whether such observed methylation is a cause or consequence of gene 
silencing. One proposed mechanism of gene silencing by methylation is through reduction of 
binding affinity of transcriptional activator for its target site. Site-specific methylation may block 
access to DNA of TFs required for optimal expression.   For instance, adenoviral TF Major Late 
Transcription Factor (MLTF) is prevented from binding its target site as a consequence of 
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methylation [311]. Another possibility for methylation mediated gene silencing is through 
recruitment of methyl CpG specific DNA-binding proteins which bind to methylated CGIs in vivo. 
It is assumed that this blocks access to the transcription factors necessary for transcription 
initiation. This model also implicates histone deacetylase activity in methylation mediated 
transcriptional repression, since this activity is shown to be recruited by methylated-DNA-binding 
proteins, such as MeCp2 [312, 313]. 
 
CGI hypermethylation of a tumour suppressor gene in a human cancer was first described  for 
the  Retinoblastoma gene (RBI) [314] and several years later, it was proposed as a mechanism 
of gene inactivation of the Von Hippel-Lindau (VHL) gene [315]. Hypermethylation of the CGI of 
the CDKN2A gene, which encodes an important cell cycle regulator (p16INK4A) occurs frequently 
in human cancers and is associated with gene silencing [316-318]. The identification of a large  
number of hypermethylated genes such as CDKN2A, CDKN2B, TP73, BRCA1, hMLH1, GST3, 
MGMT, CDH1, TIMP3, and DAPK followed, in a study of over 600 large primary tumour samples, 
representing 15 major tumour types [319]. Another large study of sporadic and inherited breast 
and colon tumours showed that the cancer cell genome undergoes a reduction of its 5-
methylcytosine content compared with normal tissue of the same origin [320]. This finding is 
difficult to explain considering that there is an overall increase in the activity of the DNMTs 
(DNMT1, DNMT3A and DNMT3B), which are shown to be upregulated in solid tumours and 
haematological malignancies such as acute and chronic myeloid leukaemia [321, 322]. 
 
One explanation for this paradoxical distribution of DNA methylation throughout the genome 
might be that DNMTs somehow become unable to recognize sequences such as DNA repeat 
regions or intronic sequences that are normally required to be methylated, whereas CGIs, which 
are not usually targets of the DNMTs in a chromatin context, become methylated. In this regard, 
it is perhaps noteworthy than mutations in many cellular epigenetic factors (e.g. BmiI, Ezh2, 
Asxl1), including DNMTs, are now being observed in cancer and leukaemia patients, and these 
may be informative of the mechanisms behind aberrant DNA methylation in these diseases.  
Apart from imprinted genes [323] and X-chromosome genes in females [324], the majority of 
CGIs are unmethylated in normal tissue.  
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As it stands, the question of what triggers the decision to include or exclude methylation in the 
cell, and how DNA methylation patterns arise in the cancer cell, specifically the hypermethylation 
of normally unmethylated gene promoter regions, remains unanswered. Studies described 
below suggest that CpG methylation of a promoter may be a progressive process, where several 
cycles of aberrant methylation may need to occur before a dense hypermethylated pattern can 
be imposed, leading to transcriptional silencing. DNA methyltransferase enzymes primarily 
target  CpG dinucleotides, but paradoxically even during development where global de novo 
methylation changes occur within the epigenome, CGIs in healthy cells are usually unmethylated 
[325]. Two mechanisms have been proposed to explain the occurrence of the aberrant de novo 
methylation in cancer. The first mechanism proposes methylation spreading into the CGI from a 
de novo methylation centre juxtaposed to that island, such as the flanking Alu repeats 
surrounding  the CDH1 and VHL tumour suppressor genes [326]. The second hypothesis is that 
there are methylation hot spots within the CGIs which succumb to methylation, leading to the 
spread until a state of hypermethylation is achieved. This has been observed for the glutathione-
S-transferase P1 (GSTP1) gene promoter in prostate cancer, where a combination of random 
site methylation and prior gene silencing lead to promoter hypermethylation [327]. Both 
mechanisms do not exclude the possibility that CGIs are kept methylation-free by the existence 
of certain boundaries which provide protection from methylation, perhaps by binding interference 
and which are progressively overridden during the disease process.   
 
Studies on the mouse and hamster adenine phosphoribosyltransferase (APRT) housekeeping 
gene promoter for example showed that the island is free of methylation, with the flanking 
regions containing methylated CpG sites. This study proposed a model by which APRT is kept 
methylation- free, most likely via Sp1 occupying 5’ sites of the promoter [328, 329]. It is also 
possible that RNA transcripts anti sense to a promoter may protect the CGIs either directly or in 
combination with 5MeC-DNA glycosylase by demethylation targeting [330]. Finally, there is a 
suggestion that specialized nucleosomal structures, chromatin signatures and/or replication 
timing  may inhibit CGI methylation [331]. CGIs are believed to be sites of both transcription and 
replication, based on their observed co-localization with the origin of replication [332]. 
Mammalian replication origins that co-localize with CGIs were observed for a number of genes 
such as Heat shock protein 70, c-MYC, and CDKN2B [333-336]. This observation has led to the 
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suggestion that replication initiation intermediates can lead to the exclusion of DNA methylation 
[337]. Issues of promoter methylation and protection will be discussed in more detail in the next 
chapter.  
 
It appears that some CGIs become hypermethylated, conferring a selective advantage for the 
survival of the cancer cell. An example for this Darwinian concept is the BRCA1 gene found to 
be hypermethylated only in breast and ovarian cancer [338], or the mismatch repair gene 
hMLH1, which is epigenetically silenced only in colon, gastric and endometrial neoplasia where 
its transcriptional  downregulation has  important cellular consequences [339]. These findings 
correlate very well with the familial tumour genetic studies on BRCA1 and hMLH1 germline 
mutations. However, the situation is not that simple, which is exemplified by two illustrative 
cases; 1) in breast cancer only BRCA1 gets hypermethylated while BRCA2 does not [340]; 2) 
the hMLH1 promoter is hypermethylated, while closely related family members with very similar 
CGIs such as hMSH2, hMSH6 and hMSH3 are not [339]. It is not clear whether a specific 
property of various CGIs protects them from methylation or if there is a more general shield that 
prevents access to DNMTs. The correlation between gene silencing and promoter 
hypermethylation is not valid in all cases. Gene silencing can occur prior to any de novo DNA 
methylation or chromatin remodelling event. This was demonstrated for the CDKN2A CGI in 
primary human mammary epithelial cell (HMEC) lines during selection, where gene silencing 
was shown to precede epigenetic suppression and low levels of de novo methylation were 
associated with a dynamic remodelling of histone modifications [341].   
In order to investigate the role of DNA methylation signatures at gene promoter regions I needed 
to reproduce methylation patterns at specific CGIs. Previously it was shown in our lab that it is 
possible to target DNA methylation to an artificial CGI and it was confirmed that such imposed 
methylation was able to down regulate gene expression and in a heritable manner [342]. This 
method of targeting DNA methylation involved expressing zinc finger proteins expressed as 
fusions with the catalytic domains of mammalian or prokaryotic methyltransferases [343-347].   
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4.2 Zinc Finger Protein Methodology 
 
The modular nature of individual zinc fingers within ZFP arrays has suggested ZFPs as 
appropriate templates for the construction of highly specific gene targeted binding proteins. The 
generation of ZFP:DNA recognition codes (explained in detail in Chapter 3) has enabled the 
design and construction of zinc fingers designed to bind virtually any DNA sequence [348]. By 
stringing zinc finger modules in a tandem array for example, unique sequences of up to 18 base 
pairs have been constructed for targeted binding in vivo [349]. ZFPs with such engineered DNA 
sequence specificities have so far been used either without any functional domain attachments 
or as fusions with various effector domains that directly interact with DNA and/or with other 
proteins. These include ZFPs for gene targeting and regulation purposes tethered to cleavage 
domains of endonuclease FokI [350], functional domains of transcription factors such as Sp1 
[351], chimeric transposases [352], chimeric recombinases with the catalytic domain from 
bacterial Tn3 resolvase [353], HIV retroviral integrase [354], repressor domains such as Kruppel 
associated box (KRAB), ERF repressor domain (ERD), TATA box binding protein (TBP), 
transcription activation domain of  herpes simplex virus VP16 region [355-359], or the p65 
domain of the human endogenous transcription factor NFκB [360] and various 
methyltransferases [361]. 
 
Some of the above mentioned examples are of ZFP-based transcription factors targeted to 
artificially integrated chromosomal loci, or to non-chromatin targets such as targeting of HSV-1 
LTR using six finger arrays [362, 363]. There are however also clear cases where artificial ZFP-
based TFs have been shown to regulate endogenous gene expression. These target genes 
include human erythropoietin (EPO1) [364], Vascular Endothelial Growth Factor A (VEGF-A) 
[365], the erbB-3 protoncogene [366], while the peroxisome proliferator activated receptor-γ 
(PPARγ) [367], multidrug resistance gene (MDR1) [358] and checkpoint kinase 2 (CHK2) [368] 
have all been demonstrably downregulated by artificial ZFP-based repressors. Some of the ZFP 
fusions such as the ZFP transcription activator VEGF-A fusion (SB-509), ZFP fusions with CCR5 
co-receptor which is used by the HIV virus to infect the cells of the immune system (SB-728), 
and ZFP/ glucocorticoid receptor gene fusion (SB-313) have been through Phase I and II clinical 
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trials which have proved their safety and efficacy in the treatment of diabetic neuropathy [369, 
370]. 
 
The first attempt to target a methyltransferase component fused to a zinc finger (ZF) was to the 
p53 DNA binding site of the CDKN1A gene. This method was shown to be capable of delivering 
methylation to the desired target regions in a site-specific manner in in vitro assays [371]. Similar 
targeting effects were observed in a yeast in vivo model examining the CAR1 promoter, using 
ZFP/M.SssI or M.CviPI fusions [372]. Additionally, it has previously been demonstrated in our 
lab that three ZF, M.HhaI or M.HpaII fusion proteins resulted in specific DNA methylation in vitro 
[346]. Extension of this work to the genomic context using cell lines harbouring integrated 
reporter genes driven by artificial CG rich minimal promoter regions confirmed targeted 
methylation specificity, gene repression due to targeted DNA methylation and the heritability of 
the silencing signal [342]. This project aims to take this process one step further by delivering 
targeted methylation to an endogenous gene promoter relevant to a specific disease. The 
success of intracellular targeting by ZFP-Methyltransferases (ZFP-MT) is highly dependent on 
the correct delivery of the zinc finger in its properly folded form and the ability of that finger to 
access its intended target.  
 
 
4.3 CDKN2B Context 
 
The CDKN2B gene represents a challenging and important model candidate gene for targeting 
studies, based on previous observations that this is one of the most frequently methylated genes 
in particular subtypes of haematological malignancies, such as MDS, AML and ALL. CDKN2B 
encodes p15INK4b, a cyclin-dependent kinase inhibitor that is expressed selectively in 
haematopoietic progenitor cells during myeloid and megakaryocytic, but not erythroid, 
differentiation [373, 374]. Aberrant promoter hypermethylation occurs in the promoter region of 
the CDKN2B gene and is associated with its transcriptional silencing [375-377].  
 
The CDKN2B CGI has a 67% GC content and structurally is a good candidate for attempts at 
methylation-mediated silencing due to the fact that the transcriptional start site is located within 
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the island. This region contains a number of regulatory element binding sites as well as 
methylation sensitive restriction endonuclease sites, such as seven HpaII sites (with recognition 
sequence CCGG) and sixteen HhaI sites (GCGC), which historically have been used to probe 
the methylation state of the CDKN2B promoter [378, 379]. 
 
 
4.4 Chapter Aim 
 
I have rationally designed six zinc finger proteins targeting different regions of the promoter of 
the endogenous CDKN2B gene. The GCG Wisconscin Package TF software was used to 
determine the putative location of important regulatory sites within the promoter in the region 
spanning ~1500 base pairs. Also, target sites were identified from published work relating to the 
key transcriptional regulator binding sited for CDKN2B.  Precise ZF sites were chosen after 
considering their proximity to these regions and the transcription start site.  Zinc finger protein 
ZMZ, was designed to recognise the 5’ flanking region of the promoter at +238 from the Initiator 
Sequence (Ir), which is relatively sparsely populated with CG residues (for details see Figure 3-
2 Chapter 3). This region harbours a Miz-1 binding site, a transcription factor putatively involved 
in up regulation of CDKN2B [380]. The rationale for targeting this relatively CG poor region of 
the promoter was based on an earlier observation that in certain promoters, such as that of the 
Interleukin 2 (Il2) gene, which is silent in naïve murine T lymphocytes but becomes expressed 
upon T cell activation, only the most proximal CG residues are proposed to play a role in 
methylation related gene regulation [381]. Additionally, this region of the CDKN2B promoter also 
contains putative Smad binding sites, which are transcription factors directly activated by 
transforming growth factor-β (TGF-β) and involved in CDKN2B transactivation via Miz-1 [382].  
Two additional six zinc finger proteins, ZMC and ZAB, were designed to recognise sites within 
the most densely CG populated region at -186 and -197 (Figure 1.20 Chapter 1). This region 
contains binding sites for many important regulatory elements, such as Sp-1, a transcriptional 
activator of the CDKN2B gene [383]. Methylation profile analysis of the CDKN2B gene in 
samples from patients with AML, ALL, and CML shows frequent methylation at the 
aforementioned Sp-1 site [384]. Although Sp-1 itself is not sensitive to DNA methylation, binding 
- 125 - 
to DNA could be blocked by recruitment of methyl-cytosine binding proteins, as discussed 
previously in Chapter 1. 
A fourth six zinc finger protein ZPU1 was designed to recognise a sequence further downstream 
at -402 in the 3’ promoter region close to the CDKN2B translation start site. Following rational 
design, all of the constructs encoding ZFPs were synthesized commercially by GenScript, with 
the exception of ZFPAB, which was assembled using the SOE-PCR approach previously 
described in Chapter 3.  
 
4.5 CMV FLAG-TAG Expression  
 
Zinc Finger Proteins targeting the CDKN2B promoter region were rationally designed using the 
Barbas’ lab Zinc Finger Tools website as specified previously in Chapter 3 Section 3-2. [385]. 
There are 64 DNA triplets that could be potentially targeted by ZFPs and up to 10kb of DNA 
sequence can be searched at once to select potential, high affinity ZFP binding sites. The amino 
acid sequence of each zinc finger protein used in these studies as well as the rationale for the 
ZFP selection based on the scoring system   was described in Chapter 3 Section 3.2. and Figure 
3-6. 
The commercially synthesized and sequenced ZFPs were evaluated in in vitro settings for their 
binding affinity. ZFPs were cloned  into human cytomegalovirus (CMV) based vectors and 
expressed either alone or as amino terminal fusions with the prokaryotic methyltransferases 
M.SssI, M.HpaII and with the catalytic domains of the murine DNMT3A and DNMT3B 
methyltransferase, for the  endogenous targeting studies. CMV expression vectors contained 
the nuclear localization signal (NLS) PKKKRKV and an N-terminal FLAG tag, for the detection 
of protein expression. The function of the NLS signal is to direct the protein to the cell nucleus 
through the nuclear pore complex via its recognition by cytosolic nuclear transport receptors. 
The general schematic for ZF-MTase constructs is shown in Figure 4-1.  The list of all of the 
constructs designed this way is shown in Table 4-1.  
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Figure 4-1.   Schematic of expression constructs for ZF-MTases.  
The schematic diagram describes the basis of Flag-NLS-ZF-Mtase expression constructs used for the studies. Various 
Mtases are fused with ZFPs, a nuclear localization sequence (NLS) and a FLAG-tag.  All ZFPs were synthesized to 
contain BamHI /PacI overhangs to enable subcloning in frame with different methyltransferases. DNMT3A and 
DNMT3B methyltransferase catalytic domains were subcloned as BspEI/XmaI fragments, whereas prokaryotic M.SssI 
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Table  4-1.   CMV constructs of ZFP/methyltransferase fusions.  
 
Four ZFPs (PU1, MIZ, AB and MYC) were fused with either eukaryotic methyltransferase catalytic domains DNMT3B 
and DNMT3A or prokaryotic methyltransferases M.SssI, M.HhaI and M.HpaII in a CMV vector for mammalian expression 
and targeting studies.  CMV constructs containing only ZFPs without methyltransferases were also generated for use 
as a negative control in targeting studies.   
 
4.6 CMV FLAG Detection  
 
Initial experiments were designed to assess whether HeLa cells transfected with the constructs 
described above expressed FLAG tagged protein fusions of the correct size. The FLAG–tag is 
a polypeptide tag with the sequence N-DYKDDDDK-C, 1012 Da in size which is detectable with 
an anti-FLAG monoclonal antibody [386]. The tag has a wide variety of applications, primarily in 
affinity chromatography as well as recombinant protein isolation and purification and is not 
known to be expressed as a part of any human gene. FLAG-TAG was originally developed as 
a  small N-terminus hydrophilic peptide engineered for the purpose of detection and purification 
of recombinant lymphokines from yeast supernatants or E. coli extracts [387]. Constructs listed 
in Table 4-1 were maxi prepped as described in Methods Chapter 2 Section 2.8.9.2. and 
transfected into HeLa cells, using the CaBES method described previously in Methods Chapter 
2 Section 2.11.3.3. Samples were taken four days post transfection for western blotting. 
Transfected HeLa cell samples at 1x106 were trypsinized, washed in PBS, and western blotted 
as described in Methods Chapter 2 Section 2.13.2. Novex ® Sharp Protein Standard was used 
ZPU1 ZMZ ZAB  ZMC  
ACMVZPU1B  ACMVZMZB ACMVZABB   ACMVZMCB  
ACMVZPU1S ACMVZMZS ACMVZABS  ACMVZMCS  
ACMVZPU1H ACMVZMZH ACMVZABH  ACMVZMCH  
ACMVZPU1A ACMVZMZA ACMVZABA  ACMVZMCA  
ACMVZPU1Hh ACMVZMZHh ACMVZABHh  ACMVZMCHh  
ACMVZPU1 ACMVZMZ ACMVZAB  ACMVZMC  
- 128 - 
for molecular weight estimation. The marker covers 3.5-260kDa range.  Monoclonal ANTI-
FLAG® M2 Clone antibody (Cat No F3165, Sigma-Aldrich) was diluted 1/2000 in PBS with 
1%BSA (w/v).   
The expression from each of the constructs shown in Figure 4-1 in HeLa cells is shown in Figure 
4-2 and the cellular localization of the ZFPs/ methyltransferase fusions by immunofluorescence 
in Figure 4-5. The FLAG-tag attached to the protein is highly hydrophilic and as such less likely 
to denature or inactivate the proteins it is attached to [388].  
FLAG-tag expression was confirmed by western blot and the results are shown in Figure 4-2. 
Expression of FLAG-tag ACMV constructs containing ZF alone (ACMVPU1, ACMVMC, 
ACMVMZ and ACMVAB) was confirmed with the observation of an expected band of 21.8 kDa, 
Panel A. Also shown in Figure 4-2 A is confirmed expression of zinc finger protein AB fused with 
either DNMT3A or DNMT3B catalytic domain methyltransferase with expected band sizes for 
ACMVABB 56.3 kDa and 58.5 kDa for ACMVABA.  Figure 4- 2 B shows three of the ZFPs (PU1, 
MYC and MIZ) either alone or as a part of DNMT3B catalytic domain fusions. The expression of 
FLAG-TAG ACMVPU1B, ACMVMZB and ACMVMCB ZFP/methyltransferase fusions was 
observed with the detection of a 56.3 kDa band size and a 21.8 kDa band size corresponding to 
ACMVPU1, ACMVMZ and ACMVMC zinc fingers alone. Finally, the expression of the same 
constructs with the DNMT3A catalytic domain methyltransferase was confirmed with the 













Table  4-2.   FLAG-TAG ZFP/methyltransferase fusion proteins.  
 
This table summarizes nomenclature of FLAG- ZF/ methyltransferase fusion proteins and their respective sizes. Proteins 
were detected by western blot.  
 
 
Vector Used Protein  Protein Size Expected 
(kDa) 
ACMVPU1 FLAG-PU1 21.8 
ACMVPU1B FLAG-PU1B 56.3 
ACMVPU1A FLAG-PU1A 58.5 
ACMVPU1H FLAG-PU1H 62.0 
ACMVPU1Hh FLAG-PU1Hh 58.8 
ACMVPU1S FLAG-PU1S 63.8 
ACMVAB FLAG-AB 21.8 
ACMVABB FLAG-ABB 56.3 
ACMVABA FLAG-ABA 58.5 
ACMVMZ FLAG-MZ 21.8 
ACMVMZB FLAG-MZB 56.3 
ACMVMZA FLAG-MZA 58.5 
ACMVMC FLAG-MYC 21.8 
ACMVMCB FLAG-MCB 56.3 
ACMVMCA FLAG-MCA 58.5 




Figure 4-2  FLAG- tag protein expression in HeLa cells. 
FLAG- ZFP/methyltransferase permutations proteins were detected using anti FLAG-tag monoclonal antibody following 
transfection of HeLa cells. The constructs shown in Table 4-1 were used to transfect HeLa cells and four days post 









































































































































- 131 - 
 
Although a weak band can be seen for ZFPU1S in Figure 4-2, no consistent FLAG- tag signal 
could be detected in subsequent experiments. The methylation status of these plasmids was 
checked using the methylation sensitive restriction enzyme  R. HpaII (CCGG) and its 
isoschizomer R. MspI, which is not sensitive to methylation (Figure 4-3). More than 50% of the 
plasmid is methylated, i.e. remains uncut using HpaII methylation sensitive restriction enzyme.  
It is not unlikely that significant levels of plasmid methylation may lead to lack of expression from 
the plasmid itself in transient assays. The plasmid also has more potentially methylatable CpG 




Figure 4 -3 Restriction digest analysis of CMVZFPU1S construct. 
CMV ZFP/SssI plasmid construct digested with methylation sensitive R.HpaII and insensitive R.MspI enzymes. 
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To better understand and assess the adaptation of the bacterial genes (M.HpaII, M.HhaI, 
M.SssI) to their mammalian hosts (HeLa cell line) as well as to possibly predict the levels of their 
expression  and gain an insight into the likely success of heterologous gene expression a Codon 
Adaptation Index (CAI) was used [389]. Comparisons of codon usage, GC content and the 
percentage of low frequency (<30%) codons of the methyltransferases used for this projects; 
M.HpaII, M.HhaI, M.SssI, and DNMT3B (Catalytic domain) were assessed using GenScript Rare 
Codon Analysis Tool (http://www.genscript.com/cgi-bin/tools/rare_codon_analysis).  
Codons can influence the translation rate of a protein in a number of ways. CAI is a useful tool 
for predicting the level of gene expression based on the pattern of codon usage [390]. It has 
been observed in Escherichia coli, that if a target protein is not derived from the same species 
as the expression host its codon usage differs significantly from that of the host organism. Using 
two different DNA fragments, one with common codons and the other with infrequent codons 
inserted into the lacZ gene, a six fold difference in translation rate between  the two  has been 
observed [391].  
A CAI value of 1.0 is considered ideal with any significant deviations from this value representing 
a potential negative effect on gene expression. The GC content of the gene can have an 
influence on transcriptional efficiency of that gene and the efficiency of translation of its mRNA 
[392].  Generally, GC content ranging between 30% and 70% is considered best. Whilst the 
favourable codons are read by the most abundant tRNAs and therefore highly translated [393], 
tandem rare codons are read by tRNA that are present in low abundance [394], which can lead 
to stalling of translation  and premature degradation of mRNA [395, 396]. Figure 4-4 summarizes 
codon usage information for methyltransferases used in this project.  
The CAI, GC content and codon usage by DNMT3B catalytic domain eukaryotic 
methyltransferase was used as a reference point against  the prokaryotic methyltransferases 
(M.HpaII, M. SssI and M.HhaI). The only significant difference was in GC % content between 
the DNMT3B (50%) and the prokaryotic methyltransferase M.SssI (27%), M.HpaII (34%) and 
M.HhaI (33%). 
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Figure 4-4   Codon Analysis Information   
Graph representation of the CAI values, GC values and Codon Usage for the three prokaryotic methyltransferases used M.HpaII, M.HhaI and M .SssI and a catalytic domain of DNMT3B eukaryotic 
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Table 4-3.   Codon Analysis Table.  
Four methyltransferases (M.HpaII, M.HhaI and M.SssI and the catalytic domain of DNMT3B) were codon analysed as 
described above. CAI values are indicators of gene adaptation with an optimum value of 1.0. For the methyltransferases 
analysed this value ranged between 0.63 to 0.70. Generally, the lower the CAI value, the higher the likelihood that the 
gene will be expressed poorly. The GC content for M.SssI was under 30% which is in the lower optimum range increasing 
the likelihood of a negative effect on its transcriptional and translational efficiency.  
 
4.7   Cellular Distribution of ZFP/Methyltransferases-       
Immunofluorescence Analysis 
 
Following analysis of protein expression, their cellular distribution was assessed using 
immunofluorescence. The method allows detection of the location and relative abundance of a 
protein of interest using light microscopy with a fluorescence microscope. The key to the whole 
procedure is the choice of an antibody capable of detecting the protein of interest (FLAG in this 
case) and targeting the fluorescent dye of choice to the correct antigen. I have employed 
secondary indirect immunofluorescence in HeLa cells with two antibodies; a primary anti FLAG® 
M2 monoclonal antibody (Sigma-Aldrich Catalogue No: F3165) to specifically bind FLAG-tag 
upon transfections with ACMVPU1 ZFP fused with the methyltransferases used in this project; 
M.HpaII, M.HhaI and M.SssI and a catalytic domain of DNMT3B and DNMT3A. The primary 
antibody was captured by a secondary anti -mouse antibody conjugated to FITC fluorophore, 
BD Pharmingen ™ FITC Rat Anti-Mouse IgG1 (Catalogue No: 553443) (used at 1:400 dilution), 
a kind gift from Dr Jonathan Morris (Cancer Cell Biology and Imaging group). FITC (Fluorescein 
isothiocyanate) was visualized in the green region with excitation and emission spectrum 
wavelengths of 495nm and 521nm respectively.   
Methyltransferase   CAI   CG%   Codon Usage% 
M. SssI  0.63 26.91            6 
M. HpaII 0.68 33.64            4 
M. HhaI 0.63          32.79            7 
CAT DNMT3B 0.70          50.48            5 
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Additionally, HeLa cells were stained for Nucleolin using an anti-rabbit Nucleolin polyclonal 
antibody (used at 1:400 dilution) a kind gift from Professor Angus Lamond, University of Dundee. 
This was followed by a secondary antibody staining with Alexa Flour 633 (Life Technologies Cat 
No A21071) conjugated anti- rabbit antibody (used at 1:400 dilutions). The fluorophore is 
fluorescent in the far red region with an absorption max at 632 nm and emission max at 647 nm). 
The staining procedure is described in detail in the Methods Chapter 2, Section 2.13.4. Briefly, 
HeLa cells were transfected in a 12 well format with the ACMVPU1, ACMVPU1H, 
ACMVPU1/SssI, ACMVPU1/3A and ACMVPU1/3B constructs using IcaFectin™ 441 as 
described in Methods Chapter 2 Section 2.11.3.2. Three days following transfections, HeLa cells 
were trypsinized, washed once in PBS, pelleted by centrifugation at 200xg for 10 minutes  and 
resuspended at 2.5x105 cell/400µl of DMEM media supplemented with 10% FBS (v/v). Following 
growth on Poly-L-lysine coated slides, cells were subjected to Paraformaldehyde (PFA) fixation, 
Triton X-100 lysis and 10% Donkey Serum (DS) blocking (see Methods Chapter 2 Section 
2.13.4.). Cells were co-stained with anti-rabbit Nucleolin polyclonal antibody (used at 1:400 
dilution) and anti- FLAG® M2 monoclonal antibody (used at 1:100 dilution) overnight at 4°C. 
Following secondary antibody staining using fluorescent antibodies described above, the slides 
were DAPI stained, to allow visualization of DNA and the nucleus.  DAPI is excited by ultraviolet 
light with absorption maximum of 358nm and emission at 461nm which appears 
blue/cyan. Following staining, slides were fixed with mounting solution and visualised using 
inverted microscopy (Zeiss microscope and AxiovertVision software version 4.3.). Results of 
staining are shown in Figure 4-4. A FITC FLAG-tag signal could be detected in all of the stained 
slides apart from the negative control, which were mock transfected cells. For the majority of the 
slides FITC FLAG-tag signals appear co-localized with DAPI and CY-5 labelled Nucleolin which 
suggests nuclear localization of the transfected constructs. Only for ACMVPU1/ HpaII did there 
appear to be some cytoplasmic localization in addition to nuclear. Overall it can be concluded 
that the NLS signals effectively drives the plasmid constructs upon transfection to its intended 
region which is essential for targeting DNA requirements for the ZFPs. 
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Figure 4-5  Indirect immunofluorescence analysis of FLAG-tag cellular localization. 
HeLa cells were transfected with CMVPU1/Mtase/FLAG-tag or CMVPU1/FLAG-tag plasmids. Four days post transfections cells were stained for FLAG-tag using anti-FLAG mouse monoclonal antibody, 
followed by anti-mouse FITC conjugated secondary antibody. Cells were also stained for nucleoli using polyclonal rabbit anti- Nucleolin which was a positive control for our staining assays, followed by anti-
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4.8 Experimental Logistics evaluation 
 
4.8.1  Cell Line Transfection Efficiency Evaluation 
 
Two different cell lines were used for transfection efficiency studies. The cell line initially chosen 
for the purposes of the project was human promyelocytic leukaemia cell line HL60, because of 
its haematological lineage and because it possess a transcriptionally active CDKN2B gene, with 
an unmethylated promoter. However, as HL60 suspension cells proved difficult to transfect, the 
human epithelial cervical cancer HeLa cell line was also investigated as an alternative model. 
 
The transfection efficiency of HL60 cells was evaluated using 1µg of DNA encoding fluorescent 
protein GFP (pGFP Amaxa). A number of different transfection reagents were tested; a novel 
synthetic compound (IcaFectin™), a linear polyethylenimine derivative (JetPEI™), and 
nucleofection – nuclear gene transfer technology Amaxa®. The transfection protocol for each 
procedure is described in detail in the Methods (Chapter 2 Section 2.11.3). HL60 transfected 
samples were analysed 24 hours post-transfection for the presence of GFP protein using FACS 
(Figure 4-6). 
The GFP signal was gated on mock transfected HL60 cells which were used as a negative 
control. The FL-1 channel was used to measure GFP intensity and FlowJo software was used 
to analyse transfection efficiency. Transfection efficiencies using different methods differed 
significantly, with nucleofection giving the best result with efficiencies of close to 70%. 
Nucleofection uses a device called a Nucleofector to electroporate plasmid directly into the cell 
nucleus with the help of cell type specific reagents and under specific electrical parameters. 
JetPEI™ a linear polyethylenimine derivative positively charges DNA to bind to anionic cell 
surface residues and enter the cell via endocytosis. Once inside the cell the amines are 
protonated resulting in an influx of counter-ions and a lowering of the osmotic potential. The 
resulting osmotic swelling  releases the DNA:PEI complex into the cytoplasm from where the 
DNA diffuses into the nucleus once unpacked from the PEI complex [397]. IcaFectin™ 441 uses 
proprietary, synthetic molecules derived from natural compounds to form discrete compact 
mushroom like structures with DNA for optimal delivery into the cells.  
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Figure 4-6 HL60 Transfection efficiency.  
pGFP Amaxa transfected HL60 cells were assayed for GFP expression 24 hours post transfection using three different 
methods; Amaxa® Nucleofection, IcaFectin™ and JetPEI™ A Untransfected HL60 cells. B IcaFectin™ transfection 
efficiency was 15%, and the cell population appears healthier compared to nucleofected samples (D). C JetPEI™ 
reagent appeared to have toxic effect on HL60 cells.  D The best transfection efficiency was achieved using Amaxa® 
nucleofection (66%).  
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In subsequent nucleofection experiments, low HL60 cell viability was observed. The cells 
appeared morphologically different compared to un-transfected HL60 cells, upon light 
microscope observation and failed to proliferate further. This was assessed by Trypan blue 





Figure 4-7 HL60 Nucleofection efficiency Assessment  
HL60 cells were nucleofected as previously described using a pGFP Amaxa plasmid.  Cells were nucleofected using 
different Amaxa programmes either for high transfection efficiency (T1 and T19) or high post-transfection cell viability 
(S11). GFP transfection efficiency was assessed 24h post-transfection using a fluorescent microscope with 60% cells 
positive for GFP expression. Cells were counted using Trypan blue exclusion at 24 hour intervals for four days. 
Irrespective of the nucleofection programme used, HL60 cells failed to proliferate further. Similar experiment was 
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As an alternative strategy to HL60 transfection lentiviral transduction approach on HL60 cells 
was investigated. Standard lentiviruses are capable of stable integration of their genome into 
the host genome. Because the goal was to deliver a transient promoter targeted DNA 
methylation event, I chose to explore the possibility of using second generation, non-integrating 
lentiviral vectors (NILVs) which harbour integrase mutations that reduce the likelihood of stable 
transgene integration.  
 
A series of plasmids were used to produce the lentiviruses  in Human Embryonic Kidney 293 
cells (293T) cell line with a biotinylated VSV-G envelope and included a lentiviral expression 
plasmid containing the GFP gene inserted between the lentiviral LTRs, a packaging plasmid, 
(pLV-HELP), encoding the pol, gag, rev and tat viral genes and containing the rev-response 
element (RRE); and a pseudotyping plasmid  pLV-iVSV-G, encoding the G protein of the 
Vesicular Stomatitis Virus (VSV-G) envelope gene. The plasmids were generously provided by 
Dr Lucas Chan of the Department of Haematological and Molecular Medicine.  Lentiviral 
particles were concentrated using streptavidin conjugated magnetic beads according to methods 
published by Dr David Darling of this department [399] and under the kind guidance of Dr Darling 
the particles were used to infect HL60 cells. Upon target cell infection, the viral RNA is reverse- 
transcribed, and imported into the nucleus.   
 
GFP expression was assessed at three day intervals for up to 18 days by FACS and analysed 
using FlowJo software Figure 4-8. Although significant transduction efficiency was obtained 
using the lentiviral transduction method, even after 18 days too high a percentage of cells 
remained GFP positive, suggesting stable integration of the GFP gene.  This was deemed 
unacceptable as we required establishment only of transient expression of targeted 
methyltransferase enzymes.  
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Figure 4-8 GFP expression in HL60 following Lentivirus transduction.  
Expression was monitored for 18 days following virus transduction by FACS. Best transfection efficiency was achieved 
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Given the inability to either efficiently transiently transduce HL60 cells using lentiviral particles 
or generate proliferating cells following nucleofection, the HeLa cell line was subsequently 
evaluated as an alternative system. This is an adherent cell line easily transfectable, receptive 
to plasmid vectors and widely used for such purposes. Additionally, the CDKN2B promoter is 
unmethylated in this cell line, and p15INK4B protein is expressed.  
Transfection efficiency and cell viability following HeLa transfections, using Icafectin 441™, 
CaBES and Amaxa® nucleofection were assessed as described above for HL60 evaluations. 
HeLa pGFP Amaxa transfected samples were analysed 24 hour post-transfection for the 
presence of GFP protein using FACS as previously described. Transfection efficiencies using 
different methods were consistently very good, at around 70% for all the transfection methods, 
as shown in Figure 4-9.  




Figure 4-9 HeLa Transfection efficiency evaluation 
Measurement of GFP expression as an indicator of transfection efficiency of HeLa cells. HeLa cells were transfected 
with pGFP Amaxa using three different methods; Amaxa® nucleofection, Icafectin™ 441 DNA transfection reagent and 
CaBES method. Best transfection efficiency (71.5%) was achieved using Amaxa® nucleofection method, followed by 
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Cells were also monitored for their proliferation rate, recovery and viability by Trypan Blue 
exclusion as shown in Figure 4-10. Nucleofected cells appeared to take longer to recover (3 
days), compared to Icafectin™ 441 and CaBES transfections. CaBES was initially selected as 
the optimal transfection method due to high transfection efficiency, good cell viability, ease of 
use and costs.  
 
 
Figure 4-10 HeLa cell proliferation assay 
HeLa cell viability was assessed using Trypan Blue exclusion, following Amaxa® nucleofection, Icafectin™441 or 
CaBES transfection. These transfection procedures are described in detail in Methods Chapter 2, Section 2.11.3. 
Following transfections, HeLa cells were counted at 24 hour intervals for up to 96 hours post transfections and were 
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4.9 In vivo targeting of methylation to the CDKN2B promoter 
Having established optimal transfection conditions and generated constructs expressing ZFP/ 
methyltransferase fusion proteins, I proceeded to an in vivo assessment of CDKN2B-targeted 
methylation. Targeting DNA methylation to the CDKN2B promoter region of HeLa cells involved 
co-transfection of cells with 10µg of plasmid DNA (various ZFP/methyltransferase constructs) 
spiked with 0.5µg of Amaxa™ GFP vector, using the CaBES method described previously.  
To determine expression of FLAG-TAG - ZFP/methyltransferase fusion proteins (outlined in  
Table 4.2.) samples of  transfected HeLa cells (1X106) four days post transfection were  western 
blotted and probed using anti-FLAG Clone M2 monoclonal antibody (Sigma-Aldrich Catalogue 
Number  F3165) as described in Section 4.6. above and shown in Figure 4-2. 
Transfected HeLa cells were routinely passaged and cell samples taken for the following 
analysis: Western Blot (1X106) for analysis of  p15INK4B protein expression, CDKN2B gene 
transcriptional status by Taqman™ RT-qPCR (1X106), and  DNA methylation analysis using 
Combined Bisulfite Restriction Analysis COBRA ,  and/or bisulfite sequencing. Therefore, 
samples taken at various time intervals, namely Day 4, 7, 10, 14 and 21, were used to monitor 
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4.9.1 Results of in vivo targeting of CDKN2B  
 
One of the primary aims of this project was to assess if it possible to target methylation to the 
endogenous promoter of an actively transcribing gene. As this had never been attempted before 
to our knowledge, the exact effects of such targeting were unknown, but it was hoped that the 
transcriptional regulation of the targeted gene would perhaps be affected due to the interference 
with transcription factor binding,  access of transcriptional machinery or methyl-CpG binding 
domain protein (MBD) mediated recruitment of histone deacetylases and other chromatin re-
modellers, leading to the formation of an inactive heterochromatin state as  discussed in detail 
in the Introduction (Chapter 1) of this thesis. This assumption is based on the previous 
observations of correlation between methylated promoters and respective gene transcriptional 
status [400].  Once laid down, DNA methylation could potentially lead to recruitment of other  
epigenetic co-factors such as maintenance methyltransferases and histone deactelyase, to 
provide a framework for a self- reinforcing propagation of a methylated state [401]. It was 
previously described that the DNA methylation density may also influence the stability of the 
epigenetic imprint.  
A second important issue to be addressed by this project was the effect of low density vs. high 
density methylation and the spread of methylation within the CDKN2B promoter. Studies on 
murine  erythroleukemia cells containing a chromosomally integrated proviral reporter, 
premethylated at different densities, have shown a  faithful propagation of  high density of 
methylation compared to low level of methylation which  was unstable, and accompanied by 
eventual complete demethylation [402]. To address this issue I have used prokaryotic (M.HpaII, 
M.HhaI) methyltransferases which have only a few target sites within the CDKN2B promoter, to 
lay down low density methylation and M.SssI, and the catalytic domain of eukaryotic 










Figure 4-11 Methylation density possibilities at the CDKN2B promoter for various targeted 
methyltransferases.    
Representative diagram of promoter methyltransferase target sites within the CDKN2B promoter. A There are seven 
HhaI sites –target sequence GCGC and four HpaII sites –target sequence CCGG upstream of the most 3’ zinc finger 
target binding site. Targeting CDKN2B using ZFPs fused with M.HpaII or M.HhaI allows for relatively low density 
methylation seeding in comparison to B. There are potentially 64 CG sites available for methylation using ZFPs fused 
with M.SssI or the catalytic domains of DNMT3A, DNMT3B methyltransferases.  
5'-CGGGATTTTT CTCTATTTTT ATGGTTGACT AATTCAAACA GAAAGACACA TCCAAGAGAA AATTGCTAAG-3' 420 
5'-TTTGATACAA GTTATGAAAC TTGTGAAGCC CAAGTACTGC CTGGGGATGA ATTTAACTTG TATGACAGGT-3' 490 
5'-GCAGAGCTGT CGCTTTCAGA CATCTTAAGA AACACGGAGT TATTTTGAAT GACTTTCTCT CGGTCACAAG-3' 560 
5'-GGAGCCACCA ACGTCTCCAC AGTGAAACCA ACTGGCTGGC TGAAGGAACA GAAATCCTCT GCTCCGCCTA-3' 630 
5'-CTGGGGATTA GGAGCTGAGG GCAGTGGTGA ACATTCCCAA AATATTAGCC TTGGCTTTAC TGGACATCCA-3' 700 
5'-GCGAGCAGTG CAGCCAGCAT TCCTGGCGGC TCCCTGGCCC AGTCTCTGGC GCATGCGTCC TAGCATCTTT-3' 770 
5'-GGGCAGGCTT CCCCGCCCTC GTGACGCGTC GGCCCGGGCC TGGCCTCCCG GCGATCACAG CGGACAGGGG-3' 840 
5'-GCGGAGCCTA AGGGGGTGGG GAGACGCCGG CCCCTTGGCC CAGCTGAAAA CGGAATTCTT TGCCGGCTGG-3' 910 
5'-CTCCCCACTC TGCCAGAGCG AGGCGGGGCA GTGAGGACTC CGCGACGCGT CCGCACCCTG CGGCCAGAGC-3' 980 
5'-GGCTTTGAGC TCGGCTGCGT CCGCGCTAGG CGCTTTTTCC CAGAAGCAAT CCAGGCGCGC CCGCTGGTTC-3' 1050 
5'-TTGAGCGCCA GGAAAAGCCC GGAGCTAACG ACCGGCCGCT CGGCCACTGC ACGGGGCCCC AAGCCGCAGA-3' 1120 
5'-AGGACGACGG GAGGGTAATG AAGCTGAGCC CAGGTCTCCT AGGAAGGAGA GAGTGCGCCG GAGCAGCGTG-3' 1190 
5'-GGAAAGAAGG GAAGAGTGTC GTTAAGTTTA CGGCCAACGG TGGATTATCC GGGCCGCTGC GCGTCTGGGG-3' 1260 
5'-GCTGCGGAAT GCGCGAGGAG AACAAGGGCA TGCCCAGTGG GGGCGGCAGC GATGAGGGTC TGGCCAGCGC-3' 1330 
5'-CGCGGCGCGG GGACTAGTGG AGAAGGTGCG ACAGCTCCTG GAAGCCGGCG CGGATCCCAA CGGAGTCAAC-3' 1400 
5'-CGTTTCGGGA GGCGCGCGAT CCAGGTAGCT GGGGCCCCAG GGCCTCGCCG GCAGGGGGCG CGCGAACGCG-3' 1470 
5'-GGGCGCGGCC TCGGCGGATC GGGGCTGGAA CCTAGATCGC CGATGTAGAT TTGTACAGGA GTCTCCGTTG-3' 1540 
5'-GCCGGAGGTG TGCATTCCAC GCGTAAAACA GGCTTTTACC CAGCAAAAAT CCTAAAGAGA GACATTGAAA-3' 1610 
5'-AACCCACTGT TTAAGCTTTT TTTAGTGGTT TTTGTTCTGC CATCTCATGA TCAGAGATGC AAGGAATAGA-3' 1680 
5'-CTGAATTGGG GAGAAAAGGA GAAAAGGAAA GCTTATTTAG GGAAGAAGAT TATCTTGTCT GTCTGCTTTC-3' 1750 







5'-CGGGATTTTT CTCTATTTTT ATGGTTGACT AATTCAAACA GAAAGACACA TCCAAGAGAA AATTGCTAAG-3' 420 
5'-TTTGATACAA GTTATGAAAC TTGTGAAGCC CAAGTACTGC CTGGGGATGA ATTTAACTTG TATGACAGGT-3' 490 
5'-GCAGAGCTGT CGCTTTCAGA CATCTTAAGA AACACGGAGT TATTTTGAAT GACTTTCTCT CGGTCACAAG-3' 560 
5'-GGAGCCACCA ACGTCTCCAC AGTGAAACCA ACTGGCTGGC TGAAGGAACA GAAATCCTCT GCTCCGCCTA-3' 630 
5'-CTGGGGATTA GGAGCTGAGG GCAGTGGTGA ACATTCCCAA AATATTAGCC TTGGCTTTAC TGGACATCCA-3' 700 
5'-GCGAGCAGTG CAGCCAGCAT TCCTGGCGGC TCCCTGGCCC AGTCTCTGGC GCATGCGTCC TAGCATCTTT-3' 770 
5'-GGGCAGGCTT CCCCGCCCTC GTGACGCGTC GGCCCGGGCC TGGCCTCCCG GCGATCACAG CGGACAGGGG-3' 840 
5'-GCGGAGCCTA AGGGGGTGGG GAGACGCCGG CCCCTTGGCC CAGCTGAAAA CGGAATTCTT TGCCGGCTGG-3' 910 
5'-CTCCCCACTC TGCCAGAGCG AGGCGGGGCA GTGAGGACTC CGCGACGCGT CCGCACCCTG CGGCCAGAGC-3' 980 
5'-GGCTTTGAGC TCGGCTGCGT CCGCGCTAGG CGCTTTTTCC CAGAAGCAAT CCAGGCGCGC CCGCTGGTTC-3' 1050 
5'-TTGAGCGCCA GGAAAAGCCC GGAGCTAACG ACCGGCCGCT CGGCCACTGC ACGGGGCCCC AAGCCGCAGA-3' 1120 
5'-AGGACGACGG GAGGGTAATG AAGCTGAGCC CAGGTCTCCT AGGAAGGAGA GAGTGCGCCG GAGCAGCGTG-3' 1190 
5'-GGAAAGAAGG GAAGAGTGTC GTTAAGTTTA CGGCCAACGG TGGATTATCC GGGCCGCTGC GCGTCTGGGG-3' 1260 
5'-GCTGCGGAAT GCGCGAGGAG AACAAGGGCA TGCCCAGTGG GGGCGGCAGC GATGAGGGTC TGGCCAGCGC-3' 1330 
5'-CGCGGCGCGG GGACTAGTGG AGAAGGTGCG ACAGCTCCTG GAAGCCGGCG CGGATCCCAA CGGAGTCAAC-3' 1400 
5'-CGTTTCGGGA GGCGCGCGAT CCAGGTAGCT GGGGCCCCAG GGCCTCGCCG GCAGGGGGCG CGCGAACGCG-3' 1470 
5'-GGGCGCGGCC TCGGCGGATC GGGGCTGGAA CCTAGATCGC CGATGTAGAT TTGTACAGGA GTCTCCGTTG-3' 1540 
5'-GCCGGAGGTG TGCATTCCAC GCGTAAAACA GGCTTTTACC CAGCAAAAAT CCTAAAGAGA GACATTGAAA-3' 1610 
5'-AACCCACTGT TTAAGCTTTT TTTAGTGGTT TTTGTTCTGC CATCTCATGA TCAGAGATGC AAGGAATAGA-3' 1680 
5'-CTGAATTGGG GAGAAAAGGA GAAAAGGAAA GCTTATTTAG GGAAGAAGAT TATCTTGTCT GTCTGCTTTC-3' 1750 
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Assessment of successful targeted methylation of the CDKN2B promoter, and its effect on the 
levels of expression/translation of the p15INK4b involved analysis of samples of HeLa cells at set 
time points; Days 4,7,10, 14 and 21 post-transfection.    
The first step was to evaluate the efficiency of targeted methylation at the CDKN2B promoter 
using ZFP/methyltransferase fusions. Samples were taken (at the above specified time points) 
from 5x105 HeLa cells, genomic DNA prepared and bisulfite converted. Bisulfite conversion 
involves deamination of unmethylated cytosine residues to uracil, but leaves 5-methylcytosine 
unaffected (Figure 4.12A). In this way specific methylation patterns within a DNA sample can be 
investigated. 
The region of interest in the CDKN2B promoter was PCR amplified using primers not biased 
towards methylation, by semi-nested PCR (- 43 to +268 bp relative to TSS). PCR samples were 
subjected to methylation status analysis, using Combined Bisulphite Restriction Analysis 
(COBRA), followed by bisulfite sequencing. COBRA is a semi- quantitative method that utilizes 
restriction enzymes to selectively distinguish between methylated and non-methylated CpGs 
[403].  
To test the robustness of the COBRA assay, HL60 and Raji cell lines were examined. The HL60 
cell line has previously been shown to have an un-methylated CDKN2B promoter [404, 405], 
and express p15INK4B [406]. This cell line is established from  human promyelocytic  leukaemia  
cells and is known to spontaneously differentiate into a number of different cell types such as 
neutrophils or   mature  granulocytes with distinct gene expression profiles during routine 
culturing [407] [408].  To ascertain if differentiation might affect the methylation status of the 
CDKN2B gene promoter in HL60 cells during differentiation, cells were cultured in the presence 
of the differentiating agent DMSO (1.5%). Differentiation was confirmed by flow cytometric 
measurements of CD11b, a well-known early differentiation marker. The Raji cell line is typically 
used as a positive control for methylation analysis, as the CDKN2B promoter is known to be 
heavily methylated in this cell line [409]. Genomic DNA was extracted from the above cell lines, 
bisulphite converted and the region of interest (- 215 to +410 bp relative to TSS) amplified using 
PCR. This was followed by a second round of semi-nested PCR to increase the specificity of the 
PCR product. 
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The product was then digested using R.BstUI restriction enzyme whose recognition site is left 
intact if the DNA is methylated at both cytosines, but converted to TGTG if unmethylated. In 
order to check for bisulphite conversion efficiency another enzyme, R. StyI, which recognizes 
the sequence CCTTGG, was used. Successful bisulphite conversion should completely destroy 
this site and the DNA will not be cleaved. The specifics of bisulfite conversion and the COBRA 
assay are outlined in Figure 4 -12. below.  
 
 
Figure 4-12 COBRA Assay  
Schematic representation of the assay principle showing A bisulfite conversion  of cytidine (C) to uracil (U) unless the 
cytidine is methylated within CG context, in which case the conversion will not occur. B Bisulfite converted DNA was 
amplified in semi-nested PCR to generate a PCR product 601bp in size.  This product was then subjected to restriction 
analysis using R.BstUI  (CGCG) which cleaved only the methylated product Raji (arrowed),  as expected whilst HL60 
with or without DMSO remained uncut.  It can be concluded that the CDKN2B region scrutinized in HL60 is 
unmethylated irrespective of cell lineage whilst Raji has methylated CDKN2B. The conversion control was a digest 
with R.StyI, which remained uncut indicating that the CCTTGG sequence within the promoter was successfully  
converted to TTTTGG which could then not be cleaved with this enzyme. Enzyme efficiency was confirmed using 
control plasmid DNA (data not shown).  
A
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4.9.1.1. Low density de novo methylation at the CDKN2B promoter is maintained through 
successive cell divisions 
 
For this aspect of the project ZFs fused with M.HpaII and M.HhaI prokaryotic methyltransferases 
were used to target low density methylation to the CDKN2B promoter region. HeLa cells were 
transfected with ACMVPU1H, ACMVPU1Hh and ACMVPU1 (negative control). Transfections 
were carried out as previously described and the samples were collected for methylation status 
analysis as described in the Section 4.9.1. at days 4,7,14 and 21. Genomic DNA was prepared 
and bisulfite converted as described previously.   
Primers for COBRA analysis and bisulfite sequencing were designed spanning a region -212 bp 
to + 260 bp relative to the TSS to capture as many M.HpaII (CCGG) and M.HhaI (CGCG) sites 
as possible. Once generated, PCR products were restriction digested using R.DpnII for 
ACMVPU1H targeted DNA, and R.BsmI for ACMVPU1Hh targeted DNA. The R.DpnII 
recognition sequence is GATC. Only methylated C would remain following bisulfite conversion 
allowing for the PCR product to be cleaved, whilst unmethylated C in this sequence would be 
converted to T and the PCR product could not be cut by this enzyme.  Similarly, R.BsmI has a 
recognition sequence GAATGCN and only methylated C can remain intact following bisulfite 
conversion, so the consequences for this restriction site will be the same.  
To show that the methylation was due to specific targeting of HpaII deposited at CDKN2B rather 
than a non- specific effect due to presence of methyltransferase an additional control, ArbFH 
was used. This ZF recognition site was not present in the CDKN2B gene promoter sequence. 
This control was used to demonstrate that the methylation observed was not just a random event 
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Figure 4-13 shows the result of restriction analysis using the enzymes discussed above on the 
samples taken at various time points.  To confirm bisulfite conversion had taken place 
R.Tsp5091 was used as a conversion control check. The recognition sequence for this enzyme 
is AATT and is present at positions 34 and 168 of the amplicon only in the bisulfite converted 
DNA. Therefore, bisulfite converted DNA would yield two bands 134bp and 338bp in size only if 
successfully bisulfite converted. R. DpnII  enzyme cuts at the underlined sequence within 
CDKN2B only if the highlighted C within TCGG (M.HpaII target site) context is methylated 
AACGGATCGGTCG. R.DpnII restriction yields two distinct bands of 219bp and 253bp in size 
only in methylated products (asterisked in red). Similarly for ACMVPU1Hh targeted sample a 
restriction with R.BsmI recognizes and cleaves only methylated (highlighted in red) region 
GCGGAATGCGCAGG to give two distinct bands 413bp and 59bp in size (asterisked in black).  
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Figure 4-13 Methylation Analysis - COBRA Assay  
Restriction digests of PCR products obtained from samples following targeting with ACMVPU1H, ACMVPU1Hh and ACMVPU1 constructs. To ascertain whether methylation occurred using ACMVPU1H 
fusion, prepared PCR products were subjected to R.DpnII restriction. Negative control used throughout all of the analysis procedures was a ZFP on its own, ACMVPU1, which due to the fact that it has no 
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As can be seen in the above figure, targeted methylation via expression of ACMVPU1H and 
ACMVPU1Hh was successful. The de novo methylation was observed four days following 
transfection, and persists through to Day 21 for the targeted HpaII methyltransferase. For 
M.HhaI constructs, methylation was observed at Day 7 and 14 but not Day 21. To confirm the 
findings I have selected Day 4 and Day 21 sample time points for bisulfite sequencing. 
Methylation within the CDKN2B promoter at Day 4 for ACMVPU1H was confirmed relative to 
control DNA and is shown in Figure 4-14 below. The figure shows sequencing data for 
ACMVPU1H vs. ACMVPU1 and the methylated TCGG vs. unmethylated TTGG HpaII target 
sites. The M.HpaII target sequence is CCGG and only the internal cytosine residue becomes  
methylated [410]. This gives TCGG following bisulfite conversion. If the site is unmethylated 
both cytosines will be converted to thymidine.  Methylation was observed at HpaII sites 300bp 
to 579 bp away from the ZF target site. There were four sites nearer to the ZF site and they 
remained unmethylated (see Figure 4-17). The implication of this will be discussed later on in 
this Chapter.  
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Figure 4-14 Methylation Analysis – Bisulfite Sequencing   
PCR products obtained from library samples at Day 4 following targeting with ACMVPU1H, and ACMVPU1 constructs were gel cleaned as described in Chapter 2, Methods Section 2.8.2. To confirm 
methylation observed by COBRA (shown in Figure 4-13) ACMVPU1H and ACMVPU1 transfected samples, prepared in the same way as for COBRA analysis were bisulfite sequenced commercially. A The 
underlined sequence within CDKN2B highlighted in red shows methylated C within TCGG (M.HpaII target site) context.  There were eight M. HpaII target sites (CCGG) available in the region upstream 
from the PU1 ZFP binding site. This PCR amplicon covers four of them and they were all found to be methylated.  Highlighted in blue are all the potential methylatable CpG sites available for endogenous 
de novo methylation. B Same region  is shown for the ACMVPU1 transfected cells with unmethylated target site shown underlined in black.  This region shows no evidence of methylation. R.DpnII 
recognition sequence (GATC) used for restriction analysis is circled.
A B
ACMVPU1/HpaII Day 4 ACMVPU1 Day 4
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The above samples were actually a library of different sequence clones. Individual sequences 
were TOPO cloned and analysed individually. The bisulfite converted samples at time-points 
Day 7 and Day 21 were PCR amplified by a semi-nested approach as described previously 
and subcloned into the TOPO® cloning vector.   DNA was subsequently extracted from eight 
individual clones and sequenced for methylation pattern assessment.  As shown in Figure 4-
15, promoter methylation is observed at Day 7 and actively maintained through following 
successive cell divisions to Day 21. The results indicate that there is no spread of methylation 
to surrounding CpGs within this region as only HpaII sites were seen to be methylated at Day7 
or 21 (data not shown, see Appendix Supplementary Data CD). For the region analysed the 
first methylated HpaII site was observed upstream at -7 from the TSS. Three HpaII sites 
located downstream at positions +148, +157 and +249 relative to TSS were also methylated. 
However, even at Day 21, no methylation at any of the other potentially available 24 CpG sites 
was detected.
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Figure 4-15 Clonal analysis of DNA methylation at HpaII sites.  
PCR amplicons generated by a semi nested approach from bisulfite converted PU1H or PU1 targeting samples at Day 
7 and Day 21 were subcloned into TOPO® vector. Eight selected colonies were assessed for methylation by sequencing. 
Open circles represent unmethylated HpaII CCGG sites, whereas closed circles show methylated CCmeGG sites.    
 
To eliminate the possibility that the observed methylation patterns seen at longer time points 
were due to the effect of the plasmid expressing the methyltransferase not being diluted out 
via replication following transient transfections, PCR was performed to detect the presence of 
M.HpaII transcripts. RNA was extracted from the samples (1x106 cells) collected at time points 
Day 7, 14 and 21, followed by cDNA preparation as described previously. Primers were 
designed to amplify a 220bp region of the M.HpaII prokaryotic gene. HpaII transcription was 
evaluated at Day 7, 14 and 21. PCR amplicon samples were collected starting at cycle 20 at 
four cycle intervals up to 40 cycles. Negative controls used in the assay were PU1 and 
PU1Hh. Shown in Figure 4-16 is the result of the analysis. It is apparent that the plasmid 
bearing HpaII construct present at Day 7 is gradually diluted out and there is no HpaII detected 
at Day 21 samples. This clearly indicates that the observed methylation patterns are a direct 
consequence of the targeted methylation and furthermore that such patterns are epigenetically 





Day 7 PU1H Day 21 PU1HControl PU1
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Figure 4-16   HpaII methyltransferase PCR 
RNA was isolated and cDNA generated from 1x106 of HeLa cells transfected with PU1H, PU1 and PU1Hh at the time 
points Day 7, 14 and 21. HpaII specific primers were used to amplify a 220bp region. PCR samples were collected 
starting at cycle 20 at four cycle intervals up to 40 cycles. A 220bp band observed at Day 7 for PU1H is not visible at 
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4.9.1.2 De novo methylation spreads into the distal region of the CDKN2B following 
targeting 
 
To investigate the mechanisms of de novo methylation spreading following targeted methylation 
delivery, a region in closer proximity to the ZF binding site was evaluated. Bisulfite converted 
samples of PU1H and PU1 at day 14 were PCR amplified using a new primer set to generate 
an amplicon 577bp in size covering a region upstream and downstream of ZF target site. 
Although the region downstream from ZF site contains no HpaII sites there are five CpG sites 
that could potentially be methylated via the methylation spread mechanisms.   
 There were four potential HpaII sites at this region for targeted methylation deposition but no 
methylation was observed. The region evaluated however contained 35 non HpaII CpG sites, 
10 of which were methylated. This means that, there was a ~29% increase in regional DNA 
methylation levels at CpG sites that could be observed 14 days following methylation targeting 
as shown in Figure 4-17. While the physical link between the 5’ and 3’ region methylation pattern 
can’t be categorically proven, the fact that all clones examined in the 5’ region had HpaII 
mediated methylation and that a high percentage of 3’ region clones are likely to share the 
methylation pattern shown in Figure 4-17, given cytosine peak intensities, suggests it is likely 
that 5’ and 3’ patterns are likely to be coincident on individual clones. Attempts to generate a 
larger PCR product encompassing both 5’ and 3’ regions failed to work, due to the size 
limitations associated with amplifying from bisulfite converted DNA.  
Analysis of methylation distribution shows a uniform spread within the region. Interestingly, the 
region downstream of the ZF target site, where five CpG sites were available for methylation 
spread remained unmethylated, and may reflect the orientation of the methyltransferase with 
regards to the ZF binding site (i.e. is it pointing in the 5’ direction from the ZF). It appears that 
de novo methylation patterns spreads within the 3’ region of the promoter, whilst no spreading 
is observed in the 5’ region relative to TSS. Whether this changes at much longer time-points is 
currently being assessed. 




Figure 4-17 Methylation Spread Analysis – Bisulfite Sequencing   
PCR products obtained from a library samples at Day 14 following targeting with ACMVPU1H, and ACMVPU1 constructs 
were gel cleaned as described in Chapter 2 Methods Section 2.8.2. and sequenced. Four HpaII sites highlighted in 
green are unmethylated. CpG sites upstream and downstream of ZF target site (blue) available for methylation and 
methylated are highlighted in black and red respectively. R.BsmI recognition sequence (GAATGCG) used for restriction 
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Following demonstration of successful low density targeted DNA methylation, the effect targeting 
had on translation of the p15INK4B protein and transcription level of CDKN2B was examined.  
To assess if any difference could be observed at the translational level samples were prepared 
for western blot analysis of p15INKB protein expression at time point Day 4, 14 and 21. Samples 
(1x106) were prepared for western blot analysis as described previously. Primary mouse 
monoclonal antibody, p15INK4B was used at 1:250 dilution in 3% (w/v) BSA. PU1H and PU1 
transfection samples were used for comparison of protein expression levels shown in Figure 4-
18. No changes in the protein levels were observed.  
To look at the transcriptional levels of CDKN2B following methylation of the promoter, samples 
taken at Days 7,14 and 21 post transfection were examined using, RT-qPCR analysis by 
Taqman®.  The method described in Methods Chapter 2 Section 2.13.1 was followed 
throughout. FAM labelled probe was used for the detection of CDKN2B transcription alongside 
the VIC labelled probe for 18S which was used as an endogenous reference in the assay Figure 
4-18.  
SDS – Sequence Detection System software was used to generate amplification plot and 
determine Cycle threshold points (Ct) for each sample The real time system uses fluorescent 
resonance energy transfer (FRET) generated by fluorogenic dual labelled probes consisting of 
a reporter and a quencher dye and the 5’ nuclease activity of Taq DNA polymerase to amplify 
PCR products exponentially. For CDKN2B,  a detection probe labelled with 6-carboxyfluorescein 
(FAM) and a carboxy-tetramethyl-rhodamine (TAMRA) quencher and primer were designed  to 
produce a 169bp fragment spanning exons 1 and 2,  to avoid potential amplification of  highly 
homologous p16 exon 2 [411]. The 189bp 18S reference PCR was generated using Abi Human 
18S VIC labelled control kit.  
The ΔΔCt approximation method was used to evaluate relative expression of CDKN2B 
normalised to the endogenous housekeeping reference 18S. The primers were checked for 
efficiency by performing 10-fold dilutions and comparing the Ct values. Data analysis however 
revealed no significant changes in CDKN2B transcription levels.  
 




Figure 4-18 CDKN2B gene expression evaluation following targeted delivery.  
HeLa cells were transfected with PU1H, PU1Hh, and PU1 and the samples (1x106 cells) were collected at time points 
Day 7 and 14 for RT-qPCR Taqman® analysis and Day 7, 14 and 21 for western blot analysis of CDKN2B transcription 
levels and p15INK4B protein expression. A Total cell lysate obtained from the transfected samples probed for p15INK4B and 
GAPDH which was used as a loading control. Cellular protein content was determined by BCA assay and the equivalent 
amounts of cell lysates were loaded per well.  Arrowed are the observed bands corresponding to 15kD for  p15INK4B and 
37kD for GAPDH. B RNA extracted from samples transfected was used as a template to prepare cDNA which was then 
used as a template for CDKN2B relative expression analysis normalised to endogenous housekeeping gene reference 
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4.9.9.1 High density methylation at CDKN2B  
 
In an attempt to lay down higher density methylation in the CDKN2B promoter region ZFPs fused 
catalytic domains of eukaryotic DNMT3A, DNMT3B expressed either  alone or in conjunction 
with DNMT3L as well as prokaryotic M.SssI methyltransferase were used. These 
methyltransferase target C residues within a CpG context and as already discussed in Figure 4-
11 of this Chapter, there are 64 potential sites that could be targeted within CDKN2B promoter 
CGI using these enzymes.  Having successfully targeted low density methylation to the promoter 
region, we aimed to investigate whether it was possible to impose higher methylation density 
and what the outcome of such targeting would be. In our studies we have used all the ZFP 
constructs (listed in Table 4-2). Additionally, ACMVPU1/3A, ACMVPU1/3B alone or co-targeted 
with ACMV/DNMT3L and ACMVPU1/SssI were used. The rationale for including DNMT3L into 
the study was based on earlier observations that this enzyme stimulates the DNA methylation 
activity of DNMT3A and DNMT3B through a direct interaction with its carboxyl terminal domain 
[412].  
HeLa cells were transfected with a variety of constructs. Samples of transfected cells were 
collected at Day 4,7,14 and 21, and genomic DNA was prepared and bisulfite converted as 
described previously. The same primer sets that were used for COBRA analysis and bisulfite 
sequencing for assessment of M.HpaII (CCGG) and M.HhaI (CGCG) target sites were also used 
for this analysis. This allowed for a region containing 35 CG sites to be analysed for methylation 
status.  Once generated, PCR products were restriction digested using R.BsmI and R.Tsp5091 
(for conversion efficiency confirmation) for ACMVPU1/3A targeted samples, but no methylation 
could be observed by this method. Bisulfite libraries were also sequenced.  Figure 4-19 shows 
the restriction digest results for time points Day 7 and 14 for ACMVPU1A. Digests were also 
carried out at time points Day 4 and Day 21 with the same outcome (data not shown).  
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Figure 4-19 Methylation Analysis – Restriction digests    
Restriction digests of PCR products obtained from samples following targeting with ACMVPU1A, and ACMVPU1 
constructs. To ascertain whether methylation occurred using ACMVPU13A fusion, prepared PCR products were 
subjected to R.BsmI restriction. The enzyme recognizes and cleaves only when the site derives from methylated DNA, 
GCGGAATGCGCAGG to give two distinct bands 413bp and 59bp in size. To confirm bisulfite conversion has taken 
place R.Tsp5091 was used as a conversion control check. The recognition sequence for this enzyme is AATT and is 
present at positions 34 and 168 of the amplicon only in the bisulfite converted DNA. Therefore, bisulfite converted DNA 
would yield two bands 134bp and 338bp in size only if successfully bisulfite converted.  








L9-ACMVPU1A D14 R.Tsp5091 
L10-ACMVPU1 D14
L8-ACMVPU1A D14 R.BsmI 
L12-ACMVPU1 D14 R.Tsp5091
L11-ACMVPU1 D14 R.BsmI
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No methylation could be observed using COBRA analysis so the prepared bisulfite libraries were 
sequenced as described in the previous section.  The results of one of sequencing reactions, 
ACMVPU1A Day 4 is shown in Figure 4-20. Possible CG sites (35) that are available for 
methylation are underlined. Out of 35 possible sites only two were potentially methylated and 
were in the region where the bisulfite conversion efficiency was not 100% which means that the 
CGs at those sites are most likely the result of incomplete conversion. Similar lack of methylation 
was observed for all other targeted samples that were analysed: ACMVPU1A and ACMVPU1B 
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Figure 4-20 Methylation Analysis – Bisulfite Sequencing   
PCR products obtained from samples at Day 4 following targeting with ACMVPU1A were gel cleaned as described in 
Chapter 2 Methods Section 2.8.2. No methylation was observed by COBRA (shown in Figure 4-16).  ACMVPU1A 
transfected samples, prepared in the same way as for COBRA analysis were bisulfite sequenced commercially. The 
underlined sequence within CDKN2B highlighted in black shows all CG sites available for methylation.  There were 35 
CG target sites available in the region upstream from the PU1 ZFP binding site within the PCR region amplified and only 
two of them possibly methylated (highlighted in red).  
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4.10 Conclusion 
 
For this project ZFPs have been expressed as fusions with various methyltransferases to target 
low and high density methylation to the CDKN2B promoter region.  To the best of my knowledge 
no one has successfully exogenously imposed DNA methylation in the promoter region of an 
actively transcribing gene before in this manner. It has long been speculated that the open 
chromatin established by an active promoter actively excludes methylation from the region. 
Therefore, it was uncertain whether accessing an actively transcribing endogenous gene 
promoter region would be an issue or not.  
Here it is demonstrated for the first time that indeed it is possible to methylate the promoter of 
an endogenous gene. CDKN2B promoter methylation is observed at Day 4 following 
transfections with ACMVPU1/HpaII, and ACMVPU1/HhaI. Initial library sequence analysis 
revealed that all of the HpaII target sites evaluated were methylated to varying extents. It is 
noteworthy that these methylated sites were in closest vicinity to the TSS, spanning the region 
between – 7 to +249 relative to TSS. Additionally, methylated HpaII sites (for the region 
analysed) were observed at 300 bp and as far as 579 bp downstream of ZF target site. This is 
much further than the (Gly4Ser)3 linker could feasibly reach, and suggests either DNA 
conformation effects, bringing the site closer to the ZF region, or diffusion of 
ZF/methyltransferase from its binding site.  
Furthermore, de novo methyl marks once established could be detected up to Day 21 for M.HpaII 
constructs and up to Day 14 for M.HhaI. Day 21 was taken as the final time point for this project. 
Studies to look at the longer term methylation status of the promoter are on-going.  The 
heritability of the newly established methylation patterns was further confirmed using restriction 
digest analysis and a finer resolution analysis of selected individual library clones.   
Next, the observation of a distinct pattern of methylation spread to the 3’ promoter region is an 
additional unique finding of this project. There is no obvious spreading of de novo methylation 
to the most immediate surroundings of the HpaII methylated sites.  It could be speculated that 
the spread of methylation further into the 5’ region of the promoter (which for the CDKN2B gene 
is a region harbouring the TSS) is inhibited by specific DNA sequences such as transcription 
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factor binding sites. However, a very distinct increase in methylation of CpG sites in the 3’ region 
of the promoter nearer to the ZF target site has been observed. At Day 14 there is around 29% 
level of methylation in this region of the promoter. Surprisingly, there was no targeted 
methylation at the four available HpaII sites in this region. One possible explanation for this could 
be that ZF/methyltransferases are prevented from accessing the HpaII sites in the region of 
immediate vicinity due to active blocking by nucleosomal presence.  Indeed the periodicity of the 
observed CpG methylation pattern is similar to the nucleosomal repeat unit of around 200bp.   
Figure 4-18 proposes a mechanistic model for targeted de novo methylation and subsequent 
spread into the distal CpGs of the promoter.   
 
The PU ZF target site was initially selected because its recognition sequence was on the 
boundary region of the gene promoter. It could be speculated that this is a region marked by 
nucleosomal positioning.  The “statistical positioning” model first proposed by Kornberg and 
supported by experimental evidence posits nucleosomes  at the boundary  regions between 
nucleosome free regions (NFRs) found at active or poised genes promoters [413]. The fact that 
there is an observed increase in methylation in this region further supports the possibility of 
nucleosomal occupancy. Global DNA methylation analysis at a single base resolution shows 
that nucleosome bound DNA is more highly methylated than flanking sequences  suggesting  
that DNMTs preferentially target nucleosomal DNA [414]. DNMT3 enzymes were shown to act 
in heteromeric complexes with two methyltransferase active sites, creating a  spacing to 
accommodate 10 nucleotides of DNA [415]. By what mechanism upstream region methylation 
might be “sensed” and what then invites CpG methylation to the nucleosome is unclear. 
Recently, a novel mechanism for DNMT3A/3B activity has been put forward which suggests that 
the levels of 5meC determine the bound levels of DNMT3A/3B. Furthermore, methylated DNA 
bound nucleosomes stabilize de novo DNMT3A/3B allowing for very little of it to remain free in 
the nucleus. Upon a reduction in DNA methylation, nucleosomal binding is disrupted leading to 
degradation of the unstable free DNMT enzyme  thereby preventing aberrant de novo 
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The observed epigenetic  inheritance of the de novo DNA methylation pattern in the upstream 
region of targeted CDKN2B confirms DNMT1 maintenance activity presumably via UHRF1 
which slides along the DNA and detects hemi methylated CpGs via its SRA domain by a base 
flipping mechanism [417] . Another part of UHRF1 may be operating  at the  histone level and 
signals to another interacting partners such as E2, an ubiquitin conjugating enzyme, via its RING 
domain, HDAC via SRA domain  and G9a via PHD and TTD domain,  to act on histone H3K9 
[418] . However it was recently demonstrated that HP1 and UHRF1, alongside a host of other 
key regulators such as PCNA,  Me-CpG binding protein 2, EZH2, and HDAC1  were not required 
for  guiding DNMT3A/3B to the nucleosome [419] suggesting  alternative localization 
mechanisms exists.   
 




Figure 4-18 Schematic of a proposed model for the methylation distribution     
Nucleosomal positioning adjacent to the ZF target site prevents access to the ZF/Mtase fusion to methylate HpaII 
sites. HpaII sites located approximately 300bp towards TSS were methylated. The observed maintenance of 
methylation indicates recruitment of DNMT1s probably aided by the activity of a “reader” UHFR1. This multidomain 
protein could provide a functional link for the cross talk between DNA methylation and histone modifications. The 
DNMT3A/B enzymes are known to selectively anchor to nucleosomes but the precise recruitment mechanism for this 
selectivity has not been fully determined. One possible molecular link  recently put forward is the observed G9A 
DNMT3 co- operativity via MPP8 [420]. Another possible molecular mechanism might involve UHRF1 RING domain 
interaction with E2 an ubiquitin-conjugating enzyme. Histone ubiquitylation may provide an additional link in the 
recruitment of DNMT3s as recently demonstrated in ubiquitin-like proteins such as  NEDD8 association with DNMT3B 
[421].  Additionally,  an already established connection between H2A  ubiquitination and DNMT3B could be another 
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A progressive increase in DNA methylation patterns arising from discrete regions and spreading 
to adjacent sites has been described for a number of neoplastic transformations. For instance, 
methylation in three discrete regions of p16 CGI in human mammary epithelial breast cancer 
(HMEC) cells escaping mortality stage 0 (M0) spreads into adjacent sites  following continued 
cell  passage leading to a gradual increase in  methylation density across the island [423]. 
Similarly, for the CDKN2B promoter CGI, methylation density increases were observed in 
advancing MDS disease subtypes [424]. Finally, recent analysis of methylation expansion 
phenotype in CGI ,methylator phenotype (CIMP) showed hypermethylation spread in the 3’ 
region in CIMP tumours [425]. The same study proposed a mechanism for the unidirectional 
expansion of methylation which occurred in 86.7% of subsets analysed. This mechanism 
postulates the involvement and targeted direction of methylation by DNA binding factors such 
as Sp1 and TFAP2A, but also some less validated candidates such as ZBTB7B and CNOT3. 
These findings add an additional dimension to an already complex model of methylation spread 
and regulation.   
Assessment of the transcriptional regulation at the CDKN2B gene showed no change in the 
gene expression levels as a result of targeted methylation at the promoter region, either at the 
transcriptional or translational level. Although, this is a short – term study, so far the data suggest 
the low density methylation observed is insufficient to have an effect on gene expression level 
and suggest lack of formation of repressive chromatin structure at the CDKN2B promoter in 
response to targeting de novo methylation.  
This is perhaps unsurprising as, evidence supporting the model of gene transcriptional silencing 
preceding the methylation has been reported. Kinetic studies to determine the timing of the 
epigenetic events involved in gene silencing using a stably integrated transgenic region in a 
chicken erythroid cell line showed rapid chromatin influenced silencing, associated primarily with 
H3 and H4 hypoacetylation and H3K4 methylation loss. These histone modifications were 
primary events in the transgene silencing, followed by the secondary events of H3K9 and 
promoter DNA methylation [426].   
Evidence from in vitro studies suggests that promoter DNA methylation can influence gene 
expression in a process mediated by MeCP-1, and is dependent on methyl CpG density and 
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promoter strength.  Densely methylated genes interact strongly with MeCP-1, and are frequently 
associated with gene repression. For sparsely methylated promoters  the level of MeCP-1 
interaction appears weaker, and can be disrupted according to the strength of the promoter, 
thereby allowing transcription of methylated genes [427]. 
During this project, I was not successful in delivering high density methylation using the catalytic 
domains of the DNMT3A/3B methyltransferases. The exact reasons are unclear, particularly 
given the fact that the DNMT3L component was simultaneously co expressed to enhance the 
enzymatic activity of the targeted DNMT3A/3B methyltransferases. The rationale behind co –
targeting with  the catalytically inactive protein DNMT3L is due to  its demonstrated stimulatory 
effect on the catalytic activity of DNMT3A and DNMT3B [428].  Additionally, DNMT3L in 
heterodimer formation with DNMT3A and DNMT3B  guides CpG site recognition  in a periodic 
pattern [429] and attenuates formation of more uniform methylation patterns [430]. However, 
DNMT3L is expressed in ES but not in somatic cells [431] which may suggest alternative 
mechanism requirement for DNMT3 activity in these cells.  
The lack of observed methylation at the target region can’t be explained by ZF binding 
interactions given the fact that the same ZFs were successfully used for M.HpaII and M.HhaI 
targeting. It is possible that the ZF/Mtase component folding is different in this case and that 
could contribute to a failure to methylate. The low enzymatic activity associated with 
DNMT3A/3B  catalytic domain Mtases is also unlikely to be the cause given the fact that the 
same catalytic domain DNMT3A and DNMT3B were previously demonstrated to have 
enzymatic activity when expressed as ZF fusions in vivo [432]. The catalytic domain of 
DNMT3A/3B fused with an engineered Cys2His2 zinc finger domain were previously 
successfully used  to target three different artificial reporter systems; the TK 
(Humanherpesvirus 1 thymidylate kinase) promoter with added binding sites for GAL4 (UAS), 
the human c-Ha-ras gene promoter with added UAS and the immediate early IE175kpromoter 
of the Herpes Simplex Virus type 1 (HSV-1). The study demonstrated site specific methylation 
associated with the repression of the reporter genes.  
What follows is an evaluation of several possible explanations for the observed lack of 
methylation targeting.  Firstly, the above studies were based on plasmid episomal target 
vectors.  There are probably differences in epigenetic regulation and nucleosomal structure of 
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the target episome compared to the in vivo setting of an actively transcribing endogenous 
gene. Secondly, their study used Human Embryonic Kidney 293T cells. The cell line was 
originally transformed by expression of the large T antigen from SV40 virus that inactivates 
pRb, leading to inhibition of cell cycle. The cellular epigenetic regulatory mechanisms between 
these cells and HeLa, which were used for this project may differ.  
Thirdly, it is noteworthy that the same study reported a low level repression (~10%) using 
catalytically inactive DNMT3A suggesting a possible repressor recruitment by the enzyme.   
Another but related point to the above is the possibility that the catalytic domain of the 
enzymes interacts with other protein components such as HDAC or HMTs which then “piggy-
back” it away, affecting the enzyme’s cellular localization. While evidence from  previous 
studies points to predominant DNMT3 interactions mostly via their N-terminal domain, 
evidence  for interaction with the catalytic domain of DNMT3B and HP1α and Suv39H1 also 
exist [433]. Additionally, the repair enzyme  thymine DNA glycosylase (TDG) was shown in 
vitro to inhibit the methylation activity of DNMT3A [434] suggesting a DNMT3A C-terminus 
interaction.  
Finally DNMT3A  enzymes show a preference for CpG sites but are also able to methylate 
CpT and CpA, which are modified only twofold slower than CpG sites [435]. That would 
suggest that background levels of   Cme  seen in Figure 4-17 may not be due to incomplete 
bisulfite conversion but actually a consequence of genuine DNMT3A non-CpG methylation 
activity. Given that the COBRA restriction digest approach is hampered by poor site 
representation and bisulfite sequencing can't easily distinguish between methylated and 
unconverted samples, a different approach is ultimately required to assess the methylation 
pattern of these samples.  
Attempts to target selective high density CpG methylation using the prokaryotic M.SssI 
methyltransferase were unsuccessful. This enzyme was previously demonstrated to target 
methylation when fused to zinc finger proteins, in yeast [436]. M.SssI is frequently used as an 
enzyme of choice to methylate DNA templates for in vitro studies on the role of DNA methylation. 
A large body of studies involving M.SssI include evaluation of promoter methylation mediated 
transcriptional control of viral and mammalian genes [437-439], demethylation studies [440], and  
investigations on effects of folate deficiency on DNA methylation [441].  
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One very interesting feature of this enzyme is its topoisomerase activity. It has also been shown 
that methylation by M.SssI in the presence of Mg2+ becomes distributive rather than processive 
resulting from the enzyme’s decreased affinity for DNA. These two enzymatic functions are not 
interdependent, with either one or the other activity being detectable [442].  
Following HeLa transfection with ZFP/M.SssI vector under the control of CMV promoter, no 
expression was detected by western blot. We assume that this is due to the M.SssI methylating 
the plasmid CMV promoter at high density, thereby rendering the expression cassette inactive. 
Evidence in support of this  comes from studies showing strong and ubiquitously expressing 
promoters being susceptible to CpG methylation[443].  
Attempts to clone  M.SssI into different expression systems  were previously shown to be 
unsuccessful, presumably due to toxicity issues associated with the expression of this gene in 
E.Coli [444]. The original M.SssI gene is known to have unusual codon usage, with four TGA 
codons presumed to code for tryptophan in the parent organism. Thus, issues of mammalian 
expression  have to be considered in this context, coupled  with the fact that M.SssI is a highly 
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                                          Chapter 5 
Investigating the role of cellular factors in maintaining the 
CDKN2B promoter in a methylation free state in vivo 
 
 




Using rationally designed ZF/HpaII methyltransferase fusion constructs I have demonstrated 
that it is possible to lay down site-specific methylation in the promoter region of the CDKN2B 
gene. Furthermore, I showed that this epigenetic tag is maintained through successive cell 
divisions and leads to the spread of methylation within the CGI in the 3’ direction as discussed 
in the previous chapter.  
 
Additionally, there appears to be no effect on CDKN2B gene transcriptional status as a result of 
this de novo methylation process. It could be speculated that promoter methylation driven gene 
silencing in vivo evolves from a series of events resulting from a substantial build-up of 
methylation rather than a short exposure low density event. Only once the region is “captured” 
by the spread of  DNA methylation, can interference with transcription factor binding occur  and 
stable gene silencing be established [445]. Studies on human (with CGI) and mouse α-globin 
and human γ-globin (without CGI) genes showed a methylation density requirement in 
transcriptional regulation. Low density methylation forms a weak complex with MeCP-1/NuRD 
which can be sufficient for repression of a weak promoter. However, when the promoter is 
strong, the complex is disrupted, allowing the transcription of a methylated gene [446].  
 
So what are the exact mechanisms associated with the spread of methylation from a methylated 
“seed” foci? What keeps some promoter regions methylation free while the others succumb to 
methylation? These are still unknowns, despite our knowledge about the promoter regions of 
actively transcribing genes. In an attempt to answer these questions, it is essential to regard the 
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5.1. 1. Transcriptional Control at eukaryotic promoters 
 
Gene promoter regions are sites at which the symphony of gene expression is orchestrated and 
where many epigenetic, as well as non-epigenetic instruments, play their part.  Promoters 
contain a number of specific regulatory sequences such as transcription factor binding sites, 
transcription start site and TATA box recognition elements. Transcriptional regulation of 
CDKN2B has been reviewed in some details, in previous chapters.  
An additional level of transcriptional control is provided by chromatin structure and nucleosomal 
organization in the promoter region as discussed in Chapter 1. Multi-protein complexes involved 
in the modulation of higher order chromatin structure helps establish transcriptional regulation. 
These complexes also mediate binding to both promoters and enhancers, ensuring cross talk 
between activators and repressors at transcriptional initiation sites, leading to specific 
nucleosomal positioning and new transcript generation. ATP provides energy for these 
complexes to ensure both non covalent chromatin signature modifications and acquisition or 
removal of histone tail marks. In principle, transcriptional repression can be achieved by the 
creation of compacted inaccessible chromatin, while transcriptional activation can be induced 
by creating open, accessible chromatin. However, these mechanisms of chromatin re-
organization are in themselves not sufficient to regulate gene expression. Other factors such as 
transcriptional activator, repressor and mediator complexes and basal transcription factors are 
also needed. 
Further, gene regulation is enabled by the activity of enhancers, silencers and silencing barrier 
insulators which sometimes  act over  long genomic distances,  up to a mega base away from 
their target gene [447]. Silencers are DNA elements which play a role in gene insulation by 
compartmentalization of different chromatin domains. The nuclear periphery is enriched for 
heterochromatic silenced loci and the repressor proteins associated with it, which help stabilize 
transcriptional silencing.  
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Promoters are often positively and dynamically regulated by enhancers, which can act  in a 
distance and orientation independent manner and aid repositioning of genes at transcription 
factories via chromatin loop interactions [448].  
The activity of enhancers and silencers  is  tightly regulated through the effects of insulators 
which can interfere with promoter communication and act as either enhancer blockers or silencer 
barriers [449]. Insulators can also serve as heterochromatin barriers, to protect a gene from 
neighbourhood influences.  
Additionally, insulators were shown to be capable of protecting promoters from DNA methylation 
as demonstrated for the multifunctional epigenetic regulator  CCCTC-binding factor  (CTCF) at 
the CGI of the pRb gene [450]. CTCF which has both insulating and  chromatin barrier activity, 
was recently shown to co-localize at the INK4 locus, providing a barrier against heterochromatin 
spread [451]. Several CTCF binding sites were identified at this divergent region, and the binding 
shown to be DNA methylation sensitive [452] [453]. Furthermore, CTCF regulates the 
transcription of genes at this locus [453].   
The  cis- acting  transcription factor - Sp1, which recognizes G - rich sequence motifs,  was  
demonstrated  to  provide methylation protection at the CGI elements of both the mouse and 
hamster APRT gene [454, 455] with Sp1 deletion leading to CGI methylation. Sp1 per se is not 
required for the unmethylated state of this CGI, as it was shown that even in Sp1 null ES cells 
the APRT gene remains unmethylated [456]. Recent evidence from  genome-scale methylation 
profiling of the human brain, where a number of  putative zinc finger protein binding sites were 
found to be over-represented at the boundary regions of methylation-resistant CGIs, lends 
support to the existence of additional routes [457].   
An example of a barrier element in vertebrates with a role in defending a gene from silencing by 
DNA methylation is Vascular Endothelial Zinc finger 1 (VEZF1).  A study carried out on the 
chicken β-globin gene marked at the 5’ region by an HS4 insulator, showed that this barrier 
element mediated gene promoter protection  from DNA methylation-mediated silencing 
independent from CTCF –mediated enhancer blocking or USF mediated recruitment of active 
histone modifications [458].  
 An additional observation was that the VEZF1 transcription factor could serve as a barrier/anti-
methylation factor at the APRT gene promoter, and given that it recognizes the same G rich 
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sequences as Sp1 frequently observed at CGIs, it was postulated that VEZF1 may play a similar 
role in promoter DNA methylation protection. The role for VEZF1 as an epigenetic regulator is  
further supported by the contradictory observation of global, genome wide DNA methylation loss 
including LINE1 elements and minor satellite repeats in VEZF1-/- mouse ES cells which is also 
associated with substantial DNMT3B downregulation [459].   
 
5.1.2. Active demethylation 
 
An alternative mechanism for maintaining the methylation free status of gene promoters is that 
methylated CpGs are continuously removed through the activity of various DNA demethylase 
pathways. DNA methylation is known to be a dynamic process with active demethylation being 
observed during specific stages of development [460]. Furthermore, a cyclical pattern of DNA 
methylation has been observed at the transcriptionally active promoter of pS2/TFF1 gene upon 
oestrogen activation. During this transcriptional cycling, a periodic, strand -specific 
methylation/demethylation is observed and is  maintained by the dual activity of DNA 
methyltransferases which lay down CpG methylation and actively demethylate methylated CpGs 
through deamination [461]. There is a handful of examples of active methylation and 
demethylation of specific CpGs such as IL-2 promoter demethylation in somatic cells [462] or  
strand specific CpG methylation/demethylation [461, 463].  
Another better established deamination enzyme is activation induced (cytidine) deaminase AID 
involved in the removal of the amino group from cytidine  converting it into uridine, which is then 
recognized as a thymidine and subjected to DNA B.E.R. repair [464].  
This, however, is only a part of the picture. The process of active demethylation is most likely 
context dependent and achieved via multiple mechanisms with a number of enzymes playing a 
role. One proposed enzyme was a  member of the methyl CpG – binding domain family, MBD, 
related to the MeCP2 transcriptional repressor and reportedly involved in hydrolysis of 5-
methylcytosine to cytosine and methanol [465, 466]. The reaction itself is, however, 
thermodynamically unfavourable due to the high activation energy required to break O-H and C-
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C  bonds to form C-H and C-O bonds, and now it seems more likely that this enzyme was a 
glycosylase.   
Two other noteworthy demethylation pathways have been proposed. One involves the action of 
5-methylcytosine DNA glycosylase to remove methylated cytosine and leave deoxyribose ready 
for local DNA repair mechanisms [467]. 
An alternative pathway involves the creation of an intermediate in the demethylation process by 
conversion of 5-methylcytosine to 5-hydroxymethylcytosine (5-hmeC) [468]. A group of enzymes 
proposed to be involved in this process and which could in theory be targeted to CGIs are Ten-
eleven translocation TET family members; TET1, TET2 and TET2 are Fe2+ and α-ketoglutarate–
dependent dioxygenases, which successively oxidise 5-methylcytosine (5mC) to 5-
hydroxymethylcytosine (5-hmeC), 5-formylcytosine (5fC), and 5-carboxycytosine intermediates 
[469]. TET1 is found as a fusion partner of the MLL gene in AML which possesses a domain 
related to the CpG-binding CXXC domain found in CFP1. TET1 was shown to catalyze the 
conversion of 5mC to 5-hydroxymethylcytosine (5-hmeC) in HEK293 cells [470]. Recent studies 
have shown preferential localization of TET1 at CGIs in mouse ES cells and depletion of TET1 
results in increased CpG methylation at CGIs [471, 472]. TET proteins were shown to co-operate 
with the base excision repair enzyme thymine-DNA glycosylase (TDG) suggesting a very 
important role for TET  in epigenetic regulation [473].  
It could be hypothesised that CGIs are continually subjected to sporadic de novo methylation, 
which is swept clean by a mechanism involving oxidation of 5-methylcytosine. Defects in such a 
mechanism such as TET2 mutations [474] could predispose the CGI to de novo methylation, as 
seen in many cancers. Recent evidence to support this idea comes from a study in mouse ES 
cells, where TET1 knockdown led to methylation of Nanog promoter and its downregulation 
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5.2 Chapter Aim 
 
On the basis of information gathered in the previous chapter regarding  targeted methylation at 
the CDKN2B promoter, epigenetic inheritance of the de novo methylation patterns, and the 
effects on transcriptional regulation of the gene, it became apparent that promoter protection 
might be an issue warranting further investigations. Existing data indicate some spread of 
methylation following targeting but there is no evidence of gene repression, suggesting a 
protective mechanism exists in this region. In this chapter, I have begun investigating the 
relationship between two postulated mechanisms for promoter methylation protection; insulator 
and active DNA demethylation at the CDKN2B promoter region, with a view to their potential 
ultimate role in aberrant CGI methylation in cancer and leukaemia.  
 
5.3 Results  
 
5.3.1 VEZF1 is enriched at the CDKN2B promoter 
Using the GCG Wisconscin Package TF software, the proposed CDKN2B regulatory region was 
screened  for putative TF binding sites. The results were then validated by further literature 
searches. Several Sp1 binding sites (GGACAGGGGGCGGAGCCTAAG), 
(AGAGCGAGGCGGGGCAGTG), (CTCTGCTCCGCCTACTGGG) and a putative CTCF site 
(CACCCCTCTCTTATGAT) were highlighted in the 5’ region of the promoter. 
 
Cell lysate samples of HeLa, Raji, K562, KG1 and HL60 cell lines which have well characterized 
CDKN2B expression and promoter methylation profiles were assessed for VEZF1 expression.  
Also, used were whole blood isolated primary T cells. The T cell isolations were kindly conducted 
by Cell Cycle group members (H. Milewicz, E. Hamilton and S.Orr). Non-activated human T cells 
- 184 - 
 
from healthy donors were isolated by negative selection from the peripheral blood. These 
quiescent T cells were then stimulated with CD3/CD28 magnetic beads (Dynal) for 48 hours.   
Following magnetic bead removal by mechanical disaggregation, samples were taken for cell 
cycle analysis at G0 – resting phase and stimulated to enter the G1 cell cycle stage. This was 
done in order to confirm that T cells had responded to the stimulus and progressed through the 
G0→G1 commitment point [475], and to determine what proportion of T cells has entered the cell 
cycle (The procedure for T cell isolation, stimulation, Cell Cycle Analysis is described in Methods 
(Chapter 2, Sections 2.20 and 2.21).  
The samples were fixed in 70% (v/v) ethanol and stained with FITC for total protein content and 














Figure 5-1 Flow Cytometry Analysis of T Cells pre and post stimulation 
Quiescent primary T cells were stimulated with CD3/CD28 beads for 48 hours.  Cell samples were taken at 48 hours.  
Cells were fixed in cold 70% (v/v) ethanol and stained with PI (DNA content) and FITC (protein content).  The 
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If VEZF1 has a role in promoter methylation protection as discussed in 5.1, as well as potential 
transcriptional contribution, it was necessary to look at the VEZF1 expression status in various 
cell lines with known CDKN2B methylation status.  Raji and KG1 have a partially methylated, 
whilst HL60 and HeLa have an unmethylated CDKN2B promoter. The K562 cell line has a 
deletion of the CDKN2B gene locus [476]. VEZF1 expression was assessed by western blot 
analysis, and  the results are shown in Figure 5-2 below. VEZF1 expression was confirmed in 
all of the cell lines and primary cell samples with the exception of KG1 which showed no 
expression. KG1 and Raji although both exhibiting 50% methylation in the CDKN2B promoter 
region are cell lines of different lineage. Raji is B lymphocyte derived and KG1 is of human 





Figure 5-2 VEZF1 protein expression in various cell lines and primary T cells. 
VEZF1 protein expression was examined in HeLa, Raji, K562, KG1, HL60, quiescent and cell cycling primary T cells 
all at 1x106, using rabbit polyclonal anti VEZF1 antibody (sc-98278 X) at 200 µg/ml at 1:400 dilution in PBS 5%  non -
fat dry milk. VEZF1 56kDa protein expression was confirmed for the majority of cell lines, except KG1 which showed 
no expression of VEZF1 protein.  Anti-GAPDH goat polyclonal antibody was used at 1:10000 in PBS 3% BSA as a 
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Having determined VEZF1 expression in a majority of cell lines, I wanted to firstly assess 
whether VEZF1 is recruited to the CDKN2B promoter. ChIP pull downs on HeLa cells were 
conducted using rabbit polyclonal anti VEZF1 antibody (5µg) as described in Methods Chapter 
2 Section 2.13.6. Negative control for the pull down was an IgG rabbit polyclonal antibody. PCR 
primers spanned the 5’ region of the CDKN2B promoter (-890 to – 757 relative to the TSS) to 
generate a product 133 bp in size.  A set of primers to detect the Endothelin 1 (ET-1) gene as a 
positive control was also designed. This gene  was previously shown to engage a VEZF1/DB1-
responsive element via  a 6 bp motif ACCCCC located 47 bp upstream of the endothelin-1 
transcription start site [477]. The result in Figure 5-3 shows significant VEZF1 enrichment at the 
CDKN2B promoter. The result is representative of triplicate experiments.  That VEZF1 binds to 
the CDKN2B promoter was hitherto unknown. GAPDH primers were used as an additional assay 





















Figure 5-3 ChIP of VEZF1 at the CDKN2B promoter 
A HeLa cell ChIP using polyclonal rabbit anti-VEZF1 antibody. Arrowed is a 133 bp PCR amplicon of the CDKN2B 
region and ET-1 region which was previously shown to engage VEZF1. IgG control in the last lane shows no band as 
expected. GAPDH was used as a negative control for each sample. B HeLa cells were x- linked and sonicated in a 























































































































Lane 1  100 bp ladder
Lane 2  Input
Lane 3  CDKN2B VEZF1
Lane 4  ET-1 VEZF1
Lane 5  IgG control VEZF1
Lane 6  Input GAPDH
Lane 7  GAPDH VEZF1
Lane 8  IgG GAPDH
1 2 3 4 5 6 7 8
1 2 3
Lane 1  100 bp ladder
Lane 2  Sonicated 3x
Lane 3  Sonicated 5x
Lane 4  ET-1 VEZF1
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Following confirmation of VEZF1 binding at the CDKN2B promoter region, I asked what effect 
VEZF1 silencing would have on the promoter methylation pattern at the CDKN2B promoter, 
based on the hypothesis that it might mediate protection from methylation.  
It was speculated that if VEZF1 has a role in CDKN2B promoter immunity to methylation then it 
would be interesting to address whether repeated knockdowns of VEZF1 would eventually lead 
to the CDKN2B promoter succumbing to more extensive de novo methylation and what its effect 
on CDKN2B transcription might be. 
Repeated knockdowns of VEZF1 were carried out using Silencer ® Select pre-designed siRNA 
(Ambion) at 4nM using Amaxa ® nucleofection at 4 day intervals. A positive control for 
transfection efficiency assessment was BLOCK-iT™ Fluorescent Oligo (Ambion, 2013). 
Transfection efficiency was assessed 48 hours following nucleofection using FACS, and for 
fluorescent control was shown to be ~98%. VEZF1 knockdown was monitored at 24, 48 and 96 
hours following nucleofection and confirmed by western blot under the same conditions as 












Figure 5-4 VEZF1 silencing in HeLa cells 
Western Blot of VEZF1 siRNA knockdown in HeLa cells. HeLa cells were nucleofected with VEZF1 specific siRNA. Cells 
at 1x106 were collected at 24, 48 and 96 hours following transfection and analysed by western blot using rabbit polyclonal 
anti VEZF1 antibody (sc-98278 X) at 200 µg/ml at 1:400 dilution in PBS 5%  non -fat dry milk. VEZF1 56kDa protein 
expression was unaffected by control siRNA, but a clear VEZF1 downregulation was observed for VEZF1 siRNA 
targeted sample. Anti-GAPDH goat polyclonal antibody was used at 1:10000 in PBS 3% BSA as a loading control to 
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Repeatedly nucleofected samples were analysed for p15INK4B expression by western blot at four 
day intervals. This time point was selected to allow time for the cells to recover in terms of cell 
numbers following repeat transfections.  Western blot analysis of p15INK4B shown in Figure 5-5 
led to the interesting observation of an emergence of a potential p15 variant, 10kDa in size, 







Figure 5-5 Alternative CDKN2B splice variant  
Western Blot showing four experiments (E1 to E4) of repeated VEZF1 siRNA and a scrambled control siRNA 
nucleofections. p15INK4B expression was analysed as described previously in Chapter 4 Section 4.9.1.2. HeLa cells 
transfected with VEZF1 si RNA and a –ve control scrambled siRNA were assessed for p15INK4B expression at 4 day 
intervals. Result clearly shows a loss of p15INK4B expression and establishment of smaller size variant for both transfected 
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Further investigations suggested two strong possibilities for the identity of this 10kDa band 
induced by repeated nucleofection. The CDKN2B gene has two coding exons encoding three 
transcript variants, p15,  p15.5 and p10 which are functionally indistinguishable, with the main 
difference being that p15.5 is an N terminal extended form of p15 generated from an  alternative 
inframe translation  initiation codon [478].  The third variant p10 derives from alternative splicing 
within intron1. This protein is  capable of cell cycle restriction, but it does not interact with CDK4 
or CDK6  [479]. This splice variant has been shown to be induced by oncogenic insults and 
TGF-β treatment. 
In mouse embryonic fibroblast (MEFs) and NIH 3T3 cells it was shown that p10 is able to induce 
cell cycle arrest and inhibit foci formation and anchorage-independent growth in a p53-
dependent manner.  This suggests that the INK4B locus with  its  different splicing variants can 
be  involved in  tumour suppression  via the two key molecular routes – the p53 and 
retinoblastoma pathways [480].  
In order to further ascertain that differential splicing of the CDKN2B  gene results in the 
expression of p10 at the expense of p15,  a set of p10 and p15INK4B specific primers spanning 
the region between  the exon 1 and exon 1β/exon 2 boundary was designed [481]. However, 
there was no time left to conduct this experiment.  
 
5.3.2 Global 5-hmeC signal intensity changes significantly during G0-G1 transition 
 
I also wished to examine a potential role for TET family members in maintaining a methylation 
free status of the CDKN2B promoter. However, cultured cell lines exhibit very low levels of 5-
hmeC. Evidence so far using an enzymatic approach of in vitro analysis of R.MspI and R.HpaII 
sensitivity to glucosylation of  5-hmeC showed that in HeLa and NIH3T3 5-hmeC amounts are 
nearly undetectable [482]. Another set of observations in HeLa cells indicates that the global 
levels of DNA methylation decrease during the G1 phase of the cell cycle and increase during 
the S phase of the cell cycle [483]. Therefore, attempts to ascertain the role of TETs in epigenetic 
regulation at the CDKN2B promoter in HeLa cells would be futile. As a prelude, to an analysis 
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of the effect of overexpression/knockdown of TETs on CDKN2B promoter 
methylation/demethylation I decided to examine TET and 5-hmeC levels in human primary T 
cells.   
Relatively little is known about the changes in the epigenetic landscape associated with DNA 5-
hmeC during cell cycle entry G0-G1. I wished to analyse levels of 5-hmeC during G0-G1 transition 
and investigate if there are changes associated with 5-hmeC levels and cell cycle entry. Total 
DNA 5-hmeC and meC content was compared in human T lymphocytes in a quiescent (G0) and 
proliferating (G1) state in response to an antigenic stimulus. T cells can remain in the peripheral 
blood for many years in the quiescent state before entering the cell cycle. Upon co-stimulation 
via CD3/CD28 cells commit to entry into the cell and growth cycle and expression of T cell 
effector functions [484].    
Isolated quiescent and stimulated T lymphocytes were counted and analysed for cell cycle and 
purity as shown in Figure 5-1. Immunofluorescence staining was used to assess changes in 5-
hmeC levels.  T lymphocytes cell suspensions at 5x104 were cytospun to adhere to poly-Lysine 
slides as described in Chapter 2 Methods, Section 2.20.2. The slides were prepared  for 
immunofluorescence staining as described in Chapter 2 Methods Section 2.15. Briefly, cells 
were fixed in 4% paraformaldehyde for 15 minutes, washed with PBS and permeabilized with 
0.4% Triton X-100 in PBS.  Permeabilized cells were then denatured with 2N HCl for 15min and 
neutralized with 100mM Tris-HCl (pH8.5) for 10min before blocking for 1h with blocking buffer 
(10% goat serum).  The cells were then incubated with polyclonal rabbit 5-hmeC specific primary 
antibody (Active Motif, 39769)  at a 1:250 dilution in 10% goat serum in PBS overnight in a 
humidified chamber at 4 °C.   
Following three consecutive 5-min washes with PBS, cells were incubated with secondary 
antibodies at 1:400 dilution in PBS. Two different secondary conjugated antibodies were used 
for the detection: Alexa Fluor ® 488 (rabbit polyclonal) and Alexa Fluor ® 647 (rabbit polyclonal). 
This was followed by DAPI staining for 15 minutes at room temperature. Finally, cells were 
washed again three times with PBS and mounted in the mounting medium. Images were 
acquired using Zeiss immunofluorescence microscope Axiovert 200 and Axiovision software. 
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We observed a significant increase in the 5-hmeC signal intensity during G0-G1 transition (shown 
In Figures 5-6 and 5-7). Figure 5-6 shows 5-hmeC signals at G0 and G1 cell cycle stages. Due 
to the high intensity of FITC signals at G1 vs. G0 an alternative secondary conjugated antibody 




Figure 5-6 IF analysis G0 –G1 5-hmeC – Alexa Fluor ® 488 
A. Quiescent T lymphocytes (G0) stained with anti 5- hmeC primary antibody, followed by FITC secondary antibody. 
Nuclei were DAPI stained for visualization. B Stimulated T lymphocytes (G1) were stained under the same conditions.  

























Figure 5-7 IF analysis G0 –G1 5-hmeC - Alexa Fluor ® 647 
Quiescent T lymphocytes (G0 stained with anti 5-hmeC primary antibody, followed by dye conjugated secondary 
antibody. Nuclei were DAPI stained for visualization. B Stimulated T lymphocytes (G1) were stained under the same 

















Given that the transition from G0 to G1 involves significant up regulation of a number of genes, 
either through promoter demethylation or chromatin restructuring, the observation of enhanced 
5hmeC levels in G1 is perhaps unsurprising [485]. However, it could also be possible that at G1 
DNA is in much more accessible, open conformation and as such more receptive to staining 
compared to a more compact closed state during G0. It has been demonstrated that  access by 
transcriptional regulators and DNA replication mediators requires alterations in chromatin 
compaction to occur [486] [487]. Furthermore, recent evidence shows that  5mC is under-
represented at gene promoters and CGIs whereas 5-hmeC is enriched and is associated with 
increased transcriptional levels[485].  
To address this issue an attempt was made to carry out methylcytosine immunofluorescence to 
look at the DNA methylation changes during G0-G1 transition under the same conditions as for 
5-hmeC staining. If DNA accessibility is an issue, then it would be resolved by this approach. 
The primary antibody used was mouse monoclonal IgG1anti-methylcytosine antibody 
(Eurogentec Catalogue No BI-MECY-0100). Unfortunately, no signals could be obtained even 
following extensive optimization procedures.  
The only way to address whether these are real changes to the global levels of 5- hmeC as the 
cell enters the cell cycle or if the signals arise due to the experimental procedure is to use either 
a different meC antibody, or an anti-DNA antibody as a reference control.  
However, given the observed differences in global 5-hmeC content between G0 and G1 cells, as 
real, one would also perhaps expect to see differences in TET family expression between the 









5.3.3 TET Expression levels change during G0-G1 transition 
 
Having possibly demonstrated cell cycle dependent differences in 5-hmeC signal intensity   and 
taking into account what is currently known about the role of TET proteins in DNA 
hydroxymethylation I wanted to investigate further the expression profiles of TET proteins during 
G0 –G1 transition. Samples of quiescent and stimulated T lymphocytes (the same as the ones 
used in the IF study) were used for RNA extraction and expression profiling. Expression of TET 
family members was assessed using gene specific TET primers for TET1, TET2 and TET3. The 
endogenous reference for the PCR reaction was the 18S housekeeping gene. SYBR Green 
qPCR was used for relative quantification analysis of TET expression levels relative to the 18S 
reference. SYBR Green is a fluorescent dye which binds double–stranded DNA and is detected 
by measuring the increase in fluorescence throughout the cycle. RT-qPCR Assay set up, and 
relative quantitation using ΔΔCt method are described in Methods Chapter 2 Section 2.13.1. 












Figure 5-9 RT-qPCR TET Expression Evaluation during G0–G1 transition normalised to 18S 
TET family member’s expression profile by RT-qPCR Sybr Green relative quantitation method was used to evaluate 
TET1, TET2 and TET3 expression changes during the cell cycle entry. A RT-qPCR expression data for each of the 
TETs at G0 vs. G1 shows downregulation of TET1, and up regulation of TET2 and TET3 as the T lymphocytes enter the 
cell cycle. B. Agarose gel of the PCR run using HotStarTaq Polymerase shows the same result.  The visual confirmation 
of qPCR using HotStarTaq plus DNA polymerase (Qiagen 203601) was employed (Figure 5-9B).  The resulting 





























































































G0 vs G1 TET Expression qRT-PCR
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The results of relative quantitation analysis indicate changes in TET family expression patterns 
during the G0–G1 transition.  Results obtained by PCR were comparable to the RT-qPCR data. 
The data generated so far indicates that there is an increase in 5-hmeC signals during the cell 
cycle entry. The  transcriptional up regulation of  TET2 is in line with what is known about the 
role for this protein in 5-hmeC generation [488]. The significance of TET3 up regulation is less 
clear at this time.  
TET1 downregulation also appears to correlate with what is currently known about TET1 
expression patterns. Recently, studies in mouse ES cells using chromatin immunoprecipitation 
coupled with high-throughput DNA sequencing  show  that TET1 preferentially binds  to CpG-
rich TSSs, a significant proportion of Polycomb group (PcG) target genes and that it also 
associates and co localizes with the SIN3A co-repressor complex. The same study also 
suggests a  role for   TET1 in transcriptional repression of PcG targeted developmental 
regulators based on the observation that  recruitment of PRC2 to CpG-rich gene promoters 
appears to be facilitated by TET1 [489]. Not much is known about the TET3 role in T cells cell 
cycle progression. It is particularly interesting that the highest up regulation is seen for this 
protein. TET3-mediated DNA hydroxylation was shown to have a role in epigenetic zygotic 
paternal DNA reprogramming during  natural fertilization [490].  
I had planned to investigate the methylation status of the CDKN2B promoter in response to 
knockdown of TET family members through siRNA action in G0  vs. G1  T cells. Due to time 










Epigenetic gene silencing associated with aberrant CDKN2B promoter hypermethylation 
patterns is one of the hallmarks of hematopoietic malignancies such as MDS and AML.    
This divergent gene is normally expressed in a lineage restricted manner and at very low levels.  
CDKN2B regulates cellular senescence, hematopoietic cell differentiation and cell cycle control. 
Under normal physiological conditions, the CDKN2B promoter region is methylation free, but in 
disease it yields to aberrant and progressive methylation of its CGI. The mechanisms which this 
and other gene promoters might employ to keep their regulatory regions methylation free are 
unknown at this time, as are the routes by which these mechanisms might be circumvented in 
disease cells. In this chapter, two distinct mechanisms of protection against widespread 
promoter methylation in the CDKN2B region were investigated.    
 
The first part of the chapter investigated a postulated role for VEZF1 as a barrier against DNA 
methylation activity. An interesting candidate, VEZF1, which was recently proposed to 
mediate  protection  from  de novo DNA methylation  at the chicken β-globin domain locus and 
the APRT CGI in ES cells [491] was an attractive model for  investigation. This transcription 
factor was demonstrated to mediate global DNA methylation levels particularly at Line1 elements 
and minor satellite repeat elements, in  studies involving  VEZF1 -/- mouse ES cells. 
Furthermore, deletion of VEZF1 was accompanied by DNMT3B depletion [492].  Given that 
VEZF1 recognizes similar G-rich sequences as Sp1, which is a known regulator of CDKN2B 
transcription, this chapter attempted to investigate the hypothesis that VEZF1 may play a role in 
providing a defence against DNA methylation.  
In this chapter, I showed using ChIP pull downs that VEZF1 is recruited at the 5’ region of 
CDKN2B promoter. This identifies a previously unknown interaction which will hopefully advance 
our understanding of CDKN2B regulation. To investigate whether VEZF1 plays a role in 
protecting the CDKN2B promoter against ‘casual’ methylation repeated knockdowns of VEZF1 
were performed using VEZF1 siRNA in HeLa cells. This resulted in the unexpected finding that 
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the p15INK4B specific band identified by western blot analysis disappears, and a 10kDa non-
specific product co incidentally appears.   
In the second part of the chapter, I considered an alternative mechanism for the maintenance of 
the methylation – free state at the promoter region of the transcribed genes which involves 
removal of methylated cytosines independent of cell division [493]. There are a number of 
proposed demethylation mechanisms ; base excision repair (BER) to remove 5meC usually via 
a DNA glycosylase, nucleotide excision repair (NER) mediated by the GADD45 family, 
deamination of 5meC to T via AID, APOBEC, or DNMTs, followed by BER to correct the T·G 
mismatch [494].  The TET family of enzymes is another group of putative demethylases.  The 
TET1 family member was first identified as a fusion with H3K4 methyltransferase MLL in AML, 
but also there is now an increasing body of evidence implicating TET1 and TET2 in a 
haematopoietic malignancies [495].   
Of particular interest was the recently proposed role for TET protein in mediating demethylation 
by 5meC hydrolysis to produce an intermediate hydroxymethylcytosine 5-hmeC. The ultimate 
aim of this research here was to evaluate the effects of TET knockdowns on CDKN2B promoter 
methylation patterns.   
Cultured cell lines such as  HeLa were shown to possess very low,  almost undetectable levels 
of 5-hmeC [496], so I decided to use primary cells as a model system. T cells seemed an ideal 
choice, firstly because methods for cell isolation from peripheral blood, and stimulation from its 
native quiescent state (G0) to enter the cell cycle following CD3/CD28   co-stimulation (G1), were 
already established in our lab. Significant differences in TET family member transcription levels 
between the two cell cycle states were observed.  Furthermore, according to preliminary 
immunofluorescence data, the 5-hmeC signals between the two states also differ, with an 
increase in 5-hmeC signal intensity at the G1 stage of the cell cycle. This is the stage 
characterized by cellular growth, restructuring of surface / secreted effector function molecules 
and an increase in gene expression by regulatory proteins. If the 5-hmeC data are true, and not 
a result of an experimental ambiguity, then this would be the first representation of global 
demethylation being observed as the cell enters the cell cycle. However, much more work is 
required before we can advance, or discount this idea.  
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6.1 Endogenous gene promoter region DNA Methylation targeting  
 
Compared to the genome, the epigenome is in a forever fluid state, modelled and shaped by a 
variety of contributing factors, one of which is DNA methylation. Large scale DNA methylation 
studies in mammalian systems have shown a genome wide methylation distribution, with the 
conspicuous exception of CGIs. The proposed  function for DNA methylation is generally 
accepted to be involvement in gene promoter silencing  and the maintenance of the repressed 
state[497].  
Despite the consensus view on the role of the DNA methylation in irrevocable transcriptional 
silencing, there is a little evidence to directly link DNA methylation to gene expression 
modulation. Furthermore, emerging evidence of a dynamic pattern of promoter methylation, 
which varies according to the cell type, and observation of the DNA methylation targeting to the 
transcriptional units of actively transcribing genes, highlights the limits of our understanding of 
this important epigenetic mechanism.  
As previously mentioned epigenetic studies of the mammalian genome so far, have helped paint 
a picture of the DNA methylation landscape, featuring global hypermethylation, interrupted by 
short un-methylated CpG rich regions regions– CGIs as a most prominent feature. These CGI 
regions are proposed as epigenetic ON/OFF switches which exist in two alternative states; 
heavily methylated (repressed) and essentially unmethylated (active). Active promoter regions 
are shown to be methylation free in the region of 500bp each side of TSS. DNA 
methyltransferases are presumed to be excluded from this region by promoter bound factors 
[498].   
Cancer and other human diseases have been linked to aberrant methylation patterns, frequently 
characterized by global hypomethylation,  promoter hypermethylation and silencing of the key 
tumour suppressor genes [499].  Similar methylation patterns are observed as healthy cells age, 
most likely contributing to age related diseases.   
Despite numerous studies investigating a co-relation between DNA methylation and gene 
silencing, the exact mechanisms of this relationship in vivo are not fully understood. One of the 
- 204 - 
 
longest standing questions in the field remains unanswered; whether DNA methylation initiates 
or is a consequence of gene silencing. By attempting to mimic DNA in vivo methylation events 
at a gene promoter region we proposed that it might be possible to perhaps dissect the temporal 
aspects and mechanisms of this relationship.  
This project approach to the above challenge was to use zinc finger peptide and DNA 
methyltransferase fusions in a specific attempt to try and replicate the kind of methylation 
patterns observed in MDS (reviewed in Chapter 1 Section 1.4). The six finger proteins used for 
this project were capable of recognizing 18 bp contiguous DNA sequence. Although unknown 
to occur in nature, the ZFs of this size were previously shown to be effective in gene regulation.  
Efforts in our lab to examine the effects of de novo methylation on gene regulation so far, have 
involved the use of site –biased  DNA methyltransferase to deliver CpG methylation directly to 
the target locus via zinc finger protein technology. Using this approach it was possible to  
demonstrate that the targeted DNA methylation to an integrated promoter leads to gene 
silencing, mediated by induced repressive chromatin signature [500]. This current project was 
to apply a similar methodology to target a disease relevant endogenous gene promoter, in order 
to better understand spatial and temporal aspects of genuine de novo DNA methylation in in 
vivo settings. 
The gene selected for this study was the CDKN2B tumour suppressor gene, which has a key 
role in cell cycle regulation, a haematopoietic cell differentiation, and cellular senescence 
(reviewed in Chapter 1). The gene is highly implicated and epigenetically silenced in various 
haematological malignancies such as MDS and AML. Aberrant methylation patterns and gene 
silencing of the CDKN2B gene have been reported, and extensively characterized for MDS. In 
fact, CDKN2B promoter methylation is currently used as a biomarker for the disease progression 
towards AML. CDKN2B suggested itself as an excellent test system for both laying down de 
novo methylation patterns, and assessing the functional outcome of such targeted methylation.  
During this PhD study I have attempted to investigate   the effects of targeting different CpG 
methylation densities to the promoter region of the endogenous gene, which included analysis 
of gene expression changes and spread of de novo methylation over time. 
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Below I will discuss the main findings of my PhD project, and how they relate to what is currently 
known about the delivery of DNA methylation to the target region, methylation spread, and its 
effect on gene transcriptional control. 
 
6.1.1 Zinc Finger Protein/Methyltransferase Fusion characterization  
 
Rationally designed zinc finger proteins fused to DNA methyltransferases were used in order to 
attempt delivery of low, medium and high density methylation to the CDKN2B key regulatory 
promoter region in HeLa cells, in an attempt to simulate the epigenetic events frequently 
observed in haematological malignancies. 
The rationale for the design of the zinc finger proteins was based on extensive literature 
searches for key CDKN2B transcriptional regulators, coupled with a TF search software 
package.  
CDKN2B specific 6ZFP proteins, fused to the HpaII FH (F35H) prokaryotic methyltransferase 
were used in titrative EMSA gel shift assays for comparative relative binding affinity assessments 
of each fusion protein.  High affinity binding for two of the zinc finger fusions (PU1/HpaII and 
AB/HpaII) to probes harbouring the relative recognition sites and the HpaII sites was confirmed. 
Analysis of the binding data showed that the PU1/HpaII bound to its target site most strongly 
(apparent Kd 5.2nM); the AB/HpaII protein binds with intermediate strength (Kd 11nM). The 
Miz/HpaII fusion protein bound relatively weakly to its target site (Kd 43nM), and Myc/HpaII 
bound very poorly indeed (Kd 992nM). The same fusion proteins were incubated with the target 
oligonucleotide harbouring a scrambled zinc finger site with the HpaII binding site left intact, and 
the binding was observed only at the highest concentrations of proteins used. These results 
suggested that the zinc finger dominates binding.  These results compare favourably to other 
studies of six finger proteins. The Kd values observed for PU1/HpaII and AB/HpaII are in a 
comparable range to similar six finger proteins previously characterized in our laboratory (Kd 
2nM). Interestingly, the Kd of PU1/HpaII used in this study (Kd 5.2nM) is lower than zinc finger 
only proteins lacking methyltransferase component (Kd 7nM) previously characterized in our 
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lab. This observation is in line with the data, which shows that the presence of the 
methyltransferases subunit increases the overall binding affinity of ZF/MT fusions for substrate 
harbouring both recognition sites. However, as already highlighted earlier, these Kd values are 
guidelines only because the issues of variation in protein and DNA concentration measurements 
and the purity of the fusion proteins have to be taken into the account.   
Given that the most of ZFs studied in these assays were designed and synthesized using the 
same approach the differences in their binding affinities are surprising.  The modular nature of 
ZFs which enables to recognize the triplet DNA subsites can adversely or sometimes even 
positively be affected by target site overlap (TSO) interactions[501].  
In vitro characterization of generated fusion proteins examined their ability to methylate the 
target site against a complex backdrop of HpaII sites.  Plasmids harbouring a zinc finger and 
HpaII site target sequence were used to assess the ex vivo enzymatic activity of the purified 
proteins. A unique restriction pattern suggestive of methylation at the target site should arise 
following HpaII restrictions of the plasmid. In this way, it is possible to comparatively assess the 
enzymatic activity of various ZFP/ methyltransferases expressed in E.Coli.   
The ex vivo enzymatic activity binding assays have been used previously in our lab, but 
inconsistencies have been noted.  The attempts to assess the enzymatic activity of the purified 
fusion proteins were unsuccessful. Gel analysis of the purified proteins did show minor issues 
associated with protein degradation. It is possible that degradation or cleavage products of the 
purified protein, possibly resulting from the purification process, interfered with the binding 
assays; for example by blocking access of the full length protein.   
These issues of protein degradation could possibly be addressed by changing the purification 
system. An alternative purification system was evaluated previously in our lab. Using the Maltose 
Binding Protein MBP, a greater amount of degradation was observed, suggesting no advantage 
to using this system (Wong.,K unpublished data). Another possibility was that the ex vivo assay 
was being influenced by the topology of the plasmid vectors used. Typical plasmid topology is a 
covalently closed circular (ccc) supercoiled form, although it can also appear in damaged 
structures, like open circular (oc) or linear forms, where one or both strands are broken, or can 
exist in larger concatemeric forms.  
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Prior to targeting the gene promoter region in its endogenous setting, which was the primary 
goal of this thesis, we wanted to validate these targeted methyltransferases in a CDKN2B 
relevant model system. To this end, the CDKN2B promoter containing primary regulatory 
regions and CGI was used to assess delivery of de novo CpG methylation by examining changes 
in reporter gene expression.  
This builds on the previous published work in our lab, where the four finger (4aFH) driven  
targeting  using the HpaII FH mutant methyltransferase, to the artificial chromosomally 
integrated  target promoter led to de novo methylation of the target region, accompanied by the 
reporter system gene silencing, and the acquisition of repressive chromatin signature-  
H3K9me2 methylation[500].  
HeLa cells were transiently co-transfected with the pBL-CAT plasmid harbouring the CDKN2B 
promoter region driving the expression of CAT reporter gene, and various CMV driven 
ZFP/methyltransferase fusion constructs.  
CAT Activity was measured principally by CAT-ELISA.  Radioactive CAT assays were also 
performed to confirm the results. Although relatively high transfection efficiencies were 
consistently achieved (80%) as confirmed by GFP fluorescence-activated cell sorter analysis, 
only very weak CAT signals, insufficient for further analysis were detected. The CDKN2B 
promoter on its own appears to be too weak to facilitate sufficient gene expression.  
To address this issue an alternative reporter system using GFP was evaluated to more readily 
measure promoter activity. It was believed that it would be more sensitive than ELISA based 
approaches given the GFP FACS readout, but no fluorescent signals could be detected upon 
HeLa cells transfections confirming the previous observation of the CDKN2B promoter 
strength. Another possible explanation for the observed lack of activity could be  that CDKN2B 
requires specific stimuli for its induction, or that  some key regulatory sequences are missing 
from the promoter region used in these assays. It is noteworthy that in our hands RT-qPCR 
CDKN2B analysis showed that this is a low abundance transcript (Ct 32), whose transcription 
improved significantly upon phorbol myristyl acetate (PMA) treatment (Ct 28).  
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The CDKN2B gene is induced in response to TFG-β signalling via SMAD phosphorylation 
[502]. Furthermore, basal promoter activity is shown to increase dramatically upon activation 
with tetradecanoyl phorbol acetate (TPA) acting in concert with Snail, EGR-1 and AP-1 
transcription factors. The TPA responsive element is  located  between -226 and 80bp relative 
to TSS, and is a binding site for SP-1 and EGR-1 TFs [503]. We have contemplated TPA 
treatment to induce the CDKN2B transcription levels but decided against it as it would have an 
effect on the endogenous CDKN2B levels, and quite likely mask the promoter/reporter signals. 
Several cell lines with CDKN2B deletions K562, Jurkat and A549 were evaluated to test 
whether low expression was a cell type specific issue, but their transfection efficiencies were 
suboptimal for any further analysis.  
 
6.1.2 Endogenous CDKN2B methylation targeting  
 
Both prokaryotic and eukaryotic methyltransferases (catalytic domain) zinc finger fusions have 
been successfully used to direct targeted methylation in bacteria, yeast and the mammalian 
mitochondrial compartment [504-506]. The effects of methylation targeting on gene expression 
modulation have also been assessed in transient assays involving viral vectors, plasmid based 
reporter genes [507] and most recently in our lab on an integrated “artificial“ target region [500]. 
To the best of our knowledge, no-one has yet successfully targeted de novo methylation to the 
more functionally complex endogenous promoter in in vivo settings. 
The promoter region of an actively transcribing gene is a highly dynamic and complex region. 
The core promoter region serves as a docking template with recognition sequences for 
numerous epigenetic and transcription factors which co-ordinate transcriptional regulation. This 
fact, coupled with the issues of DNA topology changes resulting from various cellular processes, 
mechanical stresses  and  DNA:nucleosome interactions during the highly dynamic process of 
active transcription [508] made it questionable whether the specific core promoter architecture 
in in vivo settings could be accessed by targeted methyltransferase at all.  
The benefits of successful delivery of targeted de novo methylation are manyfold. By accessing 
and methylating the region it would be possible for the first time ever to look at the broad 
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contribution this epigenetic modification makes to overall transcriptional regulation. Secondly, 
this approach could allow us to examine the dynamics of methylation spread and the factors 
associated with epigenetic inheritance. Finally, by studying the time dependant consequences 
of targeted methylation, important insights into the spatial and temporal relationship between the 
promoter gene DNA methylation and gene regulation could be gained.  
An important point to reiterate at this stage is that it is still not clearly defined if DNA methylation 
spreading into the promoter region initiates gene silencing by recruiting repressive complexes, 
or if a diminishing transcription leads to the gradual increase in methylation levels to the point 
when stable silencing is sealed by a permanently methylated promoter.  A  number of studies 
demonstrate the existence of stably inactivated methylated  promoters, where the silencing is 
probably mediated by MeCP-1 binding, and recruitment of repressive elements [509, 510]. 
However, there are studies also to support the idea of a gradually diminishing gene expression, 
that is not initially associated with DNA methylation but leading to a complete silencing ‘sealed’ 
by a methylated promoter. One such study involved using E6 papillomavirus transfected human 
mammary epithelial cells which escape senescence in correlation with gradual p16 
downregulation in the absence of promoter methylation. Following a number of cell passages, 
complete silencing occurs associated with promoter methylation [511].  
Using either single or combinatorial expression of targeted prokaryotic methyltransferases we 
attempted to lay down low density methylation at the target region, and investigate possible 
effects on the progressive methylation spread and gene transcriptional regulation.  
To position low density methylation two prokaryotic methyltransferases were used; M.HpaII 
(F35H), which recognizes the CCGG sequence and M.HhaI which recognizes GCGC, both of 
which modify the internal (bold and underlined) cytosine residue (C5) in the sequence. M.HpaII 
(FH), previously used in  methylation studies in our lab, is a mutated version with reduced binding 
affinity, thus allowing the ZF component to dominate in functional binding interactions, and 
effectively eliminate non-targeted background methylation [512]. For higher density methylation 
studies, CpG specific prokaryotic M.SssI, and the C-termini of two mammalian 
methyltransferases DNMT3A and DNMT3B were evaluated. I also evaluated co targeting of 
these enzymes with their respective co-stimulator - DNMT3L.  
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Accessing the actively transcribing, methylation free promoter, with its open chromatin 
conformation was expected to be an issue.  Therefore, I was unsure whether accessing an 
actively transcribing region would be an issue or not. It has long been speculated that the open 
chromatin established by an active promoter actively blocks the spread of methylation from 
methylated distal region.   
Here, it is demonstrated for the first time that it is possible to lay down a de novo methylation 
pattern to a defined region of an actively transcribing endogenous gene. Using M.HpaII and 
M.HhaI methyltransferases, specific de novo methylation was deposited at the target sites, as 
determined by bisulfite methylation sequencing of the library, followed by TOPO-TA cloning of 
individual clones for a more detailed analysis. Short-term studies (up to day 21)  on the spread 
of de novo methylation from the seed target foci to the surrounding methylable CpG sites showed  
that there is no obvious spreading to the flanking CpG sites. Long –term studies to address the 
temporal and spatial methylation spread are on-going.  
The analysis of the region closer to the ZF target site revealed an obvious spread of methylation 
towards the 3’ region closer to the zinc finger target site. At Day 14 an increase in the level of 
methylation of around 29% was observed in this region of the promoter in the immediate vicinity 
of ZFs.  
A second very important observation was clear evidence for epigenetic inheritance of the low 
density de novo methylation patterns. Once acquired, the methylation patterns are propagated 
through successive cell divisions long after the initial methylation stimuli of exogenous targeted 
DNA methyltransferases are lost. The fact that we demonstrated maintenance of methylation at 
the HpaII target site, but no subsequent methylation spread onto the local CpG site, implies de 
novo endogenous activities of DNMT3A or 3B.  
More distal regions of the target site were defined by highly specific target site methylation, 
indicating that M.HpaII and M.HhaI show distinct sequence preference.  
Following targeted promoter methylation, transcriptional regulation assessment of   CDKN2B 
showed no change in the gene expression levels. Again, it should be pointed out that this is a 
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short – term study, but so far the data point towards exclusion of promoter DNA methylation as 
the primary causative event in gene repression.    
Having established that imposed low density methylation in the CDKN2B promoter region was 
an inherited mark but  with no apparent effect on gene regulation,  we then asked, what would 
be the effect of targeting high density de novo methylation to that same region.  To do this we  
employed  two C-terminal mammalian methyltransferases DNMT3A and DNMT3B shown to be 
catalytically active [513] alone or co- targeted with DNMT3L, and a prokaryotic 
methyltransferase M.SssI. These enzymes preferentially methylate CpG sites and given the high 
abundance of these sites in the CDKN2B promoter target region – highly dense methylation 
patterns were expected. The prokaryotic CpG methyltransferase M. SssI was previously used 
as a Zif268 fusion,  to deliver methylation to pre- determined sequence [514]. DBD fused C-
terminal DNMT3A and DNMT3B have also been successfully used for targeted methylation of  
different reporter systems leading to gene  repression.  
The rationale behind co –targeting with the catalytically inactive protein DNMT3L is due to its 
demonstrated stimulatory effect on the catalytic activity of DNMT3A and DNMT3B [428].  
Additionally, DNMT3L in heterodimer formation with DNMT3A and DNMT3B  guides CpG site 
recognition  in a periodic pattern [429] and attenuates formation of more uniform methylation 
patterns [430].  
I was not successful in delivering high density DNA methylation using the catalytic domains 
DNMT3A or DNMT3B methyltransferases, with or without DNMT3L. The apparent lack of 
success may point to issues of enzymatic activity in our model system. It is possible that the six 
finger protein used in this instance binds with too strong an affinity to target site, overriding the 
enzymatic activity of the target methyltransferase. Another possibility is that the catalytic domain 
of these enzymes interact with other proteins, for example endogenous DNMT3L. Once bound, 
the DNMT3L coupled with DNMT3A or DNMT3B was shown to  direct DNA methylation to 
genomic regions lacking H3K4me3[515]. Given that the CDKN2B promoter  is transcriptionally 
active , it is possible that in endogenous settings targeted methyltransferases are “shuffled 
away” from the zinc finger target sites. This might make our decision to co-express with DNMT3L 
counter -productive.  
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Another possibility is that although we used catalytic domain methyltransferases shown to be 
able to methylate their target CpG substrate, additional domains of the enzyme are required for 
de novo DNA methylation in endogenous settings. Recently, it was shown that the ADD domain 
binds unmethylated H3K4 tail to preferentially methylate DNA marked by this modification. This 
is in line with the global analysis of DNA methylation pattern distribution [516].  
It has been demonstrated  that different domains of  methyltransferases provide  a link to mediate 
cross –talk between DNA methylation and chromatin signatures [517]. First shown for DNMT3L, 
followed by DNMT3A and DNMT3B, the PHD domain interaction with the amino-terminal tail of 
histone H3 is inhibited by H3K4 methylation - a marker of active genes [515, 516]. Additionally, 
DNMT3A via its PWWP domain interacts with the repressive modification  H3K36me3, and 
increases the enzymatic activity for methylation of nucleosomal DNA[518]. Therefore, it appears 
that there has to exist an interplay between histone modifications and DNA methylase 
complexes to contribute to the de novo methylation process. An additional very important finding 
from the same study was that the N-terminus of H3 binding to the PHD domain of DNMT3A, 
increased its activity.  DNMT3A carrying point mutations that diminished H3 tail binding but not 
its enzymatic activity, transfected into DNMT3A -/-, DNMT3B-/- mouse ES cells could upon 
differentiation bind to, but not methylate Oct4. This is the strongest indicator yet that the 
DNMT3A enzyme requires an interaction with H3 for its allosteric activation, and perhaps can 
be one possible explanation for its failure to methylate in our study.  According to this scenario 
DNMT3A through its interactions with DNMT3L, or via PWWP, gets recruited to the chromatin 
template, but can be activated only through its PHD/H3K4 (unmethylated) contacts. If this is the 
case a much more sophisticated approach for DNMT3A and perhaps DNMT3B delivery for 
targeted methylation is required.  
 
6.2 Mechanisms of CDKN2B promoter regulation  
 
The work described here is the first demonstration of targeted methylation at the promoter region 
of the endogenous gene. Data generated so far, has not clearly suggested that promoter 
methylation may be an early event, that leads to CDKN2B gene repression frequently observed 
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in malignant haematopoiesis. This has left a number of open –ended questions that require 
further investigation.  
How does the above observation fit in with the demonstrated aberrant promoter methylation 
patterns and associated CDKN2B gene silencing observed in  disease? Furthermore, given that 
we accessed the CDKN2B promoter to target methylation for the purposes of this project, what 
is it that protects a promoter from routinely being methylated? Why does it succumb to 
methylation in disease? Is it possible that sustained epigentic insult in a stepwise fashion 
silences this gene, and that the DNA methylation is a final seal on its fate?  
To attempt to begin answering some of the questions raised above we should start with taking 
into consideration some recent observations linking CDKN2B promoter DNA methylation with 
other components of the epigenetic silencing machinery.   
CDKN2B-AS also known as ANRIL ( anti-sense  non-coding RNA in the INK locus), runs in the 
opposite direction from the INK4A-ARF-INK4B locus, and is believed  to recruit  PRC2 
component SUZ12 leading to repression of CDKN2B [519]. DNA methylation fits into the model 
through its demonstrated  physical interaction with components of the PRC1 and PRC2 
complexes, such as EZH2, CBX7 and DNMT3B [520, 521]. These findings are further reinforced 
by a study showing loss of  DNMT3B localization and DNA methylation as a consequence of 
PRC eviction from the INK4b-ARF-INK4a locus,  upon  restoration of an active SWI/SNF 
complex [522]. 
This fits in with the observation in cancer that the Polycomb target genes are more frequently 
shown to be aberrantly methylated [523, 524], and the evidence for the overexpression of the 
p15 anti sense RNA (p15AS) [525]. The same study found an inverse correlation between the 
expression levels of the sense and anti - sense RNA in leukaemia, and even more strikingly 
heterochromatin mediated silencing of p15 in the absence of DNA methylation via p15AS in in 
vitro system. In vivo, in mouse ES cells upon exogenous p15AS expression p15 silencing 
occurred through heterochromatin formation. DNA methylation was observed as a secondary 
effect, following ES cell differentiation.  
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The expression of ANRIL is regulated by another  very important factor, a chromatin insulator 
with barrier activity, the CTCF protein which is shown to bind upstream of the INK4A gene.  
Global genome analysis of CTCF binding sites in HeLa and CD4+ T cells identified cell type 
specific  CTCF binding at these barriers, and  several more binding sites  in the INK4 locus [526]. 
Furthermore, the shRNA knock downs of CTCF  were shown to dramatically reduce the 
expression of ANRIL and INK4 locus genes [451]. Studies on the human retinoblastoma pRb 
gene promoter shows that binding of CTCF can be  disrupted by DNA methylation,  but also that 
this insulator protein  provides methylation protection for the CGI  [527].  
 
The CDKN2B promoter is normally in a methylation free state, but in disease it rapidly succumbs 
to silencing associated with aberrant hypermethylation.  So what cellular factors, and 
mechanisms have a role in protecting the CDKN2B promoter? Different scenarios are put 
forward to explain such mechanisms of CGI protection from methylation.   
 
One such model proposes a role for a combinatorial  binding of TFs to keep CGIs in an 
unmethylated state, both in cancer and in healthy cells [528].  As mentioned above, insulators 
such as CTCF and chromatin barrier proteins exclude methylation from regulatory elements are 
another proposed mechanism. In line with this observation, an interesting candidate VEZF1,  
was recently proposed to mediate  protection  from  de novo DNA methylation  at the chicken β-
globin domain locus and  the APRT CGI in ES cells[491].   Global DNA methylation studies in 
the VEZF1 -/- mouse ES cells show genome wide methylation loss accompanied by DNMT3B 
depletion. This major loss of genomic methylation occurs at specific sites such as Line1 
elements, minor satellite repeat elements, some imprinted loci, and many CGIs [492].   
Our study using ChIP pull downs revealed that VEZF1 is recruited at the 5’ region of CDKN2B 
promoter. This was previously unknown and hopefully represents an advance towards a better 
understanding of the CDKN2B regulation. The role of VEZF1 as a protective barrier against the 
methylation in this region need to be further investigated.   
 
An alternative mechanism for the maintenance of the methylation –free state at the promoter 
regions of transcribing genes is that a demethylation processes  remove methylated cytosines  
independent of  cell division  [493].   
- 215 - 
 
 
In this project we were particularly interested in one mechanism  due to  the fact that TET1 family 
member was first identified in a fusion with H3K4 methyltransferase MLL in AML, but also there 
is an increasing body of evidence implicating TET1 and TET2 in a haematopoietic malignancies 
[495].  It has recently been proposed that TET proteins mediate demethylation involving 5meC 
hydrolysis to produce an intermediate hydroxymethylcytosine 5-hmeC.  
 
Because the cultured cell lines such as  HeLa  express only very low  levels of 5-hmeC [496], 
we decided to look at the primary T cells. These cells could easily be stimulated to enter the cell 
cycle from its native quiescent state (G0). The TET family (TET1, TET2 and TET3) expression, 
and its co-relation to the 5-hmeC levels were evaluated between these two T cell states.   
 
Our data indicates significant differences in the TET expression levels between quiescent and 
cycling cells.  We also observed differences in the 5-hmeC signals between the two cell cycle 
states. Unfortunately due to time constraints we were unable to investigate further in order to 
confirm these preliminary immunofluorescence observations. More work is required to confirm 
the 5-hmeC signal differences; before we can confidently say that the observed signals are a 
representation of global demethylation being observed as the cell enters the cell cycle. 
This is the stage characterized by cellular growth, restructuring of surface / secreted effector 
function molecules and an increase in gene expression by regulatory proteins and it is likely that 
it could be a stage also characterized by significant demethylation upon cell cycle entry.   
 
6.3 Future Directions  
 
Following investigations described in this thesis several lines of research should now be further 
pursued. 
Firstly, long term targeting studies using M.HpaII and M.HhaI need to be investigated fully with 
a view of understanding the temporal nature of epigenetic inheritance of methylated CpG sites.  
When this is done further insights could be gained about the chromatin signature associated 
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with the targeted promoter. This should allow better interpretation of the epigenetic process 
associated with methylation targeting.  
Next generation of targeted enzymes to deliver high density methylation will require more focus 
on the mutagenesis of M.SssI to allow its expression in mammalian cells. On the other hand low 
density methylation studies should be carried out in concert with the knockdowns of key TFs 
involved in the CDKN2B regulation. This “promoter clearance” could possibly allow the spread 
of methylation following de novo methylation targeting.  
The second line of research which follows from Chapter 5 of this thesis, is to confirm 5-hmeC 
signal validity using an anti -DNA antibody. This should remove any ambiguity caused by the 
differences in cellular size and/or DNA accessibility between G0 and G1 T cells.  Co-relation 
between the 5 hmeC and 5meC signals needs to be determined using more specific antibodies. 
To conclude this work TETs siRNA knockdown, its effects on cell cycle entry, CDKN2B 
expression and methylation/demethylation, and global 5-hmeC levels will need to be further 
assessed.  
Given the role for TET proteins in malignant haematopoiesis it would be very interesting to use 
zinc finger TET fusions targeted to an already methylated promoter of CDKN2B in Raji or KG1 
cell lines. As has been highlighted in the work on TET expression presented in this thesis, TET2 
given its expression pattern is probably the best candidate for the pilot studies. TET targeting 
demethylation to an already methylated region has potential therapeutical applications which 
could be further investigated. 
 As I conclude this thesis, I realise that more questions are raised than answers provided. Whilst 
humbled by this thought, it is my sincere hope that some useful insights regarding the role of 
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